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Introduction
Prosopagnosia, also called face-blindness, is a cognitive disorder of 
face perception. A person’s ability to recognize faces is impaired, 
while other aspects of visual processing and intellectual func-
tioning may remain intact. There are two types of Prosopagnosia: 
Congenital or Developmental Prosopagnosia, and Acquired 
Prosopagnosia. Congenital Prosopagnosia is a face-recognition 
deficit that is life long, beginning in early childhood, and is not 
attributed to brain damage.  Acquired Prosopagnosia refers to a 
condition that follows acute brain damage, usually brain damage 
specifically to the occipito-temporal lobe. The term Prosopagnosia 
is derived from the Greek words for “face” and “lack of knowl-
edge.”  Although individuals with this disorder may be able to see 
normally, their ability to recognize faces is deficient.  This disease 
can be life altering, as individuals with this disease may have lim-
ited social and behavioralinteractions. However, there are some 
Prosopagnosiacs who are able to lead normal, happy lives despite 
their inability to recognize faces. Scientists have performed many 
case studies and much research has been done to discover the un-
derlying causes of Prosopagnosia.  Both Congenital and Acquired 
Prosopagnosia are complex conditions caused by various factors. 
What are some of the neural, behavioral, and anatomical implica-
tions of Prosopagnosia?
Materials and Methods
In order to answer the question proposed above, many research 
papers and journal articles with relation to this topic have been 
read. Touro College’s library database and the NYU library data-
base were used to search for relevant studies and reviews. The 
next step taken was to look for articles that were referenced 
by those obtained through the Touro College Library and NYU 
search engines that seemed relevant. All of the articles and in-
formation that was accumulated through this research have been 
used in the attempt to conclusively determine the neurological, 
anatomical, and behavioral results of Prosopagnosia.
Results
Background on Congenital/ Developmental Prosopagnosia
Congenital Prosopagnosia (CP) refers to the impairment in face 
processing that is evident from the time someone is born. CP is 
not due to any brain damage and can occur in a person with intact 
sensory and intellectual functions. Individuals that suffer with CP 
are usually able to acknowledge that they are looking at a face; 
however they are unable to identify the specific face. As a result, 
they have come to rely on other cues such as voices, clothing, 
or specific accessories (hairlines, eyebrow shapes, etc.) to help 
recognize a person.  CP can even affect the recognition of even 
the most familiar faces, such as close family members. In extreme 
cases, one may not even be able to recognize his- or herself. An 
important fact to understand regarding those with CP is that 
they have never experienced normal face perception. Therefore, 
research that is conducted relies largely on self-testimony and the 
testimony of parents (Behrmann, Avidan, 2005).
Developmental Prosopagnoisa, a more general label, refers to a 
disorder caused by anomalies occurring at any time during de-
velopment, whereas the title of CP automatically assumes that 
prosopagnosia occurred at birth or early infancy (Susilo, Duchaine, 
2013).  To be categorized as someone suffering with Prosopagnosia, 
impairment in face recognition is required. However, it is import-
ant to note that face recognition is complex and there are multiple 
types of face recognition and face perception. For example, one 
needs to know whether a face is present among non-face stimuli, 
to determine whether two faces are the same or different, and be 
able to recognize the individual identity of a specific face. Studies 
show most patients with CP are able to detect faces from among 
other objects. Additionally, some individuals with CP find it easy to 
match faces (usually because they are able to identify key features), 
but when the reaction time or more specific measures of discrim-
ination are measured and the tasks demanded are more difficult, 
the deficit becomes quite obvious. However, most CP patients fail 
in the area of identifying specific faces (Behrmann, Avidan, 2005). 
Congenital Prosopagnosia:  
The Thatcher Effect
Case studies have been performed regarding the discussion on 
whether CP is specific to faces, as opposed to other objects. It 
is known that face processing typically involves individual iden-
tification, where one is shown a face and one responds with the 
individual’s identity. This process is different than that for identi-
fying others objects that are usually recognized at a basic level 
(for example, as a chair, an apple,or a house); face recognition 
requires the perception of very detailed features. People are able 
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to perceive and discriminate between objects based on either a 
single feature, involving a feature process, or based on the rela-
tionship between features, involving configural processing. 
Scientists have  theorized  based on case studies that related 
configural processing to face perception.  Face perception is 
often described as a configural process and it has been suggested 
that a loss of configural processing may be a clear indication of 
Prosopagnosia.  In an effort to determine the relationship between 
configural processing and Prosopagnosia, a case study was per-
formed. The ‘Thatcher Effect’ is a phenomenon where it becomes 
more difficult for a non- Prosopagnosiac to detect local changes 
in an upside down face, despite identical changes being obvious in 
an upright face. An experiment was performed to demonstrate 
that prosopagnosiacs, both CP and AP patients, do not suffer from 
the ‘Thatcher Effect’.  A control group of people who had no indi-
cation of prosopagnosia was formed. Another group of mixed CP 
and AP sufferers were collected. Then, two pictures of faces were 
held in the upright position with pictures of the same face flipped 
upside down next to them.
 In order to recognize faces, each brain has developed configural 
processing to be able to distinguish different details of individual 
face features such as eyes, nose, etc. When a face is turned up-
side down, configural processing cannot take place and so those 
seemingly minor differences are very difficult to detect.  Patients 
suffering with CP however, do not suffer from this effect.  This can 
be because the area of their brain that controls configural pro-
cessing and face perception is impaired. These results were also 
found among the patients suffering from AP, and those patients 
exhibited an even easier time detecting the similar facial features 
between the right-side-up faces and the upside down ones than 
the CP patients (Behrmann, Avidan, 2005).
Congenital Prosopagnosia:  
The Part-Whole Effect
Impairments in configural processing may affect other visual stim-
uli as well. Recognition of faces depends on the spatial relations 
between the components which need to be represented to dis-
tinguish between individuals.  Another experiment was conduct-
ed to in order to obtain data regarding configural impairment in 
other areas.  Five CP individuals and five controls were shown 
four compound letters at global and local levels. Two of the stimuli 
had identities that were consistent at the local and global level 
and two had identities that were inconsistent.  This means that 
a large letter is composed of smaller letters, and can either be 
categorized as consistent or inconsistent. A letter consistent at 
both global and local levels  would be a large letter H made up of 
small letter H’s, while an inconsistent letter would be a large letter 
H shaped by small letter S’s. 
CP individuals showed normal speed at recognizing and identifying 
the local letters, however they were extremely slow at deriving the 
global whole from the local elements. They were able to identify 
the small components, but had difficulty in reading the large let-
ter formed by the small parts. This can be another indication of 
a failure in representing the spatial elements of a display. This 
demonstrates that CP patients can usually identify or recognize 
individual aspects and features of a face, but cannot perceive the 
global picture and recognize the face (Behrmann, Avidan, 2005).
Another case study was performed to demonstrate a similar 
idea. Unlike most types of objects, faces are represented as a per-
ceptual whole, meaning that there are many individual features 
that come together to form one image of a face. Therefore, the 
recognition of a face is referred to as holistic or configural face 
processing. This raises the possibility that face recognition deficits 
in CP patients may result from abnormal holistic face processing. 
To test this theory, a performance test was conducted called the 
‘Part-Whole Effect’. A control group of 38 non-Prosopagnosiacs 
were selected along with 38 CP patients.  Participants were briefly 
shown a target face and then asked to choose which of  two 
images placed side by side was the target face that they had been 
shown.  This test was repeated with a picture of a specific facial 
feature instead of an entire face.  Both the control group and the 
CP patients demonstrated the ‘Part-Whole Effect’ (Avidan et. al. 
2011).
This refers to a greater ability to discriminate in the whole condi-
tion than in the part condition. Each group was slower to recog-
nize target features than a target face. Although both groups were 
affected, the CP group did have a lower average accuracy than the 
control group. Interestingly, this low accuracy for discriminating 
in the part condition varied based on the specific feature. The 
patients with CP were suffered from the ‘Part-Whole Effect’ only 
when the target features were the mouth, eyes, and nose. With all 
other facial features, they were able to identify the target features 
as accurately as they could identify a target face (Susilo, Duchaine, 
2013).
Congenital Prosopagnosia:  
Anatomical Implications
The ability to recognize faces is so important in humans that the 
brain appears to have an area solely devoted to that task, the fusi-
form gyrus.  The fusiform gyrus is positioned between two lobes 
and is therefore a part of the temporal and occipital lobes. This 
area is believed to comprise the core visual representation system 
for faces. Specifically, this core is attributed with recognition of 
facial features. The fusiform gyrus is also responsible for face se-
lectivity, meaning that it responds to images of faces more strongly 
than to any other objects.
In order to determine the functional relationship between the 
anatomy of the brain and facial perception, experiments have 
been performed utilizing fMRI technology. Brain imaging studies 
consistently find that the fusiform gyrus becomes active when 
people look at faces. Studies have also shown a strong correlation 
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between activity in this area and face recognition, leading scientists 
to believe that the fusiform gyrus performs essential functions for 
facial perception. 
Face selectivity and repetition suppression, both forms of neural 
processing, were measured using fMRI technology. Their relation-
ship to face recognition ability was then determined in a case 
study. A control group of 15 non-Prosopagnosiacs was selected 
along with a group of 15 CP patients. The CP group showed re-
duced face-selective responses than the control group. In addition, 
it was demonstrated by these studies and analyses that there is 
a correlation between high performance on tasks involving facial 
identity processing and fMRI face selectivity activity in the fusi-
form gyrus. This brain-behavior relationship is associated with be-
havioral factors relating to face identification. Further tests were 
performed that measured quantitatively the relationship between 
behavioral skill in facial recognition and fMRI test results. The tests 
and analyses that were performed successfully presented correla-
tions between the anatomy of the brain, specifically the fusiform 
gyrus, and facial recognition, selection, and perception. Despite 
this, the scientists who performed these studies admit that they 
would like to improve their approach to this research. This could 
be done in a variety of ways, including greater number of partic-
ipants, a greater number of behavioral measures performed by 
those participants, and a greater diversity of the behavioral mea-
sures. These improvements would help produce more accurate 
data regarding the brain-behavior relationship (Furl et. al., 2012).
Congenital Prosopagnosia:  
Behavioral and Social Implications
Face recognition plays an important role in social and behavioral 
cognition. Therefore, tests have been performed in an effort study 
face recognition abilities in CP patients. Specifically, scientists were 
interested in processing of facial stimuli with emotional valence 
and its differences from non-facial stimuli. This is important in 
order to understand the impact of emotional facial expression 
on the success of long-term memory. A group of 49 people were 
selected; 24 of them were CP patients and the rest were non-Pro-
sopagnosiacs. The participants in this study were shown a series 
of images including neutral faces, positive and negative faces, and 
building facades. The pictures were shown for 3.82 seconds each, 
and the participants were asked to perform certain tasks. For ex-
ample, for the faces, they had to determine the gender of the face. 
For the building facades, they had to decide whether it was a pub-
lic building or a private one. The reaction times were studied, and 
there was a slightly lower performance by the CP patients than by 
the non-prosopagnosiacs. Interestingly, the slow response by the 
CP patients was only present with the images involving faces; for 
the non-face stimuli (i.e. the building facades) the CP patients had 
a quicker response time than the control participants. 
Once the responses were analyzed, voxel-based morphometry 
was used to relate anatomical differences to memory success. 
This revealed that CP patients had a lower grey matter density. 
This low density spanned a variety of areas, including the right 
middle temporal gyrus and the left precentral gyrus, which is as-
sociated with the Brodmann area. The scientists then used fMRI 
data to compare the face processing of the CP patients and the 
control participants. There were three major areas of the brain 
that correlated with the decreased face recognition activities of 
the CP patients. These areas are the left fusiform gyrus, the right 
lateral occipital complex in the core face processing area, and the 
right DLPFC. 
This data conclusively determined that CP patients have impaired 
long-term memory for faces, and for complex visual stimuli as 
well, although impaired memory is more severe with regards to 
faces as opposed to buildings (Dinkelacker et. al., 2010).
Background on Acquired Prosopagnosia
Acquired Prosopagnosia is a neurological syndrome which does 
not allow a person to recognize faces as a result of brain injury. 
This is in contrast to CP patients who have never had the ex-
perience of face recognition.  Patients with AP can have many 
different types of lesions which cause their acquisition of this 
disease. Research has shown that the most common injury to 
the brain that results in AP is damage in the inferior or medial 
occipito-temporal cortex. This is not surprising, as the core area 
for face processing is found in that region. The core is comprised 
of the fusiform gyrus, also called the fusiform face area (FFA), as 
mentioned above, as well as the occipital face area (OFA) and the 
posterior superior temporal sulcus (pSTS). 
The exact relationship between damage to each of these areas and 
the acquisition of AP is not very clear, but it has been proven that 
most cases of AP do result from injury to these areas. As is the 
case with many other acquired diseases, there are a multitude of 
possible injuries that can act as the causing factor. Therefore, it is 
difficult to determine what the extent of damage in Prosopagnosia 
patients is in these specific areas. For example, in the case of a par-
ticular patient with AP, it was determined that Prosopagnosia was 
caused by a right hemisphere lesion to the inferior occipital gyrus. 
As a result, there was no activity in the occipital face area, and the 
patient became unable to carry out face recognition. However, 
there was still activation of the right fusiform face area, containing 
the fusiform gyrus, and the pSTS. This phenomenon is hard to 
explain according to the current understanding of the hierarchical 
view of face perception. This means that a healthy human brain 
may be able to form direct pathways to bypass activation in the 
OFA, as opposed to a hierarchical pathway (Prieto et. al., 2011).
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Acquired Prosopagnosia:  
The N170/M170 Effect
According to the recently discovered view of branched pathways 
involved in face recognition, there should be an early onset time 
to preferential activation to faces. This activation time should not 
be dependent at all on the integrity of the OFA. In order to test 
the accuracy of this statement, researchers endeavored to deter-
mine the time course of brain activation in these areas in both 
healthy people and in those with AP. Using electroencephalogra-
phy and magneto-encephalography, the N170 was identified. This 
is a potential of negative polarity on the human scalp in the oc-
cipito-temporal area. The negative polarity appears between 130 
and 170 ms after the presentation of the stimulus (i.e. the vision 
of a face) and continues to increase in amplitude when a face is 
presented along with another object. This is a marker of the first 
electrophysiological response to faces by the brain and is referred 
to as the ‘N170/M170 Effect’. 
Researchers are not sure which areas of the brain are the sources 
of this neural event, but they have identified the posterior and 
middle sections of the fusiform gyrus as primary contributors. A 
study was performed that reported the electromagnetic record-
ings on the scalp of patients with AP during stimulation by faces 
and other objects. During the course of this study, the researchers 
also wanted to prove definitively whether a lesion in the OFA 
prevents activation of the FFA or pSTS. This could be determined 
by testing whether early face-preferential responses, the N170/
M170, were observed for those areas. 
The patient that participated in this study had extensive brain 
damage and a severe case of AP. However, she also exhibited 
the N170 amplitude increase as a response to faces compared 
to non-face stimuli (i.e. other objects). These results and others 
demonstrate that the deformations in the patient’s skull and scalp 
caused by her injuries, as well as the lesions in her cortex, did 
not affect her N170. When presented with a face and other ob-
ject, a larger response was measured via neuroimaging studied in 
the fusiform gyrus and pSTS. In addition, fMRI data of this patient 
appears similar to that of healthy people. This information is un-
derstood when presented along with the electromagnetic findings 
of this study. They demonstrate that the patient’s brain is able to 
differentiate between faces and other objects within 200 ms of 
seeing the image. This response time is as early as that of normal 
observers. Therefore, this confirms that the N170 face effect is 
related to the initial reaction to a stimulus, to the activation of 
a generic face representation. However, the patient’s difficulty in 
recognizing faces lies in individualizing faces. This would mean that 
the electrophysiological response to identical faces would be the 
same as the response to different faces. When healthy people are 
presented with subsequent images of the same face, the amplitude 
of the N170 is reduced when compared to the amplitude when 
shown different faces one after another. However, in a patient with 
AP, the amplitude of N170 remains the same irrelevant of the 
faces being shown. 
These results also demonstrate that the OFA is not involved, or 
not essential, in generating the N170. According to fMRI data alone, 
the FFA, the OFA, and the pSTS are all involved in preferential ac-
tivation to faces. However, the electrophysiological findings of the 
N170/M170 help explain the relationship between the activation 
of these brain regions and face recognition. Because the patient 
in this study exhibited normal N170/M170 amplitude despite her 
lesion in the OFA, that area can be viewed as unessential for gen-
erating the N170/M170 increases. This supports other claims that 
have hypothesized that at least two of these three areas must re-
main functionally intact in order to generate the N170 face effect. 
Despite these positive findings, the researchers caution that some 
inconsistencies arose during this study. For example, despite the 
fact that the N170 face effect is possible without OFA activation, 
there is evidence of OFA contribution to the generation of N170/
M170 in a non-Prosopagnosiac brain. Therefore, more research 
must be devoted to understanding the relationship between OFA 
activity and N170 generation (Prieto et. al., 2011).
Acquired Prosopagnosia:  
Residual Function
The three major areas of the brain that relate to face recogni-
tion are the FFA, the OFA, and the pSTS, as previously discussed. 
Within these regions, many aspects of face recognition take place. 
For example, perception of facial identity is linked to the fusiform 
gyrus, while initial perception of facial structures is linked to the 
OFA, and perception of facial expression is linked to the pSTS. 
These divisions of activity have been decided based on anatomic 
models but they may not be completely accurate. Therefore, it is 
interesting to study the surviving face-selective regions in patient 
with AP (Sorger et. al. 2007).
A study was performed using fMRI technology to assess the 
specific functions of cortical regions. The researchers set out 
to determine whether patients with AP exhibited any residual 
sensitivity to facial identity or facial expression in their surviving 
face-selective regions. Three patients with AP were involved in this 
study, two of whom had uninjured fusiform gyrii. Only one similar 
study had ever been performed and in that case, the fMRI data 
on the AP patient found that residual sensitivity to facial identity 
changes were present in an object-selective region of the ventral 
lateral occipital cortex. This is not the expected area; one would 
assume that the residual activity would take place in the fusiform 
gyrus area that was undamaged and therefore functionally intact. 
However, the two patients with intact fusiform gyrii involved in 
this study exhibited residual sensitivity to facial identity in the fu-
siform gyrus, consistent with its role in identity processing. This 
study successfully demonstrated that there is residual activity in 
the surviving face-selective regions of patients with AP. However, 
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because each patient’s injuries are different, and because of the 
small group of patients involved in this study, it is difficult to deter-
mine the overall accuracy of the study (Fox et. al., 2013).
Conclusion
This review has gathered much research and information, con-
cerning the anatomical, behavioral, and neurological aspects of 
Prosopagnosia. However, this disorder is extremely complex. 
Each individual with Congenital Prosopagnosia was born with 
their specific brain malfunction and the individuals with Acquried 
Prosopagnosia have   different brain lesions and damage.  As a 
result, it has become extremely difficult to understand the exact 
causes and results of Prosopagnoisa due to the specificity of this 
disorder. Research is continuing, however, to try and improve the 
understanding and the causes, along with an attempt to find a cure 
for the individuals with Prosopagnosia. 
Abbreviations
CP Congenital Prosopagnosia
AP  Acquired Prosopagnosia
DP Developmental Prosopagnosia
OFA Occipital Face Area
pSTS Posterior Superior Temporal Sulcus
fMRI (functional) Magnetic Resonance Imaging
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Introduction
Damage to DNA happens on a regular basis due to normal metab-
olism mishaps and external triggers. DNA breaks are categorized 
into two types: double strand and single strand. The healthy body 
has DNA repair pathways in place to repair both kinds of breaks. 
Both the Homologous Repair pathway and the Non-homologous 
End Joining repair pathway work to repair double strand breaks. 
The Base Excision repair pathway repairs single strand breaks. As 
long as there is damaged DNA in a cell, the cycle should be stopped, 
preventing the cell from dividing. If the damage cannot be repaired, 
the cell has systems in place to initiate apoptosis.  This paper ex-
plores the possibility of taking advantage of the systems in place to 
initiate apoptosis as a method of killing out tumorous cells.
Methods
The Touro database and PubMed.gov were used to find articles 
and original research regarding PARP inhibition in genetic cancers 
as well as cancers resulting from Homologous Recombination de-
ficiencies. Articles referenced in the articles found on the above 
mentioned databases were used as well.
Double Strand Break Repair Pathways
Although both the Homologous Recombination (HR) and Non-
homologous End Joining (NHEJ) repair pathways work to repair 
double strand breaks, the HR repair pathway is a much more 
reliable pathway. The HR pathway uses a sister chromatid as a 
template to repair the damage, which allows the repair to be ex-
tremely precise. Because sister chromatids are only available in 
the S and G2 phases of the cell cycle, HR occurs at those points 
in the cycle. NHEJ is a less complex process which does not re-
quire a template; the two broken ends are joined by ligation, a less 
precise process which often results in insertion or deletion of 
nucleotides (Murphy, 2010). (Figure 1)
The BRCA Gene: A Tumor Suppressor
The BRCA gene functions as a tumor suppressor gene, a catego-
ry of genes which repress the cell cycle and promote apoptosis. 
Tumor suppressor genes are in place to prevent damaged DNA 
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Figure1
Homologous recombination repair: A DNA lesion is recognized by the 
MRN (MRE11–RAD50–NBS1) complex, which is recruited to the DSB to 
generate single-stranded DNA by resection (see the figure; right panel). The 
single-stranded ends are bound by replication protein A (RPA), RAD51 and 
RAD52 and can subsequently invade the homologous template, creating 
a D-loop and a Holliday junction, to prime DNA synthesis and to copy and 
ultimately restore genetic information that was disrupted by the DSB.
HR: Homologous Recombination, NHEJ: Non-homologous End Joining
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from replicating and integrating into the genome.  The most estab-
lished role of the BRCA gene is its regulation of the Homologous 
Repair pathway. Cells with mutations in the BRCA gene thus lead 
the cell along the more error prone NHEJ pathway, causing an 
accumulation of chromosomal abnormalities and instability, which 
contributes to tumorigenesis. Mutations in the BRCA gene have 
been shown to cause a significant increase in the probability of 
developing tumors of the breast and ovaries. Breast cancer re-
sulting from a BRCA mutation, however, is unique in the sense 
that only the tumor cells are deficient in the HR repair pathway. 
Healthy cells have fully responsive repair pathways. This allows 
treatment targeting this deficiency to be specific only to tumor 
cells  (Murphy, 2010).
The Role of the PARP Enzyme in Single  
Strand Repair
The PARP enzymes’ main function is to initiate the Base Excision 
Repair pathway by recruiting specific proteins to the site of single 
strand DNA breaks; once the proteins are recruited, the PARPs 
are released and the resultant protein complex does the actual 
repair work. After initially binding to the DNA using its zinc fin-
ger domains, the PARP begins to transfer ADP ribose units from 
NAD+ to a variety of acceptor proteins, thus creating a negative 
charge which recruits the enzymes necessary for base excision 
repair (Drew, Calvert, 2008).  PARP inhibitors work either by trap-
ping the PARP on the DNA, preventing the protein complex from 
beginning its repair work, or by actually inhibiting the enzymatic 
activity.  Without PARP to initiate the Base Excision Repair pro-
cess, the single strand breaks accumulate and eventually develop 
into double strand breaks. (Figure 2)
Inhibition of the PARP Enzyme in BRCA 
Deficient cells is Synthetically Lethal
Inhibition of PARP causes an increase in DNA single strand breaks, 
which eventually evolve into double strand breaks at the site of 
the original damage. Cells with a functional BRCA network can 
respond to the inhibition of PARP through the use of the double 
strand repair pathways. Cells with deficient BRCA genes, however, 
are unable to properly respond to inhibition of PARP, leaving the 
double strand breaks without a reliable repair method, causing 
the two deficiencies to become a synthetically lethal combination 
(Warrener, et al., 2012).  Synthetic lethality is a condition by which 
deletion or inactivation of only one of two genes would not cause 
cell death, but deletion or inactivation of both of them is lethal 
(Reinbolt, 2013).  Thus, the inhibition of PARP in healthy cells is not 
necessarily lethal because the double strand break repair pathways 
can kick in to repair the damage. When paired with homologous 
repair deficiencies, however, the inhibition of PARP has proven to 
Figure 2: 
PARP: Poly-ADP Ribose Polymerase                   (intechopen.com)
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be lethal, because there are no efficient repair pathways for single 
or double strand damage. With no repair pathways in place, the 
cell is unable to maintain a stable cell cycle and should eventu-
ally undergo apoptosis. Inhibition of the PARP enzyme in tumor 
cells resulting from homologous repair deficiencies inhibits single 
strand repair mechanisms, initiating a selectively lethal response 
in the tumor cells, allowing for effective and targeted treatment.
Proteins Involved in the HR Pathway
Homologous recombination is a pathway which involves many dif-
ferent proteins. Identifying the roles these proteins play is a pos-
sible way of determining a biomarker to predict if tumor cells will 
respond to PARP inhibition. RAD51 is a protein which has been 
found to co-localize with BRCA2, which is suggestive of the inter-
connected roles they each play in homologous recombination. The 
HR pathway is initiated in either the S or G2 phases of the cell 
cycle by a double strand break. The broken ends then need to be 
resected to expose 3’ single stranded DNA tails, which need to 
be loaded with RAD51 in order to invade the identical homolo-
gous strand of the sister chromatid and form new identical DNA 
(Golmard, et al., 2013). BRCA2 has been shown to have binding 
sites for both DNA and RAD51 and thus facilitates the localiza-
tion and binding of RAD51 to the single strand DNA. Without 
the aid of BRCA2, the RAD51 is unable to bind to the DNA and 
the HR repair is unable to proceed (Murphy, 2010). BRCA1 is also 
involved in initiating double strand repair by playing an active role 
in resecting the broken DNA.
Cyclin-dependent kinases serve as regulators of the HR pathway 
through their roles in phosphorylation. They can phosphorylate 
BRCA2 at the RAD51 binding domain and thereby block the bind-
ing of DNA and RAD51. This decreases the rate of HR, and is 
meant to occur when the cell is exiting the G2 phase of the cycle, 
and HR can no longer occur. They also phosphorylate the protein 
CtIP, causing it to bind to a BRCA1 domain, which then becomes 
activated and is responsible for the resection of the broken strand 
of DNA to expose a 3’ tail, initiating the entire HR pathway.  Cells 
Figure 3:
HR: Homologous Repair, BER: Base Excision Repair                    (intechopen.com)
Figure 4: 
             (Google Images)
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without CtIP have been shown to have defects in the HR pathway, 
which is indicative of the involved role it plays in Homologous 
Recombination (Murphy, 2010).
ATM is a kinase involved in phosphorylating many proteins in-
volved in DNA repair and cell cycle check points. Cell cycle 
checkpoints are in place to ensure that there is no damaged DNA 
before the cell moves into the next phase. (Dujka, et al., 2010) 
Studies have been done to determine if lack of ATM induces sen-
sitivity to PARP inhibition, due to the lack of yet another DNA 
repair mechanism. ATM was genetically repressed in breast cancer 
cells which were then treated with Olaparib, a PARP inhibitor. The 
results were compared with a control group of breast cancer cells 
with active ATM. The control group cells got stuck at the G2/M 
checkpoint, but only the ATM depleted cells actually initiated 
apoptosis (Mantani, et al., 2013). These results indicate that ATM 
deficiency is not necessary for response to PARP inhibition but it 
does enhance the overall response greatly.  Deactivating ATM in 
a cell is a possible way of increasing the response it will have to 
PARP inhibition.
P53 is a tumor suppressor protein which is activated in response 
to DNA damage. P53 is normally held inactive by the mdm2 com-
plex, which it is bound to. In response to DNA damage, p53 dis-
associates from mdm2, and binds to the damaged DNA (Clegg, 
et al., 2012). Once activated, p53 activates p21, which then inhib-
its CDK2, a complex important in transitioning in the cell cycle 
(Zhao, et al., 2012). The cell cycle is then stopped, giving time for 
the proper repair proteins to be recruited to repair the damage. If 
the damage is repaired, then p53 is deactivated and the cell cycle 
continues. If the damage cannot be repaired, p53 initiates apop-
tosis. It has been found that p53 is somewhat regulated by the 
BRCA gene, implying that a mutation in BRCA will cause a similar 
deficiency in p53 (Murphy, 2010). This correlation explains why 
BRCA mutated cells are prone to becoming tumorous; the tumor 
suppression system regulated by p53 is not fully responsive, and 
is unable to properly respond to the unrepaired DNA damage.
Proteins as a Biomarker to Determine 
Sensitivity to PARP Inhibition
Identifying if cells are deficient in proteins involved in HR, such as 
RAD51, CtIP, ATM,  CDK’s and P53 can be a method of determin-
ing if a tumorous cell will respond to PARP inhibition. In addition, 
inducing mutations in these proteins and other proteins involved 
in DNA repair can be a way to prompt sensitivity to PARP inhi-
bition, even in cells that are not necessarily deficient in BRCA 
(Reinbolt, 2013).
Discussions
Trial experiments have been done to study the most effective way 
to take advantage of the synthetically lethal relationship between 
PARP inhibition and BRCA gene mutations. Different inhibitors 
have been identified and tested in varying doses. Various side ef-
fects have been identified, and the timing of the therapy has been 
experimented with. It is questionable whether to use PARP inhibi-
tion as a single agent or as an enhancing agent to other treatment 
options.
PARP inhibition has been shown to enhance the effects of DNA 
damaging agents, such as ionizing radiation and chemotherapy 
.The principle driving the success of  radiation therapy, for exam-
ple, is that oxidizing free radicals are induced to produce single 
and double strand breaks, prompting the tumorous cells to ini-
tiate apoptosis. (Abolfath, 2013) The role PARP plays in repairing 
DNA damage is a potential resistance mechanism to the desired 
effect of the radiation. Thus inhibition of the PARP enzymes is not 
only allowing the radiation to produce the desired results, but it 
enhances the effects by creating even more breaks (Basu, et al., 
2012).
Zinc deficiency and arsenic as potential PARP 
inhibitors
The zinc finger domains on PARP are what allow it to bind to 
DNA, beginning the whole Base Excision Repair process. Without 
being bound to DNA, PARP is essentially useless. Thus a deficiency 
in zinc ultimately leads to PARP inhibition due to the resultant 
inability of the PARP to bind to DNA. Research has also shown 
that arsenic can bind to the zinc finger domain in place of zinc, 
which changes the zinc finger structure, also preventing it from 
binding to DNA and causing it to lose all functionality (Sun, et al., 
2014). Practically, zinc levels can play a dual role: they are a pos-
sible biomarker to determine cell sensitivity to PARP inhibition 
and depletion of the metal is a method of inducing the inhibition. 
Arsenic, as well, although via a different mechanism than the oth-
ers, is considered to be a PARP inhibitor.
Olaparib as a monotherapy in BRCA1/2 
mutation associated breast cancers
In a study done in 2008, Olaparib, a PARP inhibitor taken orally, 
was administered to a group of women all possessing mutations in 
BRCA1 or BRCA2 genes. Olaparib was taken as a monotherapy, 
but all the patients had been given at least one chemotherapy 
regimen earlier. The study had 2 cohorts, the first was 400 mg 
of Olaparib, which was established to be the maximum tolera-
ble dose, taken twice daily. The second was 100 mg of Olaparib, 
also taken twice daily. Both study schedules lasted for 168 days. 
In the first cohort, 41% of the patients achieved the objective re-
sponse, with 4% achieving a complete response and 37% achieving 
a partial response. Forty four percent still had stable disease and 
15% had progressive disease. The second cohort had only 22% 
who achieved the objective response, with no patients achieving a 
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complete response. Forty four percent still had stable disease and 
33% had progressive disease (Tutt, et al., 2010). The results of this 
trial show definite response of tumor cells to Olaparib. The higher 
dosage produced better results compared to the lower dosage, 
implying an enhanced response when the dosage is raised.
Olaparib in combination with Paclitaxel
Triple negative breast cancer, TNBC, is defined by lack of recep-
tors for estrogen, progesterone, and human epithelial growth 
factor, and responds to few treatment options. TNBC has been 
shown to share similarities with BRCA1 associated breast can-
cers, (Nowsheen, et al., 2012) and a study was done in TNBC pa-
tients to determine the effect of combining PARP inhibition with 
Paclitaxel, a chemotherapy agent which stabilizes microtubules. 
The combined effect should prevent them from breaking down 
during cell division, causing the cell cycle to be stopped and apop-
tosis to be initiated. Patients received 200 mg of Olaparib twice 
daily and 90 mg of paclitaxel once a week for 6-10 28 day cycles. 
There was a greater than expected occurrence of neutropenia, 
a decrease in neutrophils which are responsible for destroying 
bacteria, within the first two cycles, a side effect also found in 
other studies done testing the combination of PARP inhibition 
with chemotherapy agents. Neutropenia is common side effect 
of Paclitaxel, but its occurrence increased significantly when com-
bined with PARP inhibition. At the point which patients were ex-
periencing neutropenia of grade 2 or higher, PARP inhibition was 
maintained, Paclitaxel administration was stopped and G-CSF was 
administered until the absolute neutrophil count (ANC) went up. 
If the absolute neutrophil count went up, Paclitaxel was contin-
ued, if it did not paclitaxel was discontinued. Although the rate 
of neutropenia occurrence increased, up to 40% of patients in 
the study showed partial response to the combined treatment, 
a greater response than has been seen with either treatment on 
its own (Dent, et al., 2013). Research is being done to understand 
the molecular reasoning of the increased neutropenia occurrence. 
Studies are also determining the best treatment schedule to min-
imize the side effects and maximize results.
Niraparib as a monotherapy in BRCA 
mutation carriers and sporadic cancers
Niraparib is also an oral PARP inhibitor and it has been studied as a 
monotherapy not only in carriers of the BRCA mutation carriers, 
but in patients with sporadic high grade serous ovarian cancer as 
well, which has a high prevalence of Homologous Recombination 
dysfunction. The study experimented with escalating doses to 
determine the maximum tolerable dose, which was found to be 
300 mg, taken twice daily. Thrombocytopenia and neutropenia 
presented as side effects but were easily controlled with dose 
reductions. Results of this study showed that greater response 
was seen in cells sensitive to platinum, a common base in chemo-
therapy agents, as opposed to platinum resistant cells. There was 
some response seen in platinum resistant cells, however, implying 
that the resistance mechanisms for PARP inhibition and platinum 
do not entirely overlap (Sandhu, et al., 2013).
The results of the above studies demonstrate the existence of a 
relationship between DNA damaging agents, such as chemothera-
py, and PARP inhibition. They also establish that PARP inhibition is 
not only effective in genetic tumors, but in other cancers involving 
homologous repair deficiencies. The relationship between PARP 
inhibition and platinum is logical, as they share a common goal of 
inducing DNA damage. The mechanisms of action, however, are 
clearly not the same because even the platinum resistant cells 
showed a response to PARP inhibition. Further understanding of 
the differences between the two and their resistance mechanisms 
must be understood in order to maximize the positive effect PARP 
inhibition can have on platinum resistant tumors. The response 
shown by the sporadic tumor cells shows promise in expanding 
PARP inhibition to include not only genetic cancers, but other 
cancers resulting from HR deficiencies. The key will be in finding a 
biomarker to determine which cells will respond positively.
Interferon Gamma as an enhancer of PARP 
inhibition
Because of the role they play in tumor suppression and cell cycle 
regulation, a study was done to determine if the interferon path-
way is affected by or involved in the synthetically lethal combina-
tion of PARP inhibition and BRCA gene mutations. The interferon 
pathway is a crucial response of the immune system to viruses, 
bacteria, and tumor cells. Interferons are proteins which have 
various functions, including regulation of the cell cycle, anti-viral 
responses, and apoptosis. Studies have suggested that interferons 
serve as regulators of the P53 gene, which is involved in the ini-
tiation of apoptosis (Takaoka, et al., 2003). H2AX is a gene which 
codes for the histone H2A, around which DNA gets wrapped, 
allowing for organized nucleosome formation. ATM is involved in 
the phosphorylation of H2A as a reaction to DNA double strand 
breaks in order to create space for the recruitment of repair pro-
teins.  Some of the interferons involved in cell cycle regulation and 
apoptosis are activated via an ATM dependent pathway, suggesting 
that an interconnected relationship exists between ATM, H2A, in-
terferons, P53, and PARP (Warrener, et al., 2012).
The above-mentioned study took BRCA silenced cells and stud-
ied the effect of PARP inhibition on interferon pathway activation. 
The PARP inhibited cells showed a three-fold increase in H2A 
phosphorylation, which is indicative of the increase in double 
strand breaks which results from the unrepaired single strand 
breaks. Enhanced activation of the interferon pathway was shown 
to correspond with the level of response to PARP inhibition, sug-
gesting that the role the pathway plays in promoting apoptosis 
serves as an enhancer to the effects of PARP inhibition. The study 
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also determined that when interferon gamma was administered 
together with the PARP inhibitors, the lethal response increased 
ten-fold, verifying the involvement of the interferon pathway 
in initiating apoptosis in PARP inhibited BRCA deficient cells 
(Warrener, et al., 2012).
Because of the role it plays in initiating double strand break repair, 
ATM depletion is another possible enhancer of PARP inhibition. 
When ATM is not active, H2A cannot be phosphorylated, which 
slows the response of the double strand break repair proteins. 
A decreased double strand repair response leads to more unre-
paired double strand breaks with no method of repairing them-
selves, thus increasing the amount of cells with sensitivity to PARP 
inhibition. This relationship was proven in a study which showed 
increased activation of the interferon pathway in ATM deficient 
cells, confirming both the dependency of successful PARP inhibi-
tion on lack of proper double strand repair mechanisms and the 
involvement of the interferon pathway in the apoptosis of PARP 
inhibited BRCA deficient cells (Warrener, et al., 2012).
Possible Resistance Mechanisms to  
PARP Inhibition
BRCA2 mutated cells have been found to develop resistance to 
platinum based chemotherapy due to the development of a sec-
ondary mutation which corrects the original mutation, restoring 
BRCA function (Wiedemeyer, et al., 2014). Cells harboring this 
resistance will also display resistance to PARP inhibition, whose 
success is dependent on a defective Homologous Recombination 
deficiency.  Not all platinum resistant tumor cells, however, devel-
op as a result of the secondary mutation; those cells are still ex-
pected to retain sensitivity to PARP inhibition (Weil, Chen, 2011).
P-gp, P-glycoprotein, is a protein of the cell membrane coded for 
by the ABCB1 gene that acts as a pump, pumping out foreign sub-
stances. This protein is involved in developing drug resistance, and 
has been shown to be the cause of resistance to some anti-can-
cer drugs. Up-regulation of the ABCB1 gene has been proven to 
demonstrate resistance to PARP inhibition due to the increased 
presence of P-gp. This resistance, however, has been counteracted 
with the administration of Tariquidar, a P-glycoprotein inhibitor 
(Weil, Chen, 2011).
53BP1 is a protein attached to DNA which is replaced by BRCA1 
during DNA damage repair. If 53BP1 is not replaced by BRCA1, 
the HR pathway becomes inhibited. If 53BP1 is absent in a cell, 
even in the case of a BRCA mutation, HR is still able to proceed 
because there is no 53BP1 which needs to be displaced. Only 
when 53BP1 is present and there is a BRCA mutation is HR ac-
tually impaired. An absence of 53BP1, therefore, is a possible re-
sistance mechanism to PARP inhibition, through its restoration of 
the HR pathway (Weil, Chen, 2011).
PARP inhibition as a proactive  
treatment option
 Until recently, BRCA1/BRCA2 mutation carriers have been faced 
with the disheartening knowledge that they will most likely de-
velop breast or ovarian cancer and the only proven preventative 
measure to be taken was prophylactic surgery. The evolution of 
PARP inhibition as a treatment option also introduces the possi-
bility of using PARP inhibition as a chemo-preventative measure 
for BRCA carriers who did not yet develop cancer, a much less 
drastic measure than prophylactic surgery. There have not been 
any conclusive studies done regarding using PARP inhibition as a 
preventative treatment, but the same mechanism it uses to selec-
tively kill tumor cells has been proposed as a way of preventing 
them from developing in the first place. Tumor cells resulting from 
BRCA deficiencies are the result of genetic alterations and defec-
tive DNA repair. Pre-exposing a BRCA mutation carrier to PARP 
inhibitors is a proposed method of killing the genetically altered 
cells, preventing them from developing into full blown tumors. It 
has also been proposed to use PARP inhibition as a means of 
preventing relapse, but no conclusive studies have been done at 
this point to investigate the possibility of success in this approach. 
Eventualities which must be considered in using PARP inhibition 
as a long term treatment option are the side effects as well as the 
danger in maintaining a defective repair pathway long term, espe-
cially in already high risk patients (Vinayek, Ford, 2010).
Conclusions
PARP inhibition shows promise on many different levels. The 
main factors to bear in mind in the development of treatment 
options are the specific target of only tumorous cells and minimal 
side effects, both of which are realized in PARP inhibition. The 
success of PARP inhibition expanded from genetically inherited 
breast cancers to other cancers resulting from DNA damage 
repair defects was demonstrated in clinical trials, which expands 
the network of patients eligible for treatment, making it easier 
to maintain the funding of research. PARP inhibition has elicited 
positive responses both as a mono-therapy and as an enhancer 
of other DNA damaging agents, such as chemotherapy and radia-
tion. The proteins involved in Homologous Recombination show 
great promise in functioning as predictive biomarkers of sensitivity 
to PARP inhibition. Further understanding of the roles they play 
will enable mutations of those proteins to be a method of in-
ducing and/or enhancing sensitivity to PARP inhibition. The hope 
that PARP inhibition presents not only as a treatment option but 
also as a precautionary alternative to prophylactic surgery makes 




PARP Poly ADP-ribose polymerase
HR Homologous Recombination
NHEJ Non-homologous End Joining
BER Base Excision Repair
ATM Ataxia Telangiectasia Mutated
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Introduction
A prosthetic is a device that substitutes for a body part or func-
tion that is defective or missing. The aim of a prosthetic is to re-
place the missing or damaged body part so perfectly that when a 
function is performed it is as if the original body part performed 
it. The Brain-Computer Interface (BCI) is a device that captures 
nerve signals that the brain produces when there is an intention 
to act, translates the signals through algorithms and then produces 
the action through a machine; thereby, circumventing the damaged 
limbs or missing body parts (Leuthardt et al., 2006). The system 
requires no muscular control and it can consequently liberate 
someone who is paralyzed, or it can create a prosthetic limb that 
acts as the original limb. The following paper will discuss BCI and 
TMR, explaining the basics of how each works, demonstrating 
how BCI is helpful for those with severe neural disorders and 
TMR assists amputees.
How BCI works
The BCI works through a basic four step process: signal acqui-
sition, signal processing, device output and operating protocol 
(Leuthardt et al., 2006). 
Signal acquisition is when the brain signals are recorded and am-
plified, by electrodes. The brain signals can be recorded through 
many methods: non-invasively through Electroencephalography 
(EEG) and invasively through Electrocorticography (ECog), Local 
Field Potentials (LFPs), and Single Units. The non-invasive EEG is 
the safest method because it records the signals through the scalp 
and no electrodes penetrate the brain. The EEG mainly measures 
sensorimotor rhythms, slow cortical potentials (SCPs), and P300 
potentials. The Sensorimotor cortex produces Mu (μ) rhythms 
which are typically 8-12 Hz and are found when the brain is not 
processing any new information, when it is “idling”, and Beta (β) 
rhythms, which are typically 18-26 Hz. The μ and β rhythms de-
crease in activity when there is movement or preparation for 
movement. However, more importantly, these rhythms occur even 
when there is only imagined movement and actual movements 
are not necessary for their activation. This makes them useful for 
the BCI because if someone imagines a movement, the μ and β 
rhythms will be activated and they can then activate the BCI with-
out muscular contractions (Leuthardt et al., 2006). SCPs are the 
lowest frequency signals recorded over the scalp. They are slow 
voltage changes that are generated in the cortex over .5-10 sec-
onds. Negative SCPs are associated with movement and cortical 
activation, while positive SCPs are associated with a reduction 
of movement and a reduction of cortical activity (Wolpaw et 
al., 2002). The SCPs are beneficial to the BCI because they are 
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Figure 1: 
This is a diagram of the BCI system. It shows the pathway of the signals 
(Leuthardt et al., 2006).
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directly associated with movement and cortical activity; therefore, 
when a movement is desired, the SCPs will be activated and can 
power the BCI. The P300 potentials, otherwise known as “odd-
ball” potentials are produced in the parietal cortex. The P300 is 
useful for the BCI because it differentiates the brain’s response 
to a significant stimulus from a routine stimulus (Leuthardt et al., 
2006). Additionally, unlike sensorimotor rhythms and SCPs, the 
P300 does not require any training of the user for control; it is 
a natural response to a preferred choice (Wolpaw et al., 2002). 
However, the system requires “training” to learn the user’s pref-
erences (Leuthardt et al, 2006). The EEG is the most commonly 
used signal acquisition system for the BCI as of now, because of 
its non-invasiveness (Leuthardt et al., 2006). However, the invasive 
methods are more accurate and specific in their recordings. 
The next level of recording is through ECog, which measures the 
signals from beneath the cranium. The ECog was at first assumed 
to be very similar to the EEG; however, this is not true. The ECog 
can detect signals to a much higher frequency; up until 200 Hz ver-
sus the EEG which measures only up until 40 Hz. when the elec-
trode is placed beneath the skull, as is done in the case of ECog 
electrodes, a higher frequency can be measured by the electrodes. 
This then allows for the recorded signals to be more precise and 
for there to be less other “distracting” signals (or a higher signal 
to noise ratio) (Leuthardt et al., 2006). Because ECogs are placed 
on the surface and do not actually penetrate the brain, they are 
considered more durable than the microelectrodes which mea-
sure LFPs, and Single Units (Schwartz et al., 2006). 
LFP’s are recorded through penetrating electrodes into the paren-
chyma. There the frequency can be measured typically from 300-
5000 Hz, but can record lower frequencies as well (Schwartz et 
al., 2006).  Single Units are recordings of individual neuron action 
potentials. The microelectrode is place deepest into the brain, and 
therefore, has the most accurate recordings. As a result, the use of 
Single Units can produce the most complicated actions. The fur-
ther into the brain that the electrode is placed, the more accurate 
the recordings of the signals will be.
After signal acquisition, the signals are digitized and then the more 
complicated process of signal processing occurs. Signal process-
ing is broken down into two components: feature extraction and 
signal translation (Wolpaw et al., 2002). Whenever there is signal 
acquisition, “noise”, otherwise known as artifacts, such as other 
brain signals or even muscular movements, will get mixed in and 
can even sometimes be thought of as the target signal. Therefore, 
feature extraction removes the desired signals from the total sig-
nal; it identifies the meaningful signal that was produced from the 
combination of all the signals together (Leuthardt et al., 2006). The 
purpose of this step is to identify the user’s intent, which is iden-
tified through the signals that are captured (Wolpaw et al., 2002). 
Different algorithms are used for feature extraction and artifact 
removal (Vallabhaneni et al., 2005). The algorithms adapt to the 
user on three levels: first the algorithm adapts to the signal fea-
tures that the user uses, for example if the user uses Mu rhythms, 
the algorithm will adapt to the user’s characteristic amplitude 
of Mu rhythms. The second adaption is periodic adjustments to 
spontaneous changes, because the user will produce more than 
just one kind of signal and one intensity level of that signal. The 
third adaption of an algorithm is to use the brain’s adaptive capaci-
ties. For example, as feedback occurs, hopefully the brain-comput-
er interface will improve, as each “gets used to each other”. This 
adaptive algorithm will assist the natural adaption of the brain by 
responding to the user with faster communication or other such 
“rewards” (Wolpaw et al., 2002). The more specific and exact the 
method for feature extraction and the better the adaptive algo-
rithms, the more exact the signal to noise ratio will be (Wolpaw 
et al., 2002). Signal translation converts the signal features (rhythm 
amplitudes or neuron firing rates) that were extracted, into device 
commands (Wolpaw et al., 2002). Translational algorithms are used 
for this conversion. The signals are then converted into a different 
kind of signal that is appropriate for the device that is being used. 
The signals are then sent to the device output section of the BCI 
which is the actual machine that produces the action. The action 
can be anything, whether it is controlling a cursor on a screen or 
the movement of a robotic arm (Leuthardt et al., 2006). The de-
vice output then translates the signals into physical control signals 
that can then power the device (Bashashati et al., 2007).
Figure 2: 
The different kinds of signal acquisition methods and their distances from 
the neurons. The black dot in each picture symbolizes the electrode and its 
distance from the neuron (Schwartz et al., 2006).
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 The operating protocol is how the device is controlled. How it is 
turned on and off, the feedback that is provided (such as the speed 
of the reactions), and the timing of the commands and actions. It 
is the basic operating manual of the prosthetic (Leuthardt et al., 
2006).
How Targeted Muscle Reinnervation Works
Another method for a natural acting prosthesis is through Targeted 
Muscle Reinnervation (TMR). The prosthetics that are used in TMR 
are called myoelectric prosthetics. A myoelectric prosthesis uses 
residual muscles after an amputation or other, unrelated muscles, 
to amplify and supply signals to move the prosthesis. After a con-
scious thought to move that muscle, sensors relay the information 
to a controller which then powers the motor to move the arm. A 
myoelectric prosthesis works well and almost intuitively for an am-
putation that is below the elbow because Electromyogram (EMG) 
signals or motor action potentials are recorded from the residual 
muscles that formerly powered the amputated arm. However, for 
a shoulder amputation (and for some transhumeral amputations), 
TMR is performed to make the control of the prosthesis more 
intuitive. TMR is a process that takes the residual nerves from an 
amputated limb, the nerves that had innervated the limb before 
the amputation. They then transfer the residual nerves to another 
muscle group that had also “worked with” the amputated limb, but 
is no longer functional because it is no longer attached to the limb. 
As a result, when there is a thought about movement of a part 
of the amputated limb, such as a finger, the reinnervated muscle 
will contract. Nerves that would innervate the “recipient” muscles 
are denervated so that the muscles can be reinnervated by the 
transferred nerves and there will not be as much interference. The 
reinnervated muscles serve as biological amplifiers of the nerve 
signals that are sent to the limb. Subcutaneous tissue is also re-
moved so that the myoelectric signals or the EMG signals can be 
recorded with relative ease. In this way TMR provides EMG con-
trol signals that are associated with the lost limb. This amplified, 
natural signal can then be used to power the prosthesis (Kuiken et 
al., 2007). After a signal is sent, through a mere thought or desire, 
to “lift a finger” or perform another action, electrodes record the 
EMG signals non-invasively, from the body surface. The electrodes 
are placed above the reinnervated muscles. Because the muscles 
amplify the signals, they are relatively easily recorded. The signals 
are then sent to a microprocessor chip that is in the prosthetic 
limb which interprets the signals and then powers the myoelectric 
arm to do what the signal was asking (Kuiken et al., 2007). 
In most of the cases TMR was performed on someone with a 
shoulder amputation; however, some were performed on trans-
humeral amputations as well. In the cases of a shoulder ampu-
tation, the musculocutaneous nerve, median nerve, radial nerve, 
and ulnar nerve were transferred to the pectoralis major, pec-
toralis minor, latissimus muscle, and serratus anterior (each case 
was slightly different, but overall these were the nerves and the 
Figure 3.
Diagram of the TMR process. The 3 transferred nerves are yellow, the electrodes are green (and are in reality placed on the body surface, but the diagram places 
them on the muscles because the body surface was removed for the diagram’s sake), and the microprocessor chip is in the prosthetic arm (Zhou et al., 2007).
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muscles they were transferred to). In the transhumeral cases, the 
median and distal radial nerves were transferred to the medial 
biceps and the brachialis or lateral triceps, respectively (Kuiken et 
al., 2009). Approximately three months after TMR surgery, muscle 
reinnervation was felt and at approximately five months, strong 
contractions could be seen and palpated (Kuiken et al., 2007). At 
this point the muscle contractions can be used to power the myo-
electric arm. 
The capture of the EMG signals is the signal acquisition step of 
the BCI. Therefore, next is the signal processing step. In the case 
of TMR, there are artifacts that must be eliminated; however, they 
come from a different source. Most of the artifacts that disturb 
the signal in TMR originate from electrocardiogram (ECG) signals. 
Nonetheless, it was found that the ECG interference does not 
disturb the accuracy of the signals significantly when a pattern rec-
ognition algorithm is used for signal processing (Zhou et al., 2007). 
The microprocessor chip then sends the signals to the part of the 
arm that the signal was intended for, it powers the arm, performs 
the motion that was requested, and turns the arm off.
When TMR is done on a leg, the process is very similar. The sci-
atic nerve is separated into its two smaller branches; tibial and 
common peroneal nerves. The tibial nerve was then sewn onto 
the semitendinosus muscle and the common peroneal nerve was 
sewn onto the long head of the biceps femoris. In this way, the re-
sidual nerves reinnervated the hamstring group. The process is the 
same as by the arm prosthetic; however, there are more obstacles 
or details that need to be perfected with the leg than with the 
arm. Such as, the leg is required to bear weight, maintain balance, 
have the ability to change ambulation modes, and other such func-
tions that the arm does not have to deal with. These functions are 
of vital importance and therefore, the error must be extremely 
low, because if not, the person is at risk of falling. Again a pattern 
recognition algorithm was used and it lowered the percent error 
from 12.9% to 2.2% (Hargrove et al., 2013).
Methods
Google Scholar and the PubMed database were used to search for 
information for this paper. Key words such as, “mind-controlled 
prosthetics” or “prosthetics controlled through thought” were 
used to find review articles. These articles gave a better idea of 
other key words to use, such as, “brain-computer interface” and 
“neural-machine interface” to find original papers. To find out 
about prosthetics for an amputee, key words like, “prosthetic 
limbs” were used and then “targeted muscle reinnervation” and 
“myoelectric prosthesis” were used to narrow down the search.
Discussion
Although each method for intuitive and natural control of pros-
thesis sounds like it can be a “perfect” prosthesis, each has its pros 
and cons which lends each prosthesis to a specific function. BCI 
is, in a technical sense, the perfect prosthesis because it captures 
the brain signal and performs the action through just a thought. 
However, there are some distinct issues that make it a useful pros-
thesis for someone with a severe neural disorder, but not for an 
amputee. One major concern is the problem and debate with sig-
nal acquisition. If the non-invasive EEG is used, the electrode is at 
a significant distance from the neurons because the scalp is 2-3 cm 
away from the cortex. Therefore, the signals recorded are limited 
and are not sufficiently effective to control a more complicated 
device, such as a device with more than two dimensional control 
(Schwartz et al., 2006). The information rate is only 5-25 bits/min-
ute, which is so slow that it can take several minutes to insert a 
word into a computer and the average time for a task to be com-
pleted (including signal acquisition, signal processing, and device 
output) was an approximately 6.20 seconds (Cheng et al., 2002). In 
a different study performed in 2004, the average time for a cursor 
to be moved was 1.9 seconds (which is a significant improvement 
from the study in 2002) and the movement precision or the preci-
sion in hitting the target was 92%. Although these percentages are 
a significant improvement, they can still be improved in accuracy 
and speed, through better adaptive algorithms and other such re-
forms (Wolpaw, McFarland, 2004). In addition, EEG signals can only 
detect lower frequencies, frequencies that are less than or equal 
to 40 Hz, which again limits the complexity of what the device can 
accomplish. Furthermore, if sensorimotor rhythms or SCPs are 
used, only two dimensional control or at times three dimensional 
control has been proven to be possible, such as the movement 
of a cursor on a screen or a basic movement of a robotic arm 
(separate from the body). These rhythms do not have the capa-
bility of performing more complicated functions. Regarding the 
P300 signals it has not yet been determined if gaze fixation is 
necessary for the system to work. In this case the BCI would only 
be of assistance to someone with the ability of eye movement. 
However, with the P300 signals, only a simple word processing 
program can be used (Leuthardt et al., 2006). An invasive method 
of signal acquisition (such as, LFPs or Single Units) would solve the 
above mentioned problems with EEG signal acquisition; however, 
then the problems with implanted electrodes arise. First of all, 
surgery is required to place the electrodes in the brain and that in 
itself causes the risk of damage to the brain. Furthermore, if Single 
Units are used, the microelectrodes are placed beneath the crani-
um, which automatically causes blood vessels to be broken in the 
process. This causes a reactive response from the brain; astrocytes 
and glial cells will begin to aggregate there and they then basically 
insulate the microelectrode until no signals can be recorded after 
a period of time, so signal acquisition can only occur for approx-
imately a year. Repeating the placement of the microelectrodes 
can cause scarring on the brain which can damage the person’s 
cognitive status and can further damage the person’s ability to 
function properly (Leuthardt et al., 2006).   Additionally, the elec-
trodes must remain stable for a long period of time and although 
algorithms can maintain the stability of an electrode, implanted 
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electrodes have a limited time that they are functional (Leuthardt 
et al., 2006). The ECog system was tested and it was successful in 
many instances. In a stroke patient, for the movement of a robotic 
arm, the signal acquisition method decoded 61% of the ECog sig-
nals, at least one second before the movement was performed by 
the participant’s functional arm. Selection of the movement that 
was desired (out of three different kinds of movements) was de-
tected with 69.2% accuracy (Yanagisawa et al., 2011). In patients 
with epilepsy, the ECog signals had classification rates of 70-90% in 
selection of letters from a spelling system (Birbaumer et al., 2014). 
Although the ECog’s success rates are good, they are not good 
enough. In the real world there is not so much room for error, 
especially with people who cannot help themselves if something 
goes wrong. Success rate with the patients with epilepsy was high; 
however, this is only with a simple word program. Additionally, the 
problems with implanted electrodes still exist. However, they do 
not exist to the extreme that they exist in Single Units because 
ECog electrodes are placed on top of the parenchyma and not 
within. Therefore, the electrodes do not invade the blood brain 
barrier, which causes the inflammatory response that occurs in 
Single Units. In addition to the problems with the electrodes, in 
the BCI system the signals are easily interfered with through slight 
distractions, such as an eye movement. Because of all the above 
mentioned issues with BCI, BCI is limited to people with severe 
neural disorders, to someone whose only method of communica-
tion with the world is through their brain, such as someone with 
high level quadriplegia (Ohnishi et al., 2007). The BCI system is 
satisfactory for someone with a severe neural disorder because 
it provides adequate two dimensional control and even at times 
three dimensional control of a robotic arm. However, for an am-
putee two dimensions is not enough. Consequently, the problem 
of creating a “perfect” prosthesis for an amputee still exists. To 
solve this problem, TMR was designed. TMR unites BCI and exist-
ing prosthetics to create the perfect prosthesis. TMR solves most 
of the problems with BCI; however, it does have its limitations as 
well. First of all, TMR solves the problems of non-invasive elec-
trodes because the signals are adequately biologically amplified 
through the muscle, and the signals are clear; however, they are 
not invasive and therefore overcome the problems of implanted 
electrodes as well. Compared to participants who used their own 
limbs as a control group in an experiment, the TMR patients per-
formed exceptionally well, as seen in Table 1.
The motion selection time for arm function was very good, it was 
an average of less than or equal to 220 milliseconds. For hand 
grasps it was also pretty good; the motion selection time was an 
average 380 milliseconds. The average speed of an action was be-
tween 90°/second to 120°/second. For elbow and wrist function, 
the success rates were high. For hand grasps, the success rate 
was high, but not as high, most probably because this requires 
more cognitive control of the user (Kuiken et al., 2009). The TMR 
system does not have as much interference with the signal acqui-
sition, with the exception of ECG signals which are easily taken 
care of through a pattern recognition algorithm. EMG classifica-
tion accuracy has been shown to be in the range of 90%-100% 
(Kuiken et al., 2009). Users of TMR prosthetics have reported 
intuitive use, as one participant stated “I just think about moving 
my hand and elbow and they move.” (Kuiken et al., 2007). TMR 
also provides multiple degrees of freedom. Until now, prosthetics 
Table 1 is showing the time it took for each motion to be selected and completed and the motion completion rate, compared to the control group which used 
their natural arms. (Kuiken et al., 2009)
Table 1.
Performance Metrics for Virtual Prosthesis Testing Protocol With a 5.0 Second Time Limit:
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required concentration for each movement to be performed, the 
myoelectric arm, without TMR performed, required a distinct 
thought about a muscle that was unrelated to the arm previously. 
Now one just thinks about moving his/her arm and it moves. In 
this way multiple degrees of freedom are possible, for example, 
now the shoulder can flex from -15° to 185° versus the conven-
tional prosthetic arm that used gravity to swing forward from 0° 
to 90° (Miller et al., 2008). Additionally, more than one motion 
can be performed at once with TMR, for example, when grasping 
an object the wrist can be rotated and the elbow extended in 
one motion versus each motion having to be thought about and 
performed separately; however, executing this was not desired 
by the participants because of the cognitive burden it entailed. 
With the TMR prosthesis, the participant was almost four times 
as fast than with the conventional prosthesis (Kuiken et al., 2007). 
The level of classification accuracy here was found to be very 
similar to participants “using” their real arms, 95-97% (Zhou et 
al., 2007).Nevertheless, TMR has limitations as well. First of all, 
TMR is a surgical procedure which has the same dangers that 
every surgery has; however, it is not brain surgery which con-
tains higher risks than other surgeries. Other side effects, such 
as, recurrence of phantom limb pain, permanent paralysis of the 
targeted muscles, and other painful neuromas are all risks of the 
TMR surgery (Kuiken et al., 2007). Secondly, TMR requires inten-
sive therapy after recovery from surgery to gain control of the 
prosthesis. TMR of the arm is much more developed and reliable 
as of now than the leg. The leg prosthesis is still not available for 
clinical use because of some withstanding difficulties; such as, the 
leg must be made quieter, lighter, and more reliable. Additionally, 
for the leg to work properly the EMG signals must be of very high 
clarity and the electrodes must remain in contact with the residual 
limb without causing discomfort to the wearer which is hard to 
accomplish while movement is occurring, and lastly, improvement 
of the pattern recognition algorithm is necessary (Hargrove et al., 
2013). Despite the limitations, TMR is in essence a perfect pros-
thesis for an amputee in that a signal meant directly for the limb 
is recorded through a residual muscle, processed and then used 
to power a prosthetic. In the case of a “locked in” patient, where 
TMR would not be of assistance, BCI is used. Through both BCI 
and TMR, prosthetics controlled through the mind is possible.
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Introduction
Since the middle of the nineteenth century, and perhaps even 
much earlier, mankind has been enthralled by the idea of space 
exploration. Back in 1865, Jules Verne envisioned space travel via 
a projectile shot at high speed out of a gigantic cannon in “From 
Earth to the Moon.”  In 1901, H.G. Wells envisioned space travel in 
a space “sphere” in “The First Men on the Moon.” This was closely 
followed by the very first science fiction movie: Mieles’ “A Trip to 
the Moon”, a silent movie based on Jules Verne’s earlier tale. 
Our unquenchable fascination with space travel continues until 
this very day. In fact, science fiction movies have been among the 
top grossing movies of all time. One only has to think of the six 
Star Wars movies (with more episodes coming), E.T., the numer-
ous Star Trek series and spinoffs and countless other hugely pop-
ular fictional productions. 
It is even possible that these many popular works of fiction depict-
ing the ease of future space travel may have enabled the reality of 
Nasa’s Project Mercury (1958 – 1963) and the subsequent Apollo 
space program (1961 - 1975). The dream of space exploration was 
further attained in the Skylab project (1973 - 1979), the Mir Space 
Station (1986 – 2001), in the International Space Station (assem-
bled starting from 1998; manned since 2000 - present) and the 
Space Shuttle Program (1981 - 2011). Our expectation of human 
space travel to alien worlds continues to this day, as scientists 
envision establishing a colony on Planet Mars. And Richard Branson 
of Virgin Atlantic has created Virgin “Galactic”, with plans to allow 
any person who has $250,000 to burn to experience space travel 
in the private sector. 
One thing in common in most of the previously mentioned works 
of fiction is that they all seem to imply that it will be pretty easy to 
get anywhere we want to go in the galaxy and even beyond. What 
the general public fails to understand, however, is the grim danger 
one faces every moment spent in space. Our bodies are just not 
created to exist in space. This paper reviews the research con-
ducted regarding the many things that can injure, maim or even 
kill those who dare to travel into space and recommends a safer 
alternative via robotics.
Discussion
From the very first moment, travel to space is fraught with acute 
danger to the human body. The launch of a rocket ship places 
unique strains on the body. On Earth, normal gravity conditions 
are termed “1-G”. As the rocket accelerates toward outer-space, 
however, the G-forces increase to 3-G or more.  An excessive 
G-force can have many deleterious effects on the body: The 
heart loses its ability to pump blood efficiently; circulation of the 
blood is impaired and oxygen is prevented from reaching the 
brain or other organs sufficiently. Consequently, a decrease in 
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consciousness may occur: Colors may begin to fade; vision may be 
limited to tunnel vision; and a total blackout may even occur. While 
the G-forces usually do not have such serious side-effects at take-
off, the effects can be much more severe upon reentry into the 
Earth’s atmosphere since the astronaut’s body is in a much more 
weakened state after a stay in space. (Harrison, 2001)
On Earth, the average human head weighs approximately ten 
pounds. However, if one experiences 3-G’s, the weight is tripled, 
placing enormous strain on the neck muscles which can result in 
severe neck pain. Therefore, astronauts are strapped into specially 
made seats which provide extra support to sensitive areas, such 
as the cervical and lumbar regions. Astronauts also sit facing the 
direction of acceleration, in order to spread out the forces evenly 
over the body. (Harrison, 2001)
 Upon reaching outer space, the hazards continue to multiply, but 
for the opposite reason. During takeoff, an astronaut is subject 
to the force of 3-Gs or more. On the other hand, in outer space 
there is minimal gravity which can also adversely affect many or-
gans of the body.
A major organ which degenerates during space travel is bone. 
Although bone may seem static, it is actually a dynamic, living tis-
sue. There are three types of cells found in bone dynamics: os-
teoblasts, osteoclasts and osteocytes. Osteoblasts are responsible 
for the formation of osteocytes; which are responsible for the 
deposition of bone. Simultaneously, osteoclasts resorb bone. This 
coordinated process of bone degeneration and the formation of 
new bone is intensified by mechanical stress. (Caetano-Lopes et 
al, 2007) Therefore, perhaps the most serious hazard faced by as-
tronauts is the effect of microgravity (very low forces of gravity) 
on the bones of their skeleton. 
 On Earth, the human skeleton is constantly working in opposition 
to the force of gravity. In outer space, however, the skeleton faces 
no mechanical load stimulus. As a result of this, the whole pro-
cess that is natural on Earth does not take place; bone resorption 
increases while bone formation remains constant or decreases; 
this causes a loss of bone density. Moreover, bone is made up 
significantly of calcium. The calcium freed from the bone migrates 
through the blood and the astronauts may therefore suffer from 
calcium kidney stones. (Smith et al, 2012) 
In addition to the lack of mechanical stimuli, there are several other 
causes of bone density loss. Microgravity reduces the bodily fluid 
pressure in the legs which may also contribute to bone density loss 
in the legs. (Carpenter et al, 2010) Astronauts often experience “gas-
troparesis”, a slowing of the gastric process. The bloated feeling from 
gastroparesis can cause a reduction in appetite.  (Harris et al, 1997) 
Consequently, if astronauts do not eat properly, they may suffer from 
a lack of nutrition which can also adversely affect bone density. 
A study was conducted in the year 2000 on the astronauts of the 
Mir Space Station, as well as on astronauts of the International 
Space Station (ISS). Researchers utilized a Dual-energy x-ray ab-
sorptiometry (a DEXA scan), which uses laser beams to mea-
sure bone density. The DEXA scan results showed a one percent 
decrease in bone density at the lumbar vertebrae. Furthermore, 
there was a greater loss in bone mass density at the hip (1-1.6%). 
This decrease in bone density can exacerbate the danger of bone 
fractures. (Carpenter et al, 2010)
Research conducted on astronauts of Skylab IV who stayed in 
space for eighty-four days analyzed the calcium loss, which indi-
cates bone loss, from their journey. Increasing amounts of calcium 
were secreted in the astronauts’ urine over the duration of the 
first 30 days, after which the loss leveled off. Additionally, the loss 
of calcium excreted in defecation continuously increased through-
out the journey. Overall, the astronauts lost about 200 mg of calci-
um a day throughout the mission. (Rambault et al,1979)
In order to combat bone mass loss by creating artificial mechan-
ical stress, astronauts exercise strapped down to a treadmill. The 
up-and-down movement of running may cause the body to build 
new bone. (Chang, 2014) Although exercise may prevent bone 
mass loss in most of the body, the bones found in the oral cavity 
cannot be helped by exercise. In fact, jiggling or clenching of the 
teeth does not cause bone strengthening, but rather bone deteri-
oration in that area. Furthermore, as opposed to long bone loss, 
which can possibly be reversed upon return to Earth, tooth loss 
cannot be. (Stenberg, 2001)
In order to prevent excessive bone loss in the oral cavity, as well 
as the long bones, astronauts are instructed to consume calcium 
and vitamin D supplements. However, even with the supplements, 
studies have still shown bone resorption markers in high levels. 
(Stenberg, 2001) 
The bone loss faced by astronauts is almost identical to that faced 
by sufferers of osteoporosis, a disease that affects many elder-
ly people on Earth. Therefore, drugs commonly used to combat 
osteoporosis, can be useful to prevent skeletal atrophy during a 
spaceflight. These drugs are known as bisphosphonates and are 
marketed under the names of Fosamax, Boniva, Actonel and other 
brands. They effectively prevent bone resorption, but do not help 
bone fracture healing. Therefore, anabolics, such as parathyroid 
hormone treatment may be advisable since it can improve frac-
ture healing. (Carpenter et al, 2010)
Aside from bone density loss, the spine itself is affected by micro-
gravity. The human spine is composed of vertebrae separated by 
intervertebral discs. On Earth, the discs are compressed due to 
the effects of gravity. In space, there is no compression and the 
vertebral column expands up to two inches causing astronauts to 
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actually “grow” taller in space. (Kramer, 2013) The spine’s expan-
sion, however, affects the muscles and ligaments and often causes 
backaches. (Carpenter et al, 2010) This height boost is only tem-
porary and reverses itself a few months after returning to Earth. 
Currently, astronauts on the ISS are studying the effects of mi-
crogravity on the spinal column using ultrasound scans. (Kramer, 
2013)
The lack of gravity also engenders a different problem in the 
human body. The body is composed of approximately sixty per-
cent water. Normally, gravity shifts majority of the water to the 
lower part of the body. In space, however, fluids are dispersed 
equally throughout the body, causing an irregularly high amount 
of liquid in the upper part of the body and lower than normal in 
the lower extremities. Therefore, astronauts’ faces appear puffy 
and their heads actually feel bloated. Internally, the brain is also 
subjected to higher pressure than normal, due to excessive ce-
rebrospinal fluid. (Chang, 2014) Within the first day in space, an 
astronaut may experience an upward shift of up to a liter of liquid 
volume from each leg. (White, 1998)
This upward shift of bodily fluids has both irritating effects and 
more serious consequences on the human body. The extra fluid 
in the head blocks the sinuses, causing what is known as “space 
sniffles.” Astronauts often have stuffed noses throughout their stay 
in space. (White, 1998) 
The upward fluid shift has other more serious ramifications: the 
body recognizes the excess fluids in the head and face, and re-
sponds by attempting to eliminate bodily fluids.  Therefore, blood 
plasma and red blood cell mass are reduced. As a result of the 
hemolysis or destroyed red blood cells, astronauts often suffer 
from anemia. Anemia is a condition characterized as the lack of 
erythrocytes or red blood cells which carry oxygen via hemoglo-
bin throughout the body. (De Santo et al, 2005)
A study was conducted on the astronauts of Gemini IV, who spent 
around 4 days in space and Gemini V where astronauts spent 7 
days in microgravity. Data indicated a decrease of red blood cell 
mass of 12.2% in Gemini IV and 20% in Gemini V. Plasma volume 
was reduced in Gemini IV by 8.3% and 6.75% in Gemini V. (De 
Santo et al, 2005)
Erythropoietin is a hormone that controls erythrocyte produc-
tion. Therefore, in order to combat the anemia that commonly 
occurs in microgravity, it would sensible to conduct studies on the 
usage of erythropoietin. (De Santo et al, 2005)
Another strange impact on the body after exposure to micro-
gravity is that the astronaut’s eyeballs become flattened. Scientists 
suppose this is yet another result of the excessive cerebrospinal 
fluid applying pressure to the back of the eyeballs. As a result of 
the flattened eyeballs, astronauts have reported difficulty seeing 
things up close while in space; a condition known commonly as 
farsightedness. (Kramer et al, 2012) 
In 2009, Dr. Michael R. Barratt and Dr. Robert B. Thirsk, both as-
tronauts and physicians, noted a difficulty seeing things up close 
during their six month stay in the ISS. Consequently, the doctors 
checked each other’s eyes and noticed inflammation in their optic 
nerves, and scarring on their retinas. NASA is still researching the 
long term effects of microgravity on the eye, and if the farsighted-
ness is a symptom of even more serious problems. (Chang, 2014)
Another study on astronaut vision problems seems to indicate 
that the fluid shift from the lower extremities to the upper body 
is not the sole cause of the vision problems experienced by many 
astronauts.  NASA examined urine and blood samples of twenty 
astronauts before, during and after their stay in space. The re-
searchers discovered that the astronauts who were experiencing 
vision problems also displayed lower folate levels preflight and 
consistently during the flight. This may explain why only certain 
astronauts face vision problems; the astronauts with a prior de-
ficiency in folate may be more likely to experience a change in 
eye anatomy and therefore vision changes. This is a theory which 
requires more study in order to be proven. (Zwart et al, 2012)
 It has been long noted that astronauts tend to get sick much 
more often during and after their spaceflight than normally. In 
fact, fifteen out of the twenty-nine astronauts who participated 
in the Apollo program became ill either during or right after their 
space flight. (Young, 2005) The University of California conducted 
a study on human immune cells, subjecting them to microgravity. 
The results proved that T-cells, a vital part of the human immune 
response, were not activated properly. Normally, when the body 
discovers an invader, such as a virus or bacteria, it signals nine-
ty-nine genes to turn on which activate T-cells. However, the study 
found that ninety of the genes did not turn on in the absence of 
gravity. (Boonyaratanakornkit et al, 2005) 
Another major issue faced in space, is radiation and its effects 
on the body. The Earth is protected from excess radiation by a 
natural shield known as the atmosphere. The ozone layer, which is 
found in the stratosphere, absorbs much of the ultraviolet radia-
tion which emanates from the sun. There is also a magnetic field 
surrounding the Earth which deflects harmful rays. (Setlow, 2003) 
In space, where there is no atmosphere, radiation is free to travel. 
In fact, if an astronaut would stay in space for a year in a low 
orbiting space vehicle such as the ISS, he/she would receive ten 
times the amount of radiation that he/she would have received on 
Earth. And if a solar flare would occur, the radiation risk would be 
enormously multiplied. An event such as this happened in August 
of 1972, releasing in just one day one thousand times the radiation 
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that we are exposed to in an entire year on Earth. (White, 1998) 
The danger of radiation is that it can cause mutations in DNA, 
genetic material present in every cell of the body. DNA damage 
and mutations are often the first of many steps in the carcinogenic 
process. Therefore, astronauts have an increased risk for the de-
velopment of tumors and cancer over their lifetimes. In addition 
to cancer, alterations in the genetic code can cause infertility and 
sterility, birth defects and stillbirths. (Durante & Cucinotta, 2008)
There are some actions that can decrease the risk of space ra-
diation induced cancers. A diet rich in antioxidants, such as fruits 
and vegetables, may help prevent cancer. Vitamins A, C and E 
along with hormones, such as melatonin, superoxide dismutase 
and phytochemicals from plants such as green tea, are all effective 
at preventing tumors. Proper shielding on the spaceship, utilizing 
materials such as polyethylene, may protect astronauts from the 
radiation. (Durante & Cucinotta, 2008)
The cosmic rays of space can penetrate the spaceship as if there 
was no barrier and cause some interesting effects. When cosmic 
rays pass through the retina, they seem to cause the rods and 
cones, the photoreceptors of the eye, to be stimulated. Therefore, 
astronauts perceive flashes of light that aren’t actually there. This 
occurs even when they are sleeping, at approximately three min-
ute intervals. Furthermore, the rays can impact the electronic 
equipment such as laptops and cameras causing them to malfunc-
tion. (Atkinson, 2012)
Radiation found in space is different than that on Earth. Celestial 
radiation is composed of high energy protons and high energy nu-
clei; terrestrial radiation is made of Y-rays or X-rays. The different 
rays affect the body differently. Research based on Earth, such as 
studies of atomic bomb survivors, cannot be applied to astronauts 
exposed to space radiation. Therefore, it is imperative to conduct 
more studies on celestial radiation and its impact on the body. 
(Durante & Cucinotta, 2008)     
Another danger facing astronauts due to their exposure to high 
levels of radiation and high energy particles is the thickening of the 
ocular lens, a condition known as cataracts. A study was conduct-
ed on twenty-one former astronauts and/or cosmonauts, which 
compared the opacification of their lenses to a control group of 
approximately four hundred other people of the same age group. 
Using a Scheimpflug camera system, the study found that the 
opacity of the lenses in most of the astronauts and cosmonauts 
was noticeably increased compared with the control. (Rastegar et 
al, 2002)
On Earth, muscle is strengthened when the body acts against the 
gravitational pull. Therefore, when an astronaut travels to space, 
muscle atrophy can begin within five days, and muscles continue 
to degenerate during the entire stay in space. The degeneration 
increases the risk of muscles and ligaments tearing. Along with the 
weakening of muscles, astronauts have noted an increase in muscle 
twitches and a reduction in fine motor control. (Harrison, 2002) 
A study conducted at Brown University School of Medicine an-
alyzed the effects of space travel on muscle fibers. Researchers 
placed cultured muscle cells aboard the Space Shuttle for sev-
eral days. The researchers noted that while in space there was 
a decrease in protein synthesis, while protein decay levels re-
mained normal; naturally, this would result in significant muscle 
atrophy. When the muscle tissues were brought back to Earth, 
however, protein synthesis returned to normal levels. Predictably, 
the lack of gravity was found to be a major cause of decrease 
in protein synthesis. Interestingly, the scientists discovered other 
contributing factors to the muscle attenuation, such as reduced 
levels of growth hormone, anabolic steroids and glucocorticoids. 
(Vandenburgh et al, 1999)
As a result of this study, scientists delineated steps to be taken in 
order to avoid muscle atrophy as much as possible, as a result of 
space travel. First, it was recommended that astronauts exercise 
regularly in order to build muscle. However, exercise alone was 
not deemed effective enough. The study showed that injecting 
anabolic factors or growth hormones, along with the exercise 
program, would provide a far stronger defense against muscle de-
terioration. (Vandenburgh et al, 1999)
Research has shown that the lower extremities of the body suffer 
especially from microgravity. After six months on the ISS, even with 
an exercise program of treadmill, bicycling and weight lifting, crew 
members suffered a thirteen percent loss of calf muscle mass. A 
second study conducted on the ISS crew, proved that spaceflight 
caused a four to seven percent decrease in thigh muscle mass. 
Additionally, astronauts lost up to twenty-four percent muscle 
strength at the knee and four to twenty-two percent at the ankle. 
Finally, even elbow strength decreased from eight to seventeen 
percent. (Carpenter et al, 2010)
Cosmonauts Berezovou and Lebedev, who spent two hundred 
and eleven days on Mir, were impacted so strongly that they were 
not able to walk off of the spaceship. In fact, the cosmonauts were 
not able to walk for a week following their flight and needed mas-
sive physical therapy in order to return to their muscle tone level 
before the flight. (Harrison, 2002)
In microgravity, the positioning of the organs in the human body 
actually shifts. The diaphragm is elevated, as is the liver and the 
spleen. The heart is correspondingly shifted upward; therefore, a 
space physician would have to listen for heart beat in a different 
area of the chest wall than on Earth. (Harris et al, 1997)
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Microgravity also negatively impacts the proper functioning of the 
ear. The human ear is not only used for hearing, but serves an 
important purpose in assisting balance. The vestibular system is 
the primary system of the ear responsible for this. Deep in the 
inner ear is a pretzel-like structure known as the labyrinth. The 
labyrinth connects to the semicircular canals and otolithic organs, 
both important in achieving proper balance. The semicircular ca-
nals include three loops filled with liquid which convey to the 
brain when one’s head is rotating or moving from side to side. 
The otolithic organs are comprised of two liquid filled pouches; 
the brain uses these organs in order to determine the position 
of the body, such as: standing, sitting, walking, leaning back or lying 
down. These organs are extremely attuned to the effects of gravity. 
Therefore, when a person is in a microgravity environment, the 
vestibular system cannot function properly. This often results in 
space motion sickness (SMS); symptoms of SMS include imbalance, 
vomiting, stomach ache, fatigue and irritability. (White, 1998) 
Researchers studied the frequency and severity of SMS on astro-
nauts of the Space Shuttle. The study on eighty-five crew mem-
ber found that fifty-seven (67%) suffered SMS at various levels 
of severity. Twenty-six astronauts (30%) had a mild case of SMS, 
while twenty (24%) suffered moderately and eleven (13%) on a 
severe level. Fascinatingly, there was a disparity in the effect of SMS 
between men and women. There also seemed to be a significant 
decrease in SMS severity when an astronaut experienced a second 
spaceflight. (Davis et al, 1988)  Fortunately, most astronauts accli-
mate to microgravity and symptoms subside after the first few 
days in space. (White, 1998)
Although many people may be under the impression that the 
space program has had little impact on their personal lives, they 
couldn’t be farther from the truth. In fact, se College compiled 
a list of upward of one hundred discoveries or inventions as a 
result of the NASA space program that directly enhance the lives 
of the average individual. This list includes everything from micro-
computers to new food packaging techniques. Perhaps the most 
import impact is pertaining to health and medicine; NASA paved 
the way toward the inventions of ultrasound scanning, MRI, meth-
ods of bone analyses and ocular screening techniques, to name 
just a few. Astronaut Ron Garan has stated: “the ISS provides a 
unique environment for scientific discovery that simply cannot be 
duplicated on Earth… it is leading to countless improvements for 
life on Eearth… [and] enhances our understanding of the human 
body.”  (Garan, 2014) 
Conclusion
Although humans have traveled and lived in space, even for weeks 
at a time, outer space still remains an extraordinarily unforgiving 
and dangerous environment; an alien world that humans are not 
capable of adapting to. An unprotected human being accidentally 
exposed to the vacuum of space, would only be conscious for up 
to eleven seconds or possibly less. Consequently, the body would 
begin to suffer from paralysis, followed by convulsions, then fol-
lowed by paralysis again.  Then the water of the human tissues 
would change to water vapor due to the lack of pressure. This 
would subsequently cause the body to swell enormously, up to 
double its normal volume. Heart rate might rise initially, but then 
would rapidly fall. Arterial blood pressure would decrease and 
blood circulation would cease. (Parker & West, 1973) Undoubtedly, 
death would shortly follow.
There are some recorded cases of humans who managed to sur-
vive very short term exposure to a hard vacuum. In 1966, a tech-
nician in Houston was testing a space suit in a chamber that simu-
lated the vacuum of space. Due to a malfunction, he was exposed 
to the vacuum. In just seconds, he lost consciousness. Fortunately, 
he was rescued from the chamber within thirty seconds, and he 
survived. Scientists have experimented with animals, and discov-
ered that no creature has ever survived decompression if exposed 
longer than ninety seconds. (Roth, 1968)
Robots can do almost anything humans can do, but they do not 
require food, oxygen or sleep. Robots do not get space sniffles and 
do not experience SMS. Vision is not impaired by microgravity, nor 
can it be afflicted by cataracts. Robots cannot be afflicted by skel-
etal or bone atrophy. It is true that it takes a long time to trans-
mit directions to robots located huge distances away. But even if 
robotic space exploration is slower than human exploration of 
alien worlds, it is safe. Today, many researchers even feel that the 
Apollo project climaxing with Apollo 11’s humans on the moon 
was: “mainly a geopolitical stunt during the Cold War to show 
American technological superiority over Russia, with science pig-
gybacking on the ride.” (Mann, 2012)
The present research supports this argument.  The deadly risks 
of human space exploration way overshadow the benefits. The 
countless works of fiction depicting voyaging through space, dis-
covering new planets and establishing colonies should remain just 
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Introduction
Pancreatic cancer  is one of the worst forms of cancer that can 
develop in an individual.  A growing tumor in the pancreas can 
grow for fifteen years before it metastasizes, at which point it 
becomes symptomatic. It is a silent killer growing inside the body. 
Less than 1 % of patients diagnosed with pancreatic cancer sur-
vive even five years, with a median survival of four to six months 
(Warshaw, Fernandez-del Castillo, 1992). Pancreatic cancer is re-
sistant to traditional chemotherapy treatment and therefore even 
once the cancer is detected, the treatment currently available to 
patients is mildly effective at best (Michel, Gress, 2013). 
Surgery, as well has proved only mildly effective. Researchers 
found that less than 10% of patients survived five years after surgi-
cal removal of the tumors. This failure has been attributed to small 
amounts of cells that are left behind that prove to be lethal. In fact, 
28% of patients have been found to have circulating tumor cells in 
the blood and the prevalence increased with the cancer stage (van 
Heerden, et. al. 1981). This would indicate that surgery alone is not 
effective and other treatments should be sought.
Recently, a new chemotherapy (FOLFIRINOX) was proposed 
which showed promising signs, giving patients a longer survival 
time than that associated with the traditional chemotherapies. 
However that advantage didn’t translate into actually curing the 
disease, just prolonging the patients’ lives by a few months. In ad-
dition, this drug showed an increased toxicity, which limited its use 
to only the few patients that can tolerate it (Conroy, et. al. 2011).
It is therefore obvious that new approaches must be sought to-
wards defeating this cancer. Prolonging the lives of its victims is 
not an end goal. Rather, a way of ridding them of the disease al-
together is required. It is therefore obvious that new approaches 
must be sought. Recent research has shown promising results in 
the field of immunology which could indicate some new treat-
ment approaches geared towards eliminating this disease.
Adaptive immunological protection is provided to our bodies via 
two pathways. B cells provide extracellular or humoral immunity 
and create antibodies while T cells provide intracellular or cell 
mediated immunity. Both of these pathways are crucial in order 
for our bodies to be able to fight off even the “simplest” infections. 
If these systems are compromised, even a common cold can prove 
fatal as is evidenced by the HIV virus.
Innate immunity is provided by mechanical barriers such as skin 
and epithelial linings and cellular protection by macrophages, 
other phagocytes and natural killer cells. Macrophages phagocy-
tose antigens into a phogosome and upon receiving signals pro-
vided by certain cytokines, kill the antigens that are engulfed by 
combining the phagosome with a lysosome. The lysosome con-
tains toxic chemicals that can degrade the antigens. Natural killer 
cells respond to infected cells and destroy them before more cells 
become infected.
Adaptive immunity is provided primarily by B cells and T cells. B 
cells create a number of antigen receptors. Some of these receptors 
can be secreted as antibodies and others are attached to the cell 
surface and function as B cell antigen receptors. The first receptor 
that the B cell creates is the IgM receptor, which is closely followed 
by the IgD receptor. These receptors are very specific and can de-
tect sequences of polysaccharides as well as peptide antigens and 
respond to them. The B cells can then produce different antibodies 
depending on the nature of the antigen in order to better combat it. 
The other antibodies that they can produce are IgA, IgE, and IgG. IgA 
is produced in response to mucosal infections and has the ability to 
cross mucous membranes. IgE is primarily produced in response to 
allergens and activates mast cells to release histamine. IgG is one of 
the primary antibodies used to fight infection due to its utilization 
of many mechanisms to assist in destruction of pathogens. It can 
coat antigens (opsonization) in order to assist in their phagocytosis, 
as well as directly neutralizing them by binding to their surface.
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T cells are subdivided into helper T cells and cytotoxic T cells. 
These cells are distinguished by certain biochemical markers on 
their surface. The helper T cell has a CD-4 molecule on its surface, 
while the cytotoxic T cell has a CD-8 molecule on its surface. 
The CD-4 T cell is further subdivided into Th1 helper T cells and 
Th2 helper T cells. The Th1 helper T cell is supportive of a CD-8 
cytotoxic response and help the cytotoxic T cells lyse infected 
cells. However the Th2 helper T cell is not supportive of a CD-8 
cytotoxic response and promotes immune suppression. All T cells 
can only recognize antigen by their T cell receptors if the antigen 
is presented by other cells via a molecule called MHC (Major 
Histocompatibility Complex) which is present on the other cells. 
Certain cells are specialized towards presenting antigen to the T 
cells. This is accomplished by the cell engulfing the foreign material 
(phagocytosis), degrading it and presenting peptide fragments to 
the T cell. The cells that are specialized towards presenting antigen 
are known as antigen presenting cells. These can be dendritic cells, 
B cells and macrophages. Dendritic cells are especially proficient 
at antigen presentation therefore, the presence of mature dendrit-
ic cells is important in order to present the antigen to the T cells. 
The CD-4 helper T cells recognize antigen presented via MHC 
class II which is primarily found only on these specialized antigen 
presenting cells. On the other hand, the CD-8 cytotoxic T cells 
recognize antigen presented by MHC class I which is present on 
almost all cells of the body.
The amazing thing about the immune system is its diversity. 
Because of the various genes that code for the T cell receptors, 
the amount of combinations that the T cell can use is astronom-
ical. Therefore, not only can the receptors be incredibly specific, 
but there can also be a tremendous amount of diversity. The big 
problem that the T cells and the B cells face is how to “know” 
how to react to foreign antigen and not react to self-antigen and 
cause autoimmunity. Autoimmunity is when the immune system 
targets and starts killing the body’s own cells. The way that the 
body solves this problem is by negative selection. This consists 
of a rigorous test that T cells undergo in the Thymus and B cells 
undergo in the bone marrow during development. The cells are 
exposed to self-antigen. If they recognize self-antigen with high 
affinity they undergo apoptosis and are not permitted to mature. 
If however they recognize self-antigen with only low affinity, they 
are permitted to mature and perform their function. 
In addition to regulation at the T cell and B cell development stage, 
there are certain helper T cells that ensure that T cells do not 
react to self-antigen. These are known as regulatory T cells and 
help shut down the T cell response at the end of an adaptive im-
mune response and also ensure that T cells that escaped negative 
selection in the Thymus can be prevented from attacking healthy 
tissue and causing auto-immunity. There are also receptors on the 
T cells themselves that prevent auto-immunity. One of the pri-
mary receptors is the CTLA-4 receptor. When it is engaged, even 
if the T cell is recognizing antigen, the T cell is prevented from 
mounting a response (Abbas, et. al. 2012).
It has been thought since the 1950s that one of the functions of 
the immune system is to prevent the occurrence of cancer in the 
body. This theory is known as immune surveillance. This theory is 
supported by the high incidence of cancer in immune-compro-
mised hosts such as patients with HIV and AIDS (Goedert, et. al. 
1998) as well a high incidence of tumor formation among patients 
taking immunosuppressive medications (Sanchez, et. al. 2002). This 
would indicate that there is some role in the prevention of tu-
mors by the immune system. It has therefore been assumed that 
there must be some antigens that cancerous cells express that are 
recognized by the immune system. In fact many tumor antigens 
have been identified. In some cases the antigens are normal pro-
teins that are usually only present during a particular stage of the 
cell’s life but, because of the tumor are now present during other 
stages as well. They can also be normal proteins that are merely 
over expressed in the cancer cells. Other antigens that have been 
identified are mutated proteins that are present in the diseased 
cell. However, due to the fact that even immune-competent hosts 
have developed cancer, it would seem that the immune system is 
not highly adept at fighting these tumors. Can the immune system 
be induced to fight against pancreatic cancer?
Discussion
Samples of pancreatic tumors from 80 surgically resected tumors 
were studied for signs of immune cell presence, particularly  CD-4 
and CD-8 T- cells. Some patients had one and not the other while 
some had both or none. They noticed that from the patients that 
had both CD-8 and CD-4 T cell infiltration, the overall survival 
rate was much higher than those that were missing one or both of 
these cells. In addition it was apparent that the depth to which the 
cancerous cells were able to penetrate in the pancreas was much 
less for those patients with high levels of both CD-4 and CD-8 
T cells. It would seem that the presence of the T cells indicates 
that the T cells are suppressing the cancerous cells and preventing 
them from infiltrating further. The researchers thus concluded that 
a high level of T cells in the affected pancreas positively correlates 
to an increased survival rate (Fukunaga, et. al. 2004). 
What can be used to attract the T cells? Pancreatic cancer patients 
treated with Interferon alpha after undergoing surgery to remove 
part of the pancreas were studied. Interferon alpha is a cytokine 
produced by the body and is used in the immune response to 
infected cells. When a cell is infected it produces various cyto-
kines that cause downstream signaling. This downstream signaling 
refers to signals that the antigen presenting cells receive by these 
cytokines and increase the antigen presentation to the T cells. This 
is an obvious benefit because additional antigen presentation will 
lead to an increased T cell response. Introducing Interferon alpha 
in addition to the standard chemotherapy increased the length of 
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survival for pancreatic cancer patients. 88% percent of patients 
undergoing the interferon therapy were still alive after two years 
and 55% survived to the five year mark (Tables 1 and 2). This is 
a significant increase as the normal 2 year rate of survival for 
patients being treated with standard chemotherapy alone is 40%. 
The theory is that as interferon is introduced, tumor antigen pre-
sentation is upregulated and therefore more T cells can infiltrate 
the area and fight the cancer. The study noted however that fur-
ther research was still needed (Picozzi, et. al. 2003).
However this study was conducted using patients that had already 
had surgery. Only 20% of pancreatic cancer patients have operable 
tumors and therefore it is apparent that other methods must be 
sought out as well.
Some big drawbacks of using interferon-based chemotherapy are 
the side effects. A recent study of 28 pancreatic cancer patients 
undergoing this treatment showed an increase in toxicity resulting 
in a decrease in white blood cells  (leukopenia) and a decrease 
in neutrophils (neutropenia). Although the toxicity was reversible 
and no patients died, an important consideration is the effect the 
medication has on overall quality of life. The study found that al-
though the overall quality of life decreased, it wasn’t a significantly 
larger decrease than those patients being treated with the stan-
dard chemotherapy. However, it is noteworthy that some of the 
patients being treated with this therapy needed to be hospitalized 
with vomiting, abdominal pain and dehydration (Katz, et. al. 2011).
In response to this systemic toxicity, scientists have proposed 
infecting cancer cells with adenoviruses that express Interferon 
alpha in order to restrict the effects of the interferon localy rather 
than systemically. In studies of other cancers, viruses have been 
shown to exhibit promising effects. The virus can be induced to 
specifically target cancer cells and not healthy cells by using a 
tumor specific promoter called cyclooxygenase 2 which is over 
expressed in cancerous cells. In the case of the adenovirus pro-
posed treatment for pancreatic cancer, after the virally infected 
cell goes through its replication cycle in the infected host cell, 
it produces a “death protein” causing cell death so as to release 
viral particles and infect neighboring cells (Kuruppu, Tanabe, 2005). 
Although previously pancreatic cancer has shown resistance to 
adenoviruses, that has been attributed to a lack of coxsackie-ad-
enovirus receptors on the cell surface. The newly developed ad-
enovirus has been coaxed to bind to alternate cell surface re-
ceptors namely arginine-glycine-aspartic fiber and Ad3 receptor. 
When the virally infected cell dies it releases interferon and can 
thus be contained locally and not cause widespread toxicity and 
dangerous side effects. This treatment thus combats the cancer in 
two ways. The virus itself kills cancerous cells, and the interferon 
Table 1: 
Survival statistics of patients undergoing interferon alpha therapy (Picozzi, et. 
al. 2003).
Table 2:
Survival outcomes for pancreatic cancer patients undergoing various treatments (Picozzi, et. al. 2003).
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that is released induces immunological resistance to the tumor. ( 
Armstrong, et. al. 2012).
There is another problem that must be dealt with in treating any 
cancer using immunotherapy; the problem of immunosuppression. 
As the tumor grows, it changes the local environment from one of 
immunogenicity (favorable to destruction by the immune system) 
to one of immunotolerance (unfavorable to destruction by the 
immune system). As mentioned earlier, CD-8 and CD-4 Th1 T cells 
are extremely important in proper immune function. However as 
the disease progresses there is a larger presence of Th2 T cells, in-
effective CD-8 T cells and perhaps most significantly, an increase in 
regulatory T cells which aid in immune suppression by expressing 
CTLA-4 receptors and secreting immunosuppressive cytokines 
like TGF-β, IL-4 and IL-5 (Ikemoto, et. al. 2006). There is also an 
increase in myeloid derived suppressor cells. These cells suppress 
both the innate and the adaptive immune response (Gabitass, 
et. al. 2011). In addition, rather than there being an infiltration 
of M1 - classically activated macrophages - which phagocytose 
and destroy antigens, there is an infiltration of M2 macrophages 
which are associated with tissue repair. They therefore remodel 
the matrix and in fact enhance the tumor and assist in its growth 
(Schmeider, et. al. 2012) (figure 1). 
Therefore, to truly mount an immunological assault on the cancer, 
these obstacles must be overcome. A way must be found in which 
to cause an infiltration of Th1 helper T cells, classically activat-
ed macrophages and a decrease in the number of regulatory T 
cells and myeloid derived supressor cells in the area of the tumor. 
Recent research has been exploring possible options.
Using antibodies that specifically target the CD-25 marker on 
regulatory T cells, researchers depleted a splenic cell suspension 
containing T cells, of the regulatory T cells within. They injected 
Figure 1. 
Changes in the tumor microenvironment during cancer growth (Sideras, et. al. 2014)
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nude mice (a strain of mice that due to a genetic mutation have no 
thymus and therefore have no T cells), with this sample and later 
with leukemia. They noticed that the tumors first grew and then 
regressed in most of the mice, allowing the mice to live long term 
(more than 80 months). Most of the mice that were injected with 
a non-depleted splenic cell suspension died of the tumor within 
40 days. Furthermore, when the mice were reinjected with larger 
doses of leukemia the immune system mounted an even stron-
ger response and rejected the leukemia much more vigorously. 
This indicated that the mice had become immune to the cancer. 
The conclusion of the researchers was that regulatory T cells pre-
vent other T cells from mounting an immune response. They also 
injected ordinary mice with anti CD-25 antibody and leukemia 
suspensions. These tumors also grew and then regressed within 
1 month in more than 90% of the mice whereas all the control 
mice, injected with ordinary antibodies (not specific to CD-25), 
died within 1 month indicating that even normal mice were able 
to mount a response once the regulatory T cells were depleted 
(Shimizu, et. al. 1999).
It seems that depletion of the CD-25 T cells allows activated, an-
ti-tumor CD-8 and CD-4 T cells to infiltrate and kill the tumor. In 
a clinical trial of breast cancer patients treated with Daclizumab, a 
drug containing anti CD-25 antibodies along with an anti-cancer 
vaccine a marked decrease in CD-25 T cells was observed (Rech, 
Vonderheide, 2009). However at the time of this report only three 
patients were analyzed, and it is therefore premature to declare 
this treatment a success. In addition, Dr. Vonderheide, one of the 
researchers in this clinical trial, declared a potential conflict of 
interest due to his involvement in developing  the included cancer 
vaccine administered along with the Daclizumab. More research 
on pancreatic cancer as well as other cancer patients still needs 
to be conducted before this treatment can be assumed to be 
effective.
However, regulatory T cells have been associated with prevention 
of autoimmunity. Previously, in studies done where T cells were 
removed, autoimmunity was generated. It was, however, unclear 
whether  removing T cells caused autoimmunity because of a lack 
of regulatory T cells or because of a profound lack of any T cells 
which then allowed microbial infections to occur. Recently, how-
ever a study was conducted in which specifically regulatory T cells 
were removed from mice.  Autoimmunity soon developed in var-
ious forms such as diabetes, thyroiditis, and autoimmune gastritis 
(Sakaguchi, et. al. 2001). Any treatment that attempts to eliminate 
regulatory T cells should therefore try to limit the treatment lo-
cally to the site of the tumor or cancerous cells in order to pre-
vent autoimmunity in other parts of the body.
Conclusion 
Although pancreatic cancer is one of the most difficult cancers 
to treat, a multi-pronged approach to treating this disease immu-
nologically would perhaps lengthen the survival time and maybe 
even cure this disease. A possible approach to treating this disease 
could include interferon alpha alone, or virally, in combination with 
anti CD-25 antibodies. This would attract T cells to the site of the 
cancer while at the same time limiting the amount of regulatory 
T cells that ordinarily prevent an anti-cancer response. Care must 
be taken however, to ensure patients do not suffer significant loss 
of quality of life. In addition a balance must be struck between 
eliminating regulatory T cells while still avoiding autoimmunity.
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Introduction
Pregnancy, specifically human gestation, begins even before the 
release of a mature oocyte and ends with parturition, approxi-
mately 9 months later. Pregnancy is an amazing phenomenon that 
integrates many complex physiological processes and ultimately 
results in reproduction of the human species. During this vital 
time the placenta is formed as a transient organ, and it continues 
to play a critical role in maintaining the health of both the embryo/
fetus and the mother up until the time of delivery. It continuously 
evolves to meet the changing needs of the developing fetus within 
its maternal physiological environment (Linzer and Fisher, 1999). 
The placenta has two major functions. The first function is the 
exchange of metabolic and gaseous products between maternal 
and fetal bloodstreams. In this way the placenta is able to pro-
vide oxygen and nutrients, as well as remove waste products for 
the developing fetus. The second function is hormone production 
(Linzer and Fisher, 1999). The hormones produced and released 
by the placenta assist in triggering the maternal physiological 
changes necessary to meet the needs of the fetus, as well as the 
changes needed to prepare the mother for the specific needs of 
the baby after birth. These changes are widespread amongst the 
various systems of the mother and are coordinated largely by cir-
culating hormones. Some of these hormones are hormones that 
are commonly found circulating within the adult (non-pregnant) 
female in various concentrations. Others are hormones unique 
to the pregnant female only and are not otherwise found in the 
body. This role makes the placenta an important endocrine organ 
necessary for the successful continuation of a pregnancy (Sadler, 
2012) (Linzer and Fisher, 1999).
Background
In order to understand how the placenta functions, it is important 
to first understand how it is formed, beginning with fertilization. 
During ovulation, one mature oocyte is usually released by the 
ovaries and is transported into the uterine tube by the sweeping 
action of tubal fimbriae. When all biological conditions are suit-
able, and if a sperm meets the released egg, then fertilization of the 
embryo generally takes place in the fallopian tubes. The fertilized 
egg then goes through a series of cell divisions eventually creating 
a tightly grouped ball of sixteen cells called a morula. On approxi-
mately the third or fourth day after fertilization the morula begins 
to travel down the fallopian tube, eventually reaching the uterus. 
A fluid filled cavity begins to appear within the morula, and it de-
velops into a blastocyst. The inner cell mass of the blastocyst will 
form the embryoblast, which gives rise to tissues of the embryo 
proper, and the rest of the cell mass, which surrounds the inner 
cells and blastocyst cavity, will form the trophoblast, which later 
contributes to the placenta (Sadler, 2012).
By this time, the zona pellucida, which is the glycoprotein mem-
brane that surrounded the ovum, has disappeared and implanta-
tion into the uterus begins as the blastocyst continues to evolve. 
This occurs on the sixth day after fertilization, as trophoblastic 
cells begin to penetrate between the epithelial cells of the uter-
ine mucosa (Sadler, 2012). At this time, the mucosa of the uterus 
is in the secretory phase of the menstrual cycle, in response to 
progesterone that is released by the corpus luteum that remains 
following ovulation. The corpus luteum is maintained for the first 
few weeks of pregnancy by the release of hCG from the tropho-
blast and it continues to release specific hormones that affect the 
uterus and allow implantation to occur. Eventually, however, the 
corpus luteum degenerates and is replaced by the placenta, which 
then becomes responsible for continued hormone production 
(Cole, 2012). 
In preparation for implantation, the glands and arteries of the 
uterine endometrium become coiled and three distinct layers 
form in the endometrium. The formation of the placenta then re-
sults from mutual interaction of the trophoblast and the endome-
trium. Under normal circumstances, the blastocyst implants along 
the anterior or posterior wall of uterine endometrium, where 
it becomes embedded between the openings of the glands and 
continues to root itself more deeply into the endometrium until 
it becomes completely embedded and almost entirely covers the 
uterine wall, on approximately the eleventh or twelfth day. (Sadler, 
2012).
At the time of implantation the development of the placenta be-
gins, as the trophoblast continues to develop by differentiating in 
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to two layers. These layers include the cytotrophoblast and the 
syncytiotrophoblast (Carlson, 2004). The cytotrophobast, which 
is the inner layer, consists of mononucleated cells that migrate 
and fuse to form a multinucleated syncytiotrophoblast, which will 
function as the endocrine unit of the placenta (Alsat et. al. 1997). 
The syncytiotrophoblast, which is a highly invasive tissue, soon 
surrounds the entire blastocyst and begins to insert small pro-
jections between uterine epithelial cells. It continues to spread 
towards the basal lamina underlying the endometrium, forming 
a flattened trophoblastic plate, eventually eroding maternal tis-
sue, actually penetrating the basal lamina, and making its way into 
the endometrial stroma. During this time, isolated vesicles, called 
lacunae form in the trophoblast, and as the syncytiotrophoblast 
erodes maternal vessel walls, maternal blood begins to fill the 
lacunae. As this process continues, and as maternal blood flows 
through the trophoblastic system, a basis for utero-placental cir-
culation is established (Carlson, 2004).
As the trophoblast continues to grow and develop, so does the 
embryoblast, as it differentiates into two layers. A thin membrane 
then lines the inner surface of the cytotrophoblast, forming the 
exocoelomic cavity or the primitive yolk sac. A new layer of cells 
appears between the trophoblast and this membrane, and forms 
a matrix of loose connective tissue known as the extraembryonic 
mesoderm. It lies immediately internal to the entire trophoblast, 
as well as around the layers of the embryoblast (including the yolk 
sac and amniotic cavity). Cavities soon develop and then merge to 
form a single large cavity that surrounds the yolk sac and amni-
otic cavity. This cavity is the chorionic cavity. The chorionic plate 
encompasses the part of the extraembryonic mesoderm that 
borders the fetal side of the placenta, along with its trophoblast. 
The connective stalk is then the only place where the chorionic 
plate traverses through chorionic cavity. With the development of 
blood vessels as well as other elements, the connective stalk be-
comes the umbilical cord which will form the connection between 
placenta and embryo (Sadler, 2012). 
By the beginning of the third week, the cells of the cytotropho-
blast, which continue to proliferate towards the endometrium, 
eventually penetrate the syncytiotrophoblast and form col-
umn-like structures that are surrounded by a syncytial layer. These 
are the primary villi. Mesodermal cells then penetrate the core of 
the primary villi to form secondary villi. Mesodermal cells then 
differentiate into blood cells and blood vessels, forming a capil-
lary network that makes contact with capillaries developing in the 
chorionic plate, the connecting stalk, and eventually the intraem-
bryonic circulatory system. The villous system is getting ready for 
the time that the heart begins to beat, at approximately the fourth 
week of development (Sadler, 2012).
The villi on the embryonic pole continue to grow and develop, giv-
ing rise to the chorion frondosum, which is a bushy chorion area, 
while the villi on abembryonic pole eventually degenerate. The 
portion of the endometrium that lies over the embryonic pole 
becomes abundant with lipids and glycogen and becomes firmly 
attached to the chorion. This is the decidua basalis. The remaining 
portion of the endometrium that lies over the abembryonic pole 
also degenerates. Together, the chorion and the decidua basalis 
make up the placenta, which becomes the only portion of the 
chorion where the exchange of maternal and fetal materials takes 
place. Maternal blood from the lacunae of the syncytiotrophoblast 
begins to fill the intervilli spaces of the chorion. Septa continue to 
form from the decidua, protruding into intervilli space, but never 
actually reaching the chorion. This, in turn, forms compartment-like 
structures, called cotyledons, that are not fully separated by the 
septa. It is in these compartments that high pressure arteries bring 
oxygen-rich blood towards the villous trees that have developed 
in the chorion and then back towards endometrial veins. The in-
tervillous spaces of a mature placenta contain approximately 150 
mL of blood, which is replenished about 3-4 times per minute. 
At all times there is a layer of syncytium that separates maternal 
blood from fetal tissue, as part of the placental membrane.  The 
villi serve to increase surface area and are the primary site of 
placental exchange (Sadler, 2012). 
As the pregnancy progresses, the placenta continues to grow, cov-
ering approximately fifteen to thirty percent of the internal surface 
of the uterus (Carlson, 2004). This growth serves to accommodate 
the ever growing needs and demands of the developing fetus and 
ensures sufficient transfer of nutrients. Continuous proliferation, 
differentiation, and fusion of cytotrophblast is what maintains and 
expands this syncytial interface throughout pregnancy as syncy-
tiotrophblast cells are shed into maternal circulation when they 
reach the end of their life cycle (Forbes and Westwood, 2010).  A 
clear relationship has been established, with a direct relationship 
between placental weight and fetal weight throughout pregnancy. 
This points to the ever important role that the placenta unit plays 
in fetal growth, through its various functions (Alsat et. al. 1997).
One major function of the placenta at this point, as mentioned, 
is the exchange of nutrients and wastes. Through the process of 
diffusion, gases, such as oxygen, carbon dioxide, and carbon mon-
oxide are exchanged between mother and fetus. Additionally, the 
exchange of nutrients and electrolytes, such as amino acids, fatty 
acids, carbohydrates, and vitamins are also diffused through the 
placental barrier. Although immunity is beginning to develop, ma-
ternal antibodies are also transported from the mother to the 
fetus via the placenta (DeChemey et. al. 2013).
The seconds major function of the placenta is the production of 
hormones which serve to maintain the pregnancy, to uphold an 
optimal environment within the physiology of the mother, and to 
prepare the mother for birth. The release of hormones by the 
placenta is an endocrine communication system that stimulates 
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specific reactions on target tissue, facilitating changes necessary 
for the state of the pregnancy. The myometrium, which lies just 
beneath the endometrium is a vital tissue during the pregnancy 
period, and it is a critical target for fetal placental communication. 
The major hormone changes that occur through these placental 
communications are noted specifically in the increased levels of 
estrogen, progesterone, and chorionic gonadotropin. However, 
there are other hormones as well, that participate in this complex 
system of fetal-maternal interaction, although on a smaller scale, 
(DeChemey et. al. 2013).
Steroid Hormones
Over the years much research has been done in order to de-
termine the actual role of the placenta in hormone production. 
One group of hormones produced by the placenta are the steroid 
hormones estrogen and progesterone. Various studies have been 
done to verify that it is actually the placenta that produces the 
elevated levels of these hormones during pregnancy. Studies in 
which pregnant women underwent surgery to remove the corpus 
luteum at various stages of pregnancy resulted in a substantial 
amount of lost pregnancies when the corpus luteum was removed 
before the eighth week. Removal of the corpus luteum after the 
eighth week did not result in abortions. These results suggest that 
after the eight week there are a significant amount of placental 
secretions (Csapo et. al. 1972). Furthermore, women with ovarian 
failure who participated in an ovarian assisted reproduction pro-
gram demonstrated increased peripheral blood progesterone and 
estradiol levels by the fifth week of pregnancy. These levels were 
above the background levels achieved by the constant replace-
ment regimen. With the absence of ovarian function, this study 
also suggests the role of the placenta in maintaining proper hor-
mone levels and sustaining pregnancy (Scott et. al. 1991). 
Estrogen
Estrogen is a steroid hormone that is produced in the syncytiotro-
phoblast of the placenta (Alsat et. al. 1997), with the placenta be-
coming the primary source of this hormone approximately during 
the ninth week of pregnancy. Estrogen levels remain low during 
the first trimester of pregnancy and then progressively increases, 
remaining elevated, until labor. 
An important role of estrogen during pregnancy is the synthesis 
of contractile proteins in the myometrium, as well as local concen-
tration of contraction associated proteins, such as oxytocin and 
connexin-43 (Cx-43). It also increases prostaglandin production 
and regulates the expression of nitrate oxide synthase isoforms. 
Estrogen, therefore, plays a significant role in preparing the uterus 
for labor contractions and delivering the baby. Although estrogen 
assists in the priming of the myometrium for labor, it is important 
to note that the estrogen alone is not clinically effective in the 
induction of labor. Furthermore, a pregnancy can continue to exist 
and labor is still possible, even amongst women with low levels 
of circulating estrogen (Ticconi et. al. 2006). However, in cases of 
low placental estrogen synthesis, changes that generally occur in 
the reproductive tract before parturition, such the ripening of the 
cervix, generally do not occur (Strauss et. al. 1996). The actions of 
estrogen are therefore efficient in conjunction with other factors 
(Ticconi et. al. 2006).
Other significant functions of estrogen are the stimulation of uter-
ine growth, as well as development of the mammary glands, in 
preparation for birth. The development of the mammary gland be-
gins initially at puberty with estrogen exposure and is completed 
in the third trimester of pregnancy (Sadler, 2012). 
Progesterone
Progesterone is another major steroid hormone that is produced 
by the placenta. Until approximately ten weeks gestation, pro-
gesterone is produced by the corpus luteum that remains after 
ovulation. In a normal menstrual cycle where pregnancy does 
not occur, the corpus luteum degenerates soon after ovulation. 
However, when pregnancy does occur, hCG that is released from 
the trophoblast stimulates the maintenance of the corpus luteum, 
which, in turn, releases progesterone. This prevents the shedding 
of the endometrium lining (Cole, 2012) and allows for proper 
implantation (Kumar and Magon, 2012). Progesterone continues 
to be released by the corpus luteum until approximately week 
eight to ten gestation. It then continues to be produced by the 
placenta, specifically by the syncytiotrophoblasts of the chorion, in 
response to the uptake of maternal lipoproteins. The expression 
of low density lipoproteins appears to be directly related to the 
presence of progesterone (Ticconi et. al. 2006).
Progesterone acts in multiple ways to decrease the contractility of 
the myometrium lining of the uterus. By decreasing Cx-43 expres-
sion, stimulating nitrate oxide expression, and down-regulating 
calcium channels and oxytocin receptors, progesterone serves to 
maintain a state of dormancy during most of the pregnancy. Three 
progesterone receptor subtypes, PR-A, PR-B, and PR-C have been 
identified. Only PR-B mediates the expression of progesterone re-
sponsive genes, whereas PR-A represses this activity. During most 
of pregnancy, PR-A levels are low. At the time of labor, however, 
PR-A levels increase drastically, as do PR-A receptors, thereby 
suppressing the effects of placental progesterone during this cru-
cial time and allowing uterine contractions to progress, despite 
maternal circulating progesterone (Ticconi et. al. 2006).
Although progesterone has a quiescent effect on the uterus, an-
other primary function of this hormone is its effect on the cer-
vix. Progesterone has been found to have a direct effect on the 
length of cervix, and in this way serves to prevent preterm labor. 
Studies have shown that a shortened cervix in the second trimes-
ter is often an early indicator that preterm labor will occur. Both 
natural and synthetic progesterone have been found to have a 
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strengthening and lengthening effect on the cervix, and are there-
by often effective in postponing preterm labor. Local withdrawal 
of progesterone at the cervical level appears to have the opposite 
effect of softening and effacing the cervix in preparation for deliv-
ery. Although exact mechanisms are unknown at this time, proges-
terone has been shown to have an effect on mucus plug formation 
and possibly contributes to improved antimicrobial activity in this 
area (Campbell, 2011). 
Another important function of progesterone is its contribution 
to mammary gland development. Although the mammary glands 
begin to develop at puberty, continued development and prepara-
tion for lactation is still necessary. Progesterone had been found 
to be associated with ductal proliferation and lobuloalveolar dif-
ferentiation. This enables the mammary glands to produce and 
secrete milk after delivery (Lydon et. al 2000).
Peptide Hormones
Human Chorionic Gonadotrophin
Human Chorionic Gonadotrophin (hCG) is a pregnancy hormone 
that is critical to both the establishment and maintenance of the 
pregnancy, playing a role in multiple facets of the pregnancy pro-
cess. HCG is a glycoprotein hormone that is similar in structure 
to luteinizing hormone (LH). It is synthesized and secreted pri-
marily by the syncytiotrophoblasts, and it binds to specific hCG 
receptors in target tissues (Ticconi et. al. 2007). It is detectable 
early in pregnancy, as soon as eight to nine days after ovulation 
and levels continue to rise until the final weeks of pregnancy. 
Emerging evidence continues to demonstrate a wider range of 
biological effects that hCG has on various tissues types than was 
previously recognized.
One of the major functions of hCG during the first trimester 
is the prevention of luteolysis and stimulation of progesterone 
production in the corpus luteum (Cole, 2012). As mentioned, this 
ensures that the uterus, which is generally in the secretory stage 
of the menstrual cycle at the point of fertilization, maintains an 
optimal state for implantation to occur (Ticconi et. al. 2007). By 
sustaining the production of progesterone, hCG indirectly works 
to maintain the decidual cells of the endometrium, thereby pre-
venting aptosis. At this point, hCG also functions to promote 
angiogenesis in the uterine vasculature, allowing for improved 
circulation and maximum blood supply to the area as the placenta 
forms. HCG has also been shown to control growth and develop-
ment of the umbilical cord in this way (Cole, 2012). HCG, which 
is considered to be similar to thyroid stimulating hormone (TSH), 
mildly stimulates the thyroid gland to produce more thyroid hor-
mone throughout pregnancy. This is especially important, as the 
thyroid hormone passes through the placenta and is critical for 
brain and nervous system development in the fetus. At approxi-
mately twelve weeks, the fetus begins to produce its own thyroid 
hormone (Kilby et. al. 2005).
After the first trimester, hCG continues to play a pivotal role in 
maintaining the pregnancy through various mechanisms.  Studies 
have shown that hCG strongly induces the proliferation of myo-
metrial smooth muscle cells. This contributes to the continuous 
growth of the uterus throughout pregnancy, providing an optimal 
environment for the simultaneous continuous growth and devel-
opment of the fetus. HCG also assists in inhibition of uterine con-
tractility. Just like progesterone, HCG has been found to directly 
decrease expression of connexin 43. It has also been found to 
reduce the expression of PR-A, further reducing uterine contrac-
tility in this way. HCG also decreases intracellular concentration 
of free calcium in the smooth muscle cells, thereby inhibiting 
the amplitude of response to oxcytocin-stimulated contractions. 
Additionally, hCG is the only pregnancy hormone that has been 
found to inhibit the expression of phosphodiesterase (PDE) 5 en-
zyme, which is involved in the hydrolysis of cAMP and cGMP that 
regulate myometrial relaxation.  This further assists in modulating 
uterine contractility and in inhibition of preterm labor (Ticonni et. 
al. 2007). During the final weeks of pregnancy, levels of hCG tend 
to drop, in preparation for delivery. This drop allows for increased 
responsivity to prostaglandin and oxytocin, enabling contractions 
to occur (Ticonni et. al. 2006).
Another important function of HCG is its effect on the fetal mem-
branes. A study conducted by Ticconi et al (2007) demonstrated 
increased expression of the isoform of nitric oxide synthase in 
response to hCG. This, in turn, may contribute to the relaxed state 
of the uterus as well as to immune system activity in the fetal 
membranes, although this has not yet been proven (Ticconi et. 
al. 2007). Additionally, hCG promotes anti-macrophage inhibitory 
factor, thereby preventing rejection of the foreign fetal tissue by 
the mother throughout pregnancy (Cole, 2012). Additionally, new 
studies have found hCG receptors in many fetal organs and tissues. 
This may indicate that hCG also plays a role in fetal growth during 
pregnancy. These receptors are then removed upon partuition. It 
is also interesting to note the hCG receptors are also found in 
the hippocampus, hypothalamus, and brain stem of the mother. 
This may explain the presence of nausea and vomiting that often 
occurs in pregnancy, as receptors detect this hormone in maternal 
circulation (Cole, 2012).
Another form of hCG is the sub-type hyperglycosylated hCG. 
Although it is an autocrine, and not a hormone, hyperglycosylated 
hCG promotes cytotrophobast cell growth during the early stages 
of pregnancy. HCG then promotes the fusion and differentiation 
of these cells to syncytiotrophoblast cells, leading to the forma-
tion of the villous system. This, combined with angiogenesis and 
umbilical cord formation, becomes the fetal maternal interface of 




Chorionic somatomammotrophin (hCS), also known as placental 
lactogen hormone (LH) is a lactogenic protein that is also pro-
duced by the syncytiotrophoblasts of the placenta (Ayala et. al. 
1989). It is considered to be similar, immunologically, to pituitary 
growth hormone, and it effects fetal growth in an indirect man-
ner, according to present studies. It is secreted almost exclusively 
into maternal circulation, with only small amounts crossing into 
fetal circulation. It can first be detected in the maternal blood 
stream at approximately six weeks gestation, and it plays a signifi-
cant role in maternal metabolism, as maternal hCS concentrations 
tend to rise throughout pregnancy with irregular fluctuations 
(Handwerger and Freemark, 1987). During approximately the last 
month of pregnancy, hCS levels usually level off. It has been found 
that depressed levels of maternal hCS correlate with intrauterine 
growth retardation and are associated with high risk pregnan-
cies. It should also be noted that levels of hCS have been noted 
to increase in direct proportion to increased placental volume 
(Macmillan et. al. 1976).
HCS works in a manner that is similar to human growth hormone 
(hGH). It works to effect both carbohydrate and protein metabo-
lism in the mother. Like hGH, hCS enhances insulin secretion and 
impairs glucose tolerance in the mother, thereby facilitating and 
increasing the supply of glucose and energy that is available to be 
delivered to the fetus. HCS also facilitates an increase in lipolysis 
in adipose tissue of the mother. This helps to ensure that more 
free fatty acids are available for energy use by the mother instead 
of glucose. In this way even more glucose is available for use by 
the fetus. Furthermore, ketones that are formed from the free 
fatty acids can cross the placenta and can be used by the fetus. 
Large amounts of hCS released from the second month of preg-
nancy onward appear to be related to breast, nipple, and alveolar 
growth, although exact mechanisms are uncertain (Handwerger 
and Freemar, 1987).
Placental Growth Hormone
During the early stages of pregnancy, until approximately 20 weeks, 
pituitary growth hormone (GH), which originates in the pituitary 
gland of the mother, is the primary growth hormone found in 
maternal circulation. Then, from approximately twelve to twenty 
weeks, until term, placental growth hormone gradually replaces 
pituitary growth hormone, which eventually becomes undetect-
able in maternal circulation. Placenta growth hormone is similar 
in structure to pituitary growth hormone, but is produced in the 
syncytiotrophoblasts of the placenta. Additionally, it binds to cell 
receptors with similar affinity to pituitary GH. PGH has a relative-
ly short half-life and there is a rapid fall in serum concentrations 
within one hour after removal of the placenta following delivery 
(Lacroix et. al. 2002). 
Placental GH is secreted in a continuous, non-pulsatile fashion 
into maternal circulation only and is not detected in fetal blood 
at all. This continuous secretion of placental GH into maternal 
circulation has critical implications for maternal physiological ad-
aptation to gestation, as it impacts metabolism. Although it does 
not have a direct impact on fetal growth, this hormone works to 
stimulate gluconeogenesis, lipolysis, and anabolism in the liver and 
other organs of the mother. In this way it serves to increase nutri-
ent availability for the fetal-placental unit, indirectly affecting fetal 
growth. This is especially important during the last few months of 
pregnancy when fetal growth is most prominent. Furthermore, 
intrauterine growth restriction has been found to be associated 
with decreased levels of placental GH, indicating the crucial role 
this hormone plays for the developing fetus. Both the rate of syn-
thesis, as well as maternal blood levels of this hormone, have been 
found to be directly related to growth of the placenta (Lacroix et. 
2002,) (Alsat et. al. 1997).
Placental GH demonstrates high somatogenic activity, and just like 
pituitary GH, it has been found to induce weight gain. It has also 
been found to be one of the key regulators of maternal Insulin Like 
Growth Factor 1 (IGF1). Additionally, placental GH concentration 
has been found to decrease in response to high levels of glucose. 
As the syncytiotrophoblast, which regulates the expression of 
Glut1, a major glucose transporter, comes into direct contact 
with maternal blood circulation, elevated glucose levels may be 
detected by these cells. The sycncitiontrophoblast then respond 
to variations in maternal blood glucose by modifying placental GH 
secretion. Recent data on the expression of placenta GH and its 
receptors in the villi of the trophoblast open new questions as to 
other roles that this hormone may play (Lacroix et. al. 2002).
Insulin-Like Growth Factor
The presence of various growth factors (GF) in maternal circu-
lation is generally increased throughout gestation and specific 
growth factors, such as insulin-like growth factor (IGF), have been 
found to be linked to fetal growth. Two specific IGF types, IGF 1 
and IGF 2 have been identified, and both have been found to be 
positively correlated to fetal birth weight (Forbes and Westwood, 
2010). These peptide hormones work by binding to specific re-
ceptors on target tissues in order to mediate a variety of met-
abolic and mitogenic processes. Although IGF 1 and IGF 2 each 
have individual receptors, both typically bind to IGF 1 receptor 
(IGF1R) through the aid of binding proteins. This receptor is found 
in all cell types of the placenta, including trophoblast, villous en-
dothelium, and mesenchymal cells and is thought to regulate the 
mitogenic effects of IGF 1 and IGF 2. IGF binding proteins that are 
generally found in abundance in the area of the placenta are also 
correlated to fetal growth (Hiden et. al. 2009).
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Although exact mechanisms remain unclear, it appears that one 
way in which IGFs affects fetal growth is through its effect on the 
placenta. Placentally derived IGF2 have been found to have a role 
in promoting trophoblast invasion, thereby promoting placental 
growth and function. Studies have also shown that exposure of 
the syncytial surface to IGFs enhanced cytotrophoblast prolifera-
tion and differentiation. Because placenta growth has been closely 
associated with fetal growth, continuous proliferation of cytotro-
phblast cells in order to maintain the placenta is crucial. By stimu-
lating placental growth, IGF works to enhance nutrient transport 
and delivery to the fetus, thereby promoting fetal growth (Forbes 
and Westwood, 2010)
Vascular Endothelial Growth Factor
Vascular endothelial growth factor (VEGF) is an essential hor-
mone for placental growth, and it has a significant impact on 
coordinating angiogenesis, blood flow, and the breakdown of the 
extracellular matrix in the placenta. It is found to be present in 
the blood vessels of both placenta and the umbilical cord, and it is 
hypothesized that it acts as a paracrine hormone on fetoplacental 
circulation. In this way it contributes to the growth and mainte-
nance of the placenta as well as delivery of oxygen and nutrients 
to the fetus. This hormone further assists in vasodilation, as there 
is no sympathetic innervation in the spiral arteries and in the pla-
centa. These functions are vital for the growth and development of 
the fetus, as adequate nutrient supply is crucial. Studies have noted 
a decreased vascular response to VEGF in cases of intrauterine 
growth retardation. This indicates the importance of the effects of 
this hormone, and further research is needed to verify the exact 
mechanisms of the decreased responsivity in these cases, and how 
this can be prevented (Krukier and Pogorelova, 2006) (Szukiewicz 
et. al. 2005).  
Relaxin
Relaxin is a peptide hormone that is considered to be similar to 
insulin. It is produced and secreted during pregnancy, at first by 
the corpus luteum in the ovary, and then later by the decidua, 
endometrium, and trophoblast of the placenta. Highest levels of 
relaxin are detectable in the first trimester of pregnancy. Then, 
levels tend to drop and stabilize. It mediates its effect both on 
the reproductive organs, as well as on other organs in the body 
(Dschietzig and Stangl, 2003).
This peptide hormone originally received its name due to its re-
laxing and elongating effects on the interpubic ligament. It further 
assists in softening the cervix and the tissues of the birth canal, 
thereby facilitating the passage of the fetus during parturition. This 
was later attributed to the ability of relaxin to reduce cervical col-
lagen concentration and increase collagen solubility during preg-
nancy. Estrogen was then found to further enhance these effects 
(Dschietzig and Stangl, 2003). 
As years went on, more research has been conducted to try to 
uncover some other important functions of this hormone. Relaxin 
has been found to have regulating effects on oxytocin secretion, 
although data is conflicting in regard to exactly how. Other effects 
of relaxin include its ability to inhibit uterine contractile activity 
throughout gestation. However, this effect has been found to be 
mild in humans. Relaxin also promotes the growth and differenti-
ation of the mammary parenchyma and stroma in preparation for 
lactation. It is further considered essential for the development of 
mammary nipples (Dschietzig and Stangl, 2003). 
Conclusion
The placenta is a transient organ that is formed during pregnancy 
for the purpose of nourishing the developing embryo/fetus and 
for maintaining an optimal physiological environment within the 
mother in order to sustain the pregnancy. During this approxi-
mately ninth month period, the placenta undergoes continuous 
growth and change in order to accommodate the ever changing 
needs of the mother and fetus. One of the major roles of this 
organ is its function as an endocrine unit with its release of many 
hormones which have widespread effects on the maternal tissues 
and organs. This is what allows the pregnancy to continue and 
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Introduction: Eating Disorders
The term “eating disorders” constitutes a range of disorders in-
cluding anorexia nervosa, bulimia nervosa, binge eating disorder, 
and other unnamed eating disorders. Overall, these disorders are 
characterized by a distorted body image and abnormal behaviors 
pertaining to food intake or weight loss that lead to decreased 
quality of life and extreme distress. 
Up to 24 million people in the United States suffer from an eating 
disorder (National Association, 2014). For years it was believed 
that eating disorders typically affect white, wealthy, well-educated 
females living in major cities. However, new studies are proving 
otherwise (Mitchison & Hay, 2014). Eating disorders are common-
ly found in adolescents; 13.4% of female teenagers display signs of 
a disorder, while 7.1% of males exhibit those signs (Treasure et 
al., 2010). Overall, eating disorders are slightly more predominant 
in individuals of lower socioeconomic status, and bulimia is more 
common among minorities. Education, marital status, and urbanic-
ity, studies find, do not play a significant role in eating disorders. It 
is also evident that individuals who participate in specific sports, 
such as aesthetic (e.g. dancing and gymnastics) and leanness- or 
weight-related (e.g. wrestling), have a higher prevalence of devel-
oping an eating disorder. Modeling is associated with an increased 
incidence of anorexia and subclinical anorexia. Individuals who live 
with a great amount of stress report higher incidence of eating 
disorders. While not thoroughly studied, evidence is emerging that 
even minor stresses such as moving to a new house or a change in 
family dynamic may lead to the development of an eating disorder. 
With this new research, scientists have come to a general un-
derstanding about the demographics of eating disorders; however, 
they still admit that there are some limitations to the studies that 
have been performed on epidemiology, and they may never know 
the true prevalence of eating disorders (Mitchison & Hay, 2014).
Much of the information about individuals with eating disorders 
comes from those who are treated. However, many patients are 
embarrassed about their condition and do not seek treatment. 
For example, males with eating disorders tend to be ashamed, 
as it is more accepted for a female to be diagnosed with an 
eating disorder, and they therefore do not seek help (National 
Association, 2014). In addition, teenagers living at home may be 
brought to a doctor by their parents, whereas adults or the elder-
ly who live alone have no one looking after them and forcing them 
to get help. Therefore, much of the research fails to include those 
who do not seek treatment, which may skew statistics (Mitchison 
& Hay, 2014).
There are various factors that cause an individual to develop an 
eating disorder. Some theories suggest that the root of eating dis-
orders is possibly biological, genetic, and psychological in nature. 
Treasure et al. in their article explore the biological causes and 
believe that the structure of the appetite system and the way it 
functions can cause eating disorders. They believe that the three 
components of the appetite system can aid in the understanding 
of eating disorders.
The first component of the appetite system involves a homeo-
static system that is primarily situated in the hypothalamus and 
brainstem. This system utilizes signals from the gastrointestinal 
tract and specific metabolic markers to affect hunger and satiety. 
The second component is the drive system that registers the re-
ward value associated with food, such as the pleasure or energy 
obtained from eating, and also helps motivate a person to want to 
eat and therefore look for suitable food. This drive system is com-
prised of striatum with afferent inputs from sense organs, neural 
structures that are involved in memory and learning, and neural 
circuitry that is distributed throughout the mesolimbic cortex. 
The third component is a self-regulation system which controls 
appetite and lets a person how much he needs to eat. When there 
are abnormalities in any of these three components, an individual 
is at risk of developing an eating disorder or of maintaining and 
exacerbating a pre-existing disorder (Treasure et al., 2010).
Despite the fact that eating disorders are often referred to as a 
whole, each type is characterized by distinguishing features that 
differentiate one from another. Since eating disorders are large-
ly classified as psychological in nature, they are included in the 
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Diagnostic and Statistical Manual of Mental Disorders (DSM), the 
standard classification of mental disorders used by mental health 
professionals in the United States (DSM, 2014).
Anorexia Nervosa
The most recent update of the DSM, DSM-5, has published chang-
es to the previously-used classification system of eating disorders. 
According to DSM-5, a patient must exhibit the following symp-
toms to be appropriately diagnosed with anorexia: 
1. Patient has low body weight relative to age, gender, physical 
health, and developmental trajectory; this is due to limited energy 
intake compared to what is actually required.
2. The patient is underweight; however, he/she has constant unre-
alistic worry about weight gain or becoming fat.
3. Patient denies his/her low body weight as problematic; patient 
is overly concerned with the way his/her body looks to the point 
it affects the way he/her thinks about him/herself – he/she has a 
false perception about the way his/her body looks (The alliance 
for eating disorders awareness, 2014).
Anorexia has a higher mortality rate than any other psychological 
disease (National Association, 2014) and is associated with a host 
of devastating metabolic changes to the body. Patients may experi-
ence dangerous arrhythmias due to low potassium levels, seizures 
due to sodium or fluid depletion from constant vomiting or di-
arrhea, thyroid problems, increased infections due to decreased 
white blood cells, dehydration, tooth decay, and reawakening of 
the bones. An obvious result of anorexia is malnutrition (Anorexia 
nervosa, 2014).  
Approximately 75% of anorexia patients are female making 25% of 
the cases belong to the male gender, however there is not much 
known about the anorexic male population. (Wooldridge & Lytle, 
2012).
Eating disorders negatively affect the skeletal system; growth re-
tardation, bone loss, and osteoporosis are common. Weight gain 
will improve the bone density and reduce these effects. In addition, 
many patients with anorexia suffer from concomitant psychologi-
cal ailments such as depression and anxiety due to hormonal im-
balance (Misra & Klibanski, 2014).
The brain is the most important organ affected by eating disor-
ders. The brain uses approximately 20% of the calorie intake and 
is also very dependent on the glucose from food. Therefore, when 
the body has poor nutrition, the brain is not receiving the correct 
amount of glucose and other nutrients. Most cases of eating dis-
orders occur during adolescence, and this can be a major problem 
because this is the time of optimum growth and development. 
When a person starves his brain, his brain is actually shrinking 
from lack of nutrition. This can lead to several behavioral and psy-
chosocial disturbances. If a person would regain his lost weight 
and restore the brain mass to its normal level, his condition would 
most likely improve (Treasure et al., 2010).
Another important body system which is affected by eating dis-
orders is the reproductive system. Since reproduction and nu-
trition are connected, severe weight loss will inhibit the cycle of 
reproduction from functioning properly. The records of a num-
ber of infertility clinics were reviewed to determine the various 
sources of these women’s infertility. Almost 17% of the patients 
in the clinics were suffering from eating disorders in general, in-
cluding 7.6% suffering from anorexia and bulimia (Stewart et al., 
1990). In a London-based study, 11,088 pregnant women were 
questioned. Of those women, 171 (1.5%) said they had a history of 
anorexia, and 199 (1.8%) had suffered from bulimia at some point. 
Eighty-two women (0.7%) suffered from both. These women were 
compared with the remaining 10,636 women (96%). The following 
statistics were recorded: 39.5% of those who suffered from an 
eating disorder took over 6 months more to conceive than did 
the 25% of the general population. Of those women with a history 
of anorexia or bulimia who did become pregnant, 6.2% said they 
had undergone treatment to help them get pregnant, while in the 
general population the number was only 2.7% (Easter et al., 2011).
A hindrance in the reproductive system due to a lack of nutrition 
can be seen from Holocaust survivors who lived to tell the tale 
of those terrible times. One lady, who was hiding in Siberia, hardly 
ate anything for the few years she was there because of the lack of 
food. This caused her menstrual cycle to stop for those years that 
she was not receiving proper nutrition.  Another lady was in the 
Auschwitz concentration camp, where she was literally starving; 
the inmates were given potato peels and moldy bread to eat. This 
caused her to also experience a cessation of her monthly periods. 
Both of their menstrual cycles resumed within a few years after 
the war, and with that, each of them was able to begin a family. 
This paper will go on to explain in detail why this is so. What is 
the connection between these two aspects? What are the under-
lying factors which cause a lack of nutrition to lead to an inability 
to become pregnant? While infertility caused by eating disorders 
was once thought to be untreatable, new research is identifying 
various hormones, such as GnRH, Kisspeptin, and Leptin, which 
boost LH and FSH to make it possible for women with anorexia 
to conceive. How do these three hormones regulate the repro-
ductive system?
Methods
The question above will be answered based on the information 
compiled from various articles and reviews. These references 
were obtained through Pubmed and Touro College’s database 
which connected further to a variety of medical journals and 
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publications.  The information was narrowed down to those di-
rectly relevant to the topic at hand. Once all the information was 
in place, an attempt could be made to answer the question re-
garding these specific hormones and their involvement in the re-
productive system when adequate nutrition is and is not present.
Discussion
The two hormones, FSH and LH?
Follicle-stimulating hormone, better known as FSH, is a hormone 
which controls and maintains development, maturation, and all 
reproductive processes in the human body. In males, a low FSH 
level can result in a cessation of normal sperm development, while 
in females it can halt the reproductive cycle. The Luteinizing hor-
mone, or LH, is a hormone that triggers ovulation. When there is 
an LH surge in the female body, this indicates that ovulation will 
occur within the next 24-48 hours. (When a woman is pregnant, 
there is a decreased level of LH since a similar hormone, HCG, 
takes over. HCG is the hormone which helps preserve the uter-
ine lining in pregnancy and will further produce progesterone.) A 
deficiency in LH will cause the same effects as the FSH deficiency 
does in both males and females (Barker et al., 2012).
The menstrual cycle
The menstrual cycle is on average a 28-day cycle of various hor-
mones and activities circulating the female reproductive system. The 
goal of the menstrual cycle is to produce eggs and to prepare the 
uterus for pregnancy. In cases where pregnancy is not achieved, the 
uterus will shed the eggs. The endocrine system is in charge of the 
cycle because of the various hormonal changes. At the beginning of 
the cycle, there is an increased level of estrogen and the lining of the 
uterus thickens, forming what is called the corpus luteum. Various 
hormones assist with the development of follicles in the ovary. 
Eventually, only one will become dominant while the others die. At 
mid-cycle, there is a surge in LH; this occurs when the egg has ma-
tured and the estradiol, or estrogen, begins to stimulate the produc-
tion of LH from the anterior pituitary gland, initiating a surge of LH. 
This surge causes the dominant follicle to release an egg, an event 
known as ovulation. Unless it is fertilized to become an embryo, this 
egg will survive only up to 24 hours. FSH and LH aid the formation 
of the uterine lining from the remains of the dominant follicle, and 
this produces progesterone. This increased amount of progesterone 
leads to a rise in estrogen levels. If pregnancy is achieved, the embryo 
will implant itself within the uterus for the duration of the pregnancy. 
If, however, the egg is not fertilized, then approximately two weeks 
later, the corpus luteum will begin to disintegrate. The uterine lin-
ing will atrophy, causing the progesterone and estrogen hormones 
directly influencing the FSH and LH levels to diminish. As a result, 
there will be a large drop in the estrogen and progesterone levels, 
which will then cause the uterus to shed its corpus luteum and egg, 
bringing about another menstrual cycle (Chrousos, 2009).
GnRH, Gonadotropin-releasing hormone
“In mammals, a sparsely populated and widely dispersed network 
of hypothalamic neurons, the Gonadotropin-releasing hormone 
(GnRH) neurons, serve as the pilot light of reproduction via coor-
dinated secretion of GnRH” (Balasubramanian et al., 2010).
A network of approximately 1500 GnRH neurons is found in the 
hypothalamus. These neurons originate elsewhere in the body and 
migrate to the brain during embryological development. Scientists 
tested rodents to investigate the origin of these GnRH neurons 
and found that they originate in the nose, outside of the CNS, 
and migrate into the brain, where they scatter throughout the 
hypothalamus. It is obvious from the neurons’ specific path from 
the olfactory placode to the preoptic area of the hypothalamus 
that they play a large part in a number of body systems which 
ultimately transfer data, including body weight and nutritional sta-
tus, over to the reproductive system. GnRH is initially secreted 
from early fetal life until a few months of infancy. It is then quiet 
until the child reaches puberty, when it is once again secreted, 
resulting in sexual maturation. Since this neural network spurs the 
reproductive system in mammals, the GnRH neurons will deter-
mine, upon receipt of information, whether it is the right time and 
place and under the right body conditions for the reproductive 
system to prompt fertility. Once in the hypothalamus, the neurons 
bundle together to pass chemical signals to each other, causing the 
release of GnRH.  In order for GnRH to be emitted, the neurons 
must extend their axon projections into the median eminence 
of the hypothalamus, the part of the hypothalamus that connects 
it to the pituitary glands (Balasubramanian et al., 2010). GnRH is 
then secreted in a coordinated, pulsatile manner into the pituitary 
gland, where it activates its own receptor, GnRHR, to release the 
gonadotrophin hormones, Luteinizing hormone (LH) and Follicle-
stimulating hormone (FSH), from the gonadotrope cells located 
in these glands (Counis et al., 2009). This unique pulsatile pattern 
in which the GnRH is released is directly responsible for the de-
gree of LH and FSH produced; low-frequency GnRH pulses lead 
to FSH release, while high-frequency pulses stimulate LH release 
(Jayes et al., 1997). In males, the GnRH pulses are constant, but in 
females, the pulses vary throughout the monthly menstrual cycle, 
and a large surge of GnRH occurs just before ovulation. Thus, LH 
is released prior to ovulation due to the large surge (Chrousos, 
2009). The fact that the gonadotropes react to the fluctuations in 
the GnRH pulses demonstrates that these pulses are critical for 
the reproductive system to function properly. This further proves 
a strong correlation between a healthy neuroendocrine system 
and a properly-functioning reproductive system (Counis et al., 
2009). Therefore, GnRH is a neurohormone that mediates brain 
control of the reproductive system; all of human reproductive ac-
tivity is generated by GnRH and the network of neurons in the 
hypothalamus.
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Kisspeptin
There is a neuropeptide in the hypothalamus known as Kisspeptin, 
whose role is to regulate the GnRH neurons. In the last decade, 
studies have been done to prove the role that Kisspeptin plays 
in the reproductive system. This further enhanced scientists’ un-
derstanding of neuroendocrine regulation of reproduction (De 
Roux et al., 2003). Kisspeptin was originally discovered in 1996 in 
Hershey, Pennsylvania and was amusingly named after the famous 
Hershey “Kisses” that were produced in this town (Skorupskaite 
et al., 2014).
 “Kisspeptin is now recognized as a crucial regulator of the onset 
of puberty, the regulation of the sex hormone-mediated secretion 
of gonadotropins, and the control of fertility” (Pinilla et al., 2012, 
in Skorupskaite et al., 2014 article).
It does so by stimulating the hypothalamus to secrete GnRH at 
the appropriate time, thereby maintaining a homeostatic environ-
ment in the body. In order for the reproductive system to function 
properly, there must be a balance of energy, and the Kisspeptin 
neurons ensure this. They signal to the GnRH neurons to release 
GnRH, which stimulates the secretion of LH and FSH from the 
gonadotropes (Clark & Cummins, 1985). The secretion of LH is 
much greater than that of FSH (Dhillo et al., 2005). In this way, 
Kisspeptin plays a key role in fertility; it activates the GnRH neu-
rons and locates itself near the GnRH neuron which stimulates 
LH release. Because Kisspeptin plays a large role in reproduction, 
it is evident that it can help individuals who are in a state of nega-
tive energy. During a study, when Kisspeptin was administered to 
a group of starving rats, their LH and FSH levels rose (De Bond & 
Smith, 2013). Kisspeptin accomplishes this by sensing the energy 
storage and initiating the secretion of GnRH, providing a connec-
tion between nutrition and reproductive function.  This demon-
strates the possibility of using Kisspeptin to restore reproductive 
activity in individuals who are in a negative state of energy, as in 
cases of anorexia nervosa (Skorupskaite et al., 2014). 
Most GnRH neurons contain a receptor for the Kisspeptin neu-
rons (Kiss1r). However, there are many other Kisspeptin recep-
tors located in different areas of the brain. This suggests that 
Kisspeptin does not only play a role in controlling the energy bal-
ance in reproduction, but has other functions, as well. (De Bond 
& Smith, 2013).
Leptin
Leptin is a hormone derived from the adipose tissue. It comes 
from the Greek word “Leptos” meaning thin (Meier & Gressner, 
2004). It is a recently-discovered hormone from the OB gene 
(Grasemann et al., 2004). It regulates energy balance along with 
hunger and metabolism, and it tells the brain when the body has 
enough energy and when it needs more food to provide ener-
gy. Due to its role in regulating food intake, Leptin is sometimes 
referred to as the satiety hormone. Each person has a set Leptin 
threshold that is specific to him, which is believed to be genetically 
determined. When the Leptin level is above the threshold, such as 
after a person eats a sufficient amount of food, the brain receives 
a message that it has enough energy to expend on daily activities, 
such as exercising and eating, and on expansive metabolic activi-
ties, such as pregnancy and puberty. However, the Leptin level is 
low due to a food deprivation, the brain senses this and goes into 
starvation mode, and basic metabolic processes are halted due to 
a lack of energy. The pituitary gonadal axes become suppressed 
and other critical neuroendocrine axes malfunction. It is believed 
that Leptin affects the neuroendocrine system because it sup-
presses neuropeptide Y (NPY) production and prevents its secre-
tion from neurons in the arcuate nucleus. NPY strongly stimulates 
appetite and regulates many of the hormones that are secreted 
by the pituitary gland, such as stimulating the pituitary adrenal 
axes, suppressing growth hormone by stimulating somatostatin, 
and suppressing gonadotropins (Meier & Gressner, 2004). A de-
crease in Leptin levels demonstrates a lack of energy; this will lead 
to a non-operative reproductive system, since it requires a lot of 
energy to function properly. Women with anorexia generally have 
low amplitude secretion levels of Luteinizing hormone, similar to 
those in young women who have not yet reached puberty or just 
begun it. This may be due to the decreased amount of fat mass and 
the alterations of the hormones produced by the adipocytes, such 
as Leptin. Leptin is an important factor in the timing of puberty, 
and as such, it facilitates the secretion of normal gonadotrophic 
hormones. Therefore, when an anorexia patient has reduced levels 
of Leptin due to the lack of necessary energy, her menses can 
be affected (Misra &  Klibanski, 2014). A study done on rodents 
proved that in a state of starvation they displayed a reduction 
in LH pulse frequency, and when Leptin was administered, these 
rodents experienced an LH surge prior to ovulation as well as 
restored menstrual cycles, which led them to be fertile once again. 
The lack of energy present in patients with anorexia nervosa re-
sulted in low Leptin and gonadotropin levels. These levels were 
restored with the aid of administering Leptin and adding nutrition 
to the patients’ diets. There is a hypothesis that Leptin initiates 
puberty, since studies indicate that a critical amount of body fat is 
required in order for a person to begin maturation. This suggests 
a positive correlation between the energy stored up in a human’s 
body and the onset of puberty (Elias & Purohit, 2012). 
Leptin concentration is based on BMI. Therefore, in patients with 
anorexia and bulimia, Leptin levels are low, leading to a starvation 
state in which menstrual cycles are disrupted and fertility is se-
verely affected (Meier & Gressner, 2004). However, these studies 
indicate that Leptin is not the only component necessary in pu-
berty. A study in Jackson Laboratories observed Leptin-deficient 
mice. It was discovered that even though these mices’ gonads 
and gonadotropes were fully developed and ready for puberty, 
they were GnRH deficient. Based on this piece of information, 
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scientists theorize that Leptin affects the hypothalamic part of the 
brain by stimulating GnRH secretion (Elias & Purohit, 2012).
“It is now well-accepted that Leptin is a key metabolic cue that 
signals energy sufficiency to control adequacy and timing of repro-
ductive function”  (Elias & Purohit, 2012).
Reproductive issues that anorexia can cause
In the DSM IV, amenorrhea is listed as a criterion for the diagnosis 
of anorexia nervosa; however, this obviously does not include the 
male population who make up 10% of the anorexic patients, which 
is the reason that amenorrhea is not included as a criterion in the 
DSM V. (Misra &  Klibanski, 2014).
Hypothalamic oligoamennhorhea, a symptom of anorexia nervosa 
in which a woman’s menstrual cycle is infrequent due to the de-
creased available energy, can lead to infertility. However, fertility can 
be restored once the body weight is stabilized and a normal period 
cycle resumes (Misra &  Klibanski, 2014).
Hypothalamic Amenorrhoea: Amenorrhea is defined as the cessa-
tion of a regular monthly period for more than six months. 68-89% 
of women with anorexia reported an absence of their monthly 
period for at least 3 months (Hoffman et al., 2011). This signifies 
that there is a lack of normal ovarian activity, probably due to a 
disturbance in the proper secretion of hormones. This condition 
occurs when the GnRH pulse is low because the hypothalamus is 
not functioning as it should be and cannot produce GnRH, there-
by causing a decline in LH and FSH secretion and follicular activity. 
This demonstrates the importance of a normally-operating hypo-
thalamus, as all ovarian activity and hence the menstrual cycle is 
completely dependent on its smooth functioning. Some functional 
defects which can interfere with the normal operating system can 
include eating disorders, stress, and exercise, since they can all 
potentially decrease GnRH secretion, which will lead to reduction 
of the other hormones (Baird, 1997).
Kallman’s Syndrome: a genetic condition which affects three to 
five times more males than females and is associated with the 
inability to conceive. This hypogonadotropic hypogonadism dis-
order occurs because there is a low amount of sex hormones 
(testosterone in males, and estrogen and progesterone in females) 
circulating in the body. The low levels of these hormones are due 
to a low level of FSH and LH which is caused by the hypothalamus 
not releasing GnRH properly. This could be a result of a defect 
in any part of the GnRH neurons’ migration from the olfactory 
placode to the hypothalamus, or it may be a failure of the pituitary 
gland to secrete GnRH. Without GnRH secretion, LH and FSH will 
not be secreted and therefore they will not “turn on” the ovaries 
or the testes, and eggs and sperm will not be produced (Mitchell 
et al., 2011). This concert of events is illustrated in Figures 2 and 3.
Although this paper mainly discusses the effects of malnutrition 
and fertility in females, the instabilities in the reproductive system 
in males with anorexia have also shown to affect male fertility. 
This is an effect of the low leptin, gonadotropin (LH and FSH), and 
testosterone secretion levels. A study done to demonstrate the 
levels of fertility in anorexic males and females shows that from 
140 women with anorexia, 50 women had a total of 86 children, 
and none of 11 anorexic men had children. As shown, anorexia can 
affect male fertility, but the extent is not documented thoroughly 
(Misra & Klibanski, 2014). 
Treatments
An increase in fat mass has proven to be a key role in restoring 
the menstrual cycle. Figure 4 shows a study done on adolescents 
suffering from anorexia nervosa which demonstrates that the 
menses returned to girls with body fat greater than 24%, while in 
those with less than 18% body fat, it did not (Misra &  Klibanski, 
2014).
LH concentration in a patient with anorexia nervosa (upper) is drastically 
lower than it is in a normal pattern when the patient is in remission (lower) 
(Boyar et al., 1974).
Figure 1: 
LH pattern in an anorexia case vs LH pattern in a normally-functioning 
system (Boyar et al., 1974).
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Figure 2: 
Hormones and their function during normal puberty; the release of 
GnRH, LH, and FSH from the hypothalamus and pituitary glands and 
their effect on the ovaries and testes (Smith, 1995).
Figure 3: 
Hormones and the Kallmann’s syndrome; the failure of the 
hyopothalamus to release GnRH and this will eventually result in a 
non- functioning testes and ovaries (Smith, 1995).
Figure 4: 
Proportion of body fat and relation to menstrual function (Misra, MD &  Klibanski, MD, 2014)
Menstrual cycles resume in individuals with an increase in body fat. For individuals with a low body fat (<18%) menses did not resume to 




The Southern Ontario Fertility Technologies (S.O.F.T.) was faced 
with several cases of hypothalamic amenorrhea, and since treat-
ments with gonadotropins are expensive, they sought a more 
affordable option. In 2011, they purchased two pumps to help 
alleviate the agony of these childless couples. Because hypotha-
lamic amenorrhea is caused by a lack of GnRH, reinstating GnRH 
seemed like the most practical solution. The only catch is that 
GnRH has to be released in pulses because a constant flow will 
desensitize the hypothalamus and pituitary gland. Pulses of GnRH 
will cause a release of LH and FSH which will then target the 
ovaries and testes and achieve the desired results of producing 
eggs and sperm. The pulses are emitted through a device called 
a GnRH pump, which is a small battery-operated machine. There 
is a programmable timer attached in order to emit the GnRH 
in pulses every 90-120 minutes. The pump is worn around the 
waist or thigh the entire time that the drug is being administered, 
usually starting from day three of the menstrual cycle until the 
time the woman ovulates. This form of treatment has been proven 
to be very successful, with a success rate of 90% in people with 
Kallmann’s syndrome. These fortunate women became pregnant 
within six months of beginning this treatment. For women with 
hypothalamic amenorrhea, their success rate of achieving preg-
nancy per cycle with this treatment is 25% (Martin J., 2011). In 
women suffering from hypothalamic amenorrhea, this therapy re-
sembles the beginning of puberty and these women will begin to 
experience normal menstrual cycles with the follicular maturation, 
ovulation, and corpus luteum formation. Once this is achieved, 
these women have a pregnancy rate comparable to those with 
healthy and normal cycles. The side effects of this pulse therapy are 
mild. Multiple pregnancies are a common occurrence as a result 
of the GnRH pulse level being too high for the required amount 
of that specific ovulation (Martin J., M.D., 2011). The GnRH pulse 
generator accomplishes its goal because it imitates the dynamics 
of a normal menstrual cycle; it releases GnRH at various frequen-
cies throughout the period over which it is performed (Santoro 
et al., 1986).
Hypothalamic amenorrhoea can be corrected by injecting 
Kisspeptin-54 twice a day for two weeks at a dosage of 6.4 nmol/
kg. This will result in a tenfold increase of LH secretion and a 2.5-
fold increase in FSH secretion. However, ovarian activity is not 
necessarily restored (Jayasena et al., 2009). Kisspeptin has proven 
to be a very useful therapy in restoring a normal LH level from a 
relatively high or low LH pulse (Skorupskaite et al., 2014).
When Leptin was administered to females suffering from hypo-
thalamic amenorrhea due to weight loss and excessive exercise, 
it was found that Leptin increased the LH volume and created 
a more favorable environment for reproduction (Elias & Purohit, 
2012).
Figure 5: LH and FSH response to injections of GnRH every two hours (Marshall & Kelch, 1979).
The FSH (dotted line) and LH (solid line) patterns increase significantly when administered with injections of GnRH; these 
pulses are much greater with GnRH than they are with a saline (Marshall & Kelch, 1979).
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There is more pertinent information available on the connec-
tion of infertility with specifically anorexia nervosa than with any 
other eating disorder. Whether bulimia nervosa has an effect on 
fertility is unknown, even though patients tend to display various 
menstrual irregularities. A study done on 173 women with bulimia 
provides information on this area. At first, 38.2% of these women 
were experiencing regular menstruation, while 4.6% had amenor-
rhea. 10-15 years later, the rate of amenorrhea was much higher 
at 13.9%. However, when the study was first conducted, 34.7% of 
the women had been pregnant at least once, while 10-15 years 
later this number rose to 74.6%, with only 1.7% of the women 
experiencing infertility. This demonstrates that while bulimia may 
be associated with menstrual dysfunction, it does not seem to 
have much of an effect on ability to conceive (Crow et al., 2002). 
For those who have struggled with infertility, the cause is most 
probably menstrual irregularities, because infertility from anorexia 
is a result of a dysfunctional menstrual cycle. The same treatments 
which help alleviate the anxiety caused by anorexia would likely be 
appropriate for these individuals who are suffering from infertility 
due to bulimia. 
Conclusion
This paper describes the importance of a proper nutrition to 
encourage a healthy reproductive system. Whenever the body 
is lacking necessary energy, as it is in cases of anorexia nervosa, 
there are alterations in the endocrine axis to help divert the en-
ergy that is present to perform the key body functions instead 
(Misra & Klibanski, 2014). There are various hormones present in 
every female body which will help boost LH, the chief hormone in 
a healthy menstrual cycle, in order to enable a malnourished body 
to conceive. GnRH, Kisspeptin, and Leptin are such hormones 
which will work together to help achieve a healthy pregnancy in 
individuals suffering from eating disorders. 
If people knew that there are treatments for fertility affected by 
eating disorders, they would not be so embarrassed and ashamed 
to seek help. Since the success rate of the treatments has been 
proven to be quite high, people should be made aware of the var-
ious treatment options. Unfortunately, in today’s society, the prev-
alence of eating disorders is very great, and there is no real way 
to stop this trend. Therefore, it is important that people become 
aware of the ways they can improve their situation to ensure 
themselves a healthier future.  Once people are diagnosed with 
an eating disorder, their physician should administer Kisspeptin, 
GnRH, and Leptin to prevent the damage that eating disorders can 
cause. Based on research which highlights the importance of these 
hormones on the reproductive system, the additional dosage of 
these can only be beneficial for them.
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Prevalence of cervical cancer
Cervical cancer is the third-most common cancer in the world 
and the second-most fatal in women, causing about 274,000 
deaths annually (Vici, 2014; de Noronha, 2013). Cervical cancer 
is a resilient cancer that is hard to eliminate. Screening programs 
are beneficial, even in young to middle-adult ages, when it leads 
to early detection and treatment, increasing chances of surviv-
al (de Noronha, 2013). Possible but unpleasant and not always 
successful treatments are monotherapy, radiation, chemotherapy, 
and drugs like Benacizumab (Vici, 2014). Researchers are also con-
cerned with quality of life, since the pelvic floor is affected after 
cancer has developed (de Noronha, 2013).  For these reasons, 
researchers decided to focus on the preventive aspect so fewer 
treatment options will be necessary. An individual can check for 
cervical cancer with a Pananicola test which detects precancer-
ous lesions that may eventually develop into cancer. Because of 
the increase of Pananicola testing recommended and performed, 
more people are aware of their cervical wellbeing (Markowitz et 
al., 2007). Many researchers noted that when they studied the 
pathogenesis of cervical cancer, 99% of cases and over 90% of 
squamous intra-epithelial lesions that appear before the cancer 
fully appears are actually caused by a virus, Human Papillomavirus 
(HPV) (Monie et al., 2008).  In fact, the biggest widespread sexually 
transmitted infection (STI) in the world is HPV; About 79 million 
people in the US currently are infected with HPV and about 14 
million people become infected each year (Markowitz et al., 2007). 
The cases increase with age until the mid-thirties age group, 
where the number of cases of HPV begins to decrease. HPV can 
cure itself, as it actually does in about 90% of cases. However, if 
an individual’s cervix does not heal, then she becomes at high risk 
for developing cervical cancer (Basu et al., 2013). Besides cervical 
cancer, HPV can also cause vaginal and vulvar cancer in women, 
penile cancer in men, and some oropharyngeal cancers and genital 
warts in both genders. Every year, about 26,200 new cancers are 
linked to HPV, and two-thirds of them affect women (Markowitz 
et al., 2007).
Pathogenesis of HPV
Of the 200 HPV genotypes, the majority of them can cause in-
fections that may result in “benign or self-limited tumors (warts) 
in the skin or in the genitals.” Those genotypes of HPV that do 
form warts are the oncogenic category of HPV (Wang & Roden, 
2013). There are about 13 high-risk HPV strains and another seven 
probable high-risk strains. The most common HPV strains world-
wide are HPV 16, 18, 31, 52 and 58 (Tachezy et al., 2013). The HPV 
virus can lead to cervical, vaginal, anal, pelvis, vulvar and oropha-
ryngeal cancers (Wang & Roden, 2013). The two most common 
HPV strains that are related to cervical cancer are HPV 16 (50% 
of all cases) and HPV 18 (20% of all cases). However, in anatomic 
locations other than the cervix that can be infected by HPV, such 
as the head and neck centers, HPV 16 is the cause of cancer 90% 
of the time (Monie et al., 2008). During intercourse, the epithelial 
cells of the cervix and vagina might acquire some abrasions, which 
raise the possibility of undifferentiated basal cells being exposed to 
a strain of HPV. If HPV is present, the cells might differentiate with 
the viral genome and begin to replicate (Wang & Roden, 2013).
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 HPV’s genome “encodes two classes of genes – early and late. The 
early genes control replication (E1, E2), transcription (E2), reorga-
nization (E4), and transformation (E5, E6, E7). The late proteins are 
structural components of the viral capsid.” However, the expres-
sion is controlled by the differentiation of the host - now infected 
- cell.  When development occurs, the HPV genome mixes into 
the host’s genome, causing E2, which is the main regulator of the 
virus’s genes, and L1 and L2 to be suppressed (Monie et al., 2008). 
That allows E6 and E7 to overregulate. E7 would lead the cell into 
the S-phase of uncontrollable replication and the cell cycle will 
be disrupted. Eventually a thickened epithelial lesion will form. Its 
cells will flow from the epithelium and a virus will spread.  HPV 
will then evolve into an HPV-related neoplasia and develop into 
warts or cancer if the immune system fails to protect the body 
(Basu et al., 2013).  
Genital warts are the largest cause of sexually transmitted infec-
tion in the Western world. Their treatment is excruciating and 
also not permanent, as the warts commonly recur. Besides the 
high costs of treatments for genital warts, the recurrence is also 
nerve-wracking and frustrating to a patient’s mental state. Genital 
warts generally come about from HPV 6 and 11 – two low risk 
HPV strains – but more research is needed to test for the pres-
ence of other strains, like the high risk HPV 16 and 18 (Szarewski 
et al., 2013).
Development of a vaccine
Because it takes years for an HPV infection to become a cancer, it 
is probably going to take years before researchers will be able to 
see the full results of the vaccines (Markowitz et al., 2007).  Two 
vaccines over the past decade were created to prevent the “grave 
outcomes of a long-lasting HPV infection and HPV-related ano-
genital maliganancies, high grade cervical intraephithelial neoplasia 
(CIN), VIN, VaIN, and AIN” (Wang & Roden, 2013).  The develop-
ment of vaginal, vulvar, and anal cancer is not yet fully understood. 
Unlike cervical cancer, there is no routine screening developed yet 
for vaginal and vulvar cancer. Vaginal and vulvar are not common 
cancers; 1,070 and 3,507 cases were reported in the US, respec-
tively (Markowitz et al., 2007).
The vaccines to prevent HPV are created by the use of virus-like 
particles (VLP) as the antigens needed to combat in the vaccines 
which come from the L1 surface protein of the precise types of 
HPV used in that specific vaccine (Basu et al., 2013). These VLPs 
are assisted by monoclonal antibodies (mAbs) for correctly fold-
ing into epitopes, virus typing and activating the proper immune 
response (Vidyasagar et al., 2014). The vaccine is considered dead 
as the VLPs are non-pathogenic and cannot cause other cells to 
become infected. Most importantly, the VLPs lack the viral ge-
nome. When a person is injected with the vaccine, the body re-
sponds and develops a high concentration of serum immunoglobin 
G antibody against those specific HPV types. Those antibodies are 
released in the cervico-vaginal secretion, and are also released 
when the epithelium acquires micro-abrasions. In this case, the 
antibodies will fight off any hint of infection before the virus has 
a chance to penetrate the basal keratinocytes in the vagina and 
cervix and infect them with HPV (Basu et al., 2013). 
CIN usually precedes HPV and can be graded from CIN 1 through 
CIN 3, with CIN 3 being the most severe. CIN 2 and CIN 3 are 
dangerous and are believed to be “pre-malignant lesions, as over 
time CIN 3 has a 30 to 50 percent chance of becoming cancer-
ous.” Screening for cancerous cells in the cervix is generally ob-
served during the CIN 2 and CIN 3 stages and with treatment, the 
cells may be stopped from developing into a cancer. Vaccines can 
stop CIN 2 and CIN 3 from developing altogether by preventing 
the infection of the common HPVs which eliminates the chance 
of cancer growth of those specific strains. The goal of the HPV 
vaccine is to prevent at least CIN 2 (Basu et al., 2013).
Because the vaccine is made from VLPs, it is considered a dead 
vaccine, since no live HPV ever enters the body in order to pro-
duce antibodies. Cervarix and Garsdasil are based on insect and 
yeast cells, yielding a high cost for the vaccinations compared to 
those that are based on Escherichia Coli. The vaccines are actually 
from virus-like particles (VLPs) that can be created by expressing 
the recombinant L1 from mammals, insects, yeast, and bacteria. 
VLPs are similar to the virions in structure and immunology. 
Studies have shown that these VLPs can cause high concentrations 
of serum antibodies (IgG) and can also protect against papillo-
mavirus in the outside body layers.  When trials began for the 
L1 vaccines, it was noted that they caused a 40 times increase in 
concentration of antibodies in the serum in the average person 
(Basu et al., 2013). 
Vaccine coverage
Both vaccines prevent the two most common HPV strains, HPV 16 
and HPV 18. Gardasil is a quadrivalent vaccine, preventing against 
four different types of HPV – HPV 6, 11, 16, and 18. However, HPV 
6 and HPV 11 are low-risk HPV strains which are the main causes 
of “genital warts and laryngeal papillomas.” This creates Gardasil’s 
ability to prevent cervical cancer and genital warts. Gardasil is 
prepared using VLPs from recombinant yeast (Basu et al., 2013). 
Cervarix is bivalent, meaning it can only inhibit two types of HPV, 
which are the most potent types, HPV 16 and HPV 18. The vac-
cinated population remain at risk of developing cervical cancer 
that is caused by other strains of HPV, yet the chances of this 
happening are much lower. Nevertheless, recent studies show that 
Cervarix also protects against HPV 31 and HPV 45 because of 
its close genotype, making Cervarix’s protection rate of all HPVs 
close to 80 percent (Basu et al., 2013). It has also been proven that 
these vaccinations “inhibit HPV-associated neoplasia in the vagina, 
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vulvar, anus, in addition to HPV 16 detection in oral rinses” (Wang 
& Roden, 2013). Cervarix is also different from Gardasil in that it 
is made from insect cells, allowing those with yeast allergies to be 
vaccinated.
Another important difference between the two vaccines is the ad-
juvant used. Because synthetic antigens and pure recombinant do 
not yield sufficient antigens in the body to build a strong response 
of antibodies, a new idea of adjuvants, something added to a vac-
cine to promote the antibodies’ response to the antigen, began 
to spread in the immunological world. Merck uses an alum-based 
adjuvant for Gardasil. Alum-based adjuvant is actually the most ac-
cepted adjuvant worldwide because of its effective Th2 response 
and its side effects – local and systemic effects like myofascitis 
and eosinophilia are atypical and infrequent (Petrovsky & Aguilar, 
2004). Vaccines also have an adjuvant to help expose the antigen 
to the body for long periods of time so that the body can build a 
complete adaptive response for future use. The adjuvant used for 
Cervarix is ASO4, but not much is known its effects (Monie et al., 
2008).
Who should be vaccinated
Cervarix and Gardasil are the first vaccine pair in history that 
focus on the same objective the same way just made by different 
companies. However, they are not interchangeable. Besides that 
Gardasil is a quadrivalent vaccine and prevents more than cervical 
cancer, it can also be used on the male population, while Cervarix 
cannot. 
  Gardasil is approved for males and females ages nine through 
twenty-six. However, the recommended age of HPV vaccination is 
ages 10-25.  Based on studies performed on various ages, the pre-
teens (10-15 years old) contained a higher “anti-HPV neutralizing 
antibodies response” than the group of 16- to 23-year-old females. 
Also, for maximum vaccine effect, it should be administered before 
the person engages in sexual activity (Basu et al., 2013). Pregnant 
women should not be vaccinated (Gardasil.com, 2013; Cervarix.
com, 2013). It is recommended that boys also receive the vaccine 
during their teenage years. The vaccine seems to be less effective 
for boys than for girls. The fact that boys may depend on the girls 
being vaccinated also downplays the urgency of all boys getting 
vaccinated. Gardasil recommends boys and men to be vaccinated 
from ages nine through twenty-six to prevent anal cancer caused 
by HPV 16 and 18, genital warts caused by HPV 6 and 11, and anal 
intraepithelial grades 1, 2, and 3. Cervarix has not yet been ap-
proved in the US for males as more studies are needed to decide 
whether it is potent.
Administration
Gardasil is an intramuscular injection; is administered three times 
in either the deltoid muscle or the upper thigh region. The second 
dose is given two months after the first, and the third dose is 
administered four months later. Clinical studies have shown that 
three doses administered within one year create maximum effica-
cy for the patient (Gardasil.com, 2013). 
Cervarix’s instruction label has similar directives as Gardasil’s. 
Cervarix is for females ranging from ages 9-25, and it is an 
Table 1-
The similarities and differences of the two available vaccines for HPV prevention:  Some countries only have one vaccine available, like Canada, and others have 
both vaccines available, like the United States. (Source: Dawar et al., 2007)
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intramuscular injection –preferably in the deltoid – that should 
be administered three times: the second a month after the first 
injection and the third six months after the original injection. The 
common side effects are swelling and redness in the area of where 
the vaccine was administered, headaches, fatigue, syncope, myalgia, 
and gastrointestinal symptoms.  Because of the dangers of syn-
cope, as with a Gardasil injection, it is necessary for all patients 
to wait fifteen minutes in the medical office before leaving for 
observation (Cervarix.com 2013).
One major concern about Cervarix and Gardasil is their limita-
tions in preventing cervical cancer. They do not guarantee a 100% 
success rate against cervical cancer, as Cervarix only fully protects 
against two strains of HPV and partially cross-protects against 
another two. HPV 33, HPV 52 and HPV 58 are other highly po-
tent strains that are not protected and may cause cervical cancer. 
Therefore, a broader vaccine is still needed to protect fully against 
around 90 percent of all cancer-causing strains. Some researchers 
believe that the future plans of cervical cancer vaccines should 
implement L2 as the antigen to use to cultivate a broad spectrum 
of antibodies (Basu et al., 2013).
Another major concern which Basu, Banerjee, Singh et al., raise 
is the unknown knowledge of how long the vaccine is viable and 
active. Because these vaccines are new, studies regarding their ef-
ficacy are not abundant. Perhaps a booster is needed after a few 
years. Banerjee and his fellow researchers state in their report 
that studies show that immunity seems to last for about 5.5 years. 
However, that is not long enough, as pediatricians believe that pre-
teens are the ideal age for the vaccines and as aforementioned, the 
manufacturers’ recommended age for receiving these vaccines is 
between ages 10-25. Therefore, if a child is 11 when she receives 
the vaccine, she will be 16.5 when the vaccine loses its effect, 
while she is still a growing and developing teenager.  In addition, 
not enough years have passed to fully observe the long-term ef-
fect this vaccine has on people.
Basu says that around the age of thirty people begin to develop 
their own antibodies against the virus. However, there is a 12.5-
year gap between the time when the vaccine diminished and when 
an individual became naturally immune to it. On the other hand, 
more research is needed on the exact length of protection against 
HPV in order to conclude whether a longer length of vaccine 
protection is needed, a booster should be administered, or the 
current vaccines Cervarix and Gardasil are sufficient (Basu et al., 
2013).
Prevention, not treatment
The vaccine does not mitigate or affect pre-existing HPV in any 
way.  The basal epithelial cells and cervical cancer cells do not 
seem to exhibit a considerable amount of their capsid antigen, L1 
or L2. If a vaccine targets the L1 or L2, these cells would remain 
untouched. The true need is to rid all HPV from the world; how-
ever, there are too many people who are already infected and are 
infecting those who are unprotected. (Basu et al., 2013). Therefore, 
it is crucial to remember that for an individual already infected 
by HPV, the best course of action is to consider treatment with 
medications, as the vaccine would be ineffective at this point. New 
research is being done to perhaps target the E6 and E7 proteins 
to help those who are already infected and therefore cannot use 
the vaccine as a solution. In the meantime, infected patients should 
resort to chemotherapy, radiation, surgery, and antibody therapy 
as possible treatments (Han & Sin, 2013).
Side effects of Gardasil
According to Gardasil’s website, the vaccine has a few minor side 
effects: redness or swelling around the injection site, headaches, 
dizziness, nausea, fainting and fever. In 2009, due to an increase 
of fainting and syncope, the FDA took initiative and ordered the 
manufacturer of Gardasil, Merck, to add on to the instruction label 
that it is mandatory for every patient to sit in the office for 15 
minutes upon injection.  The FDA says that by having the patient lie 
or sit in one position for fifteen minutes, the medical supervisor 
can monitor for the initial symptoms that generally develop into 
syncope, such as paleness, dizziness, sweating, changes in vision 
and ringing in the ears (Sullivan, 2009).  According to Gardasil, the 
most common side effect is headaches. However, Sullivan states 
that syncope following injection should not be taken lightly, as 
about 40 percent of syncope cases as a side effect develop into a 
tonic-clonic seizure-like activity which necessitates hospitalization. 
If a syncope or seizure-like activity occurs, the health professional 
should have the patient lie down to allow blood to continue circu-
lating throughout the body. (Merck points out that fainting is not 
a side effect only to Gardasil, as it is also common after donating 
blood, receiving other injections, and is a typical response to pain.) 
(Sullivan, 2009)
From January 2005 until July 2007, 70 cases of syncope resulting 
from a Gardasil injection were reported. According to Sullivan 
in her Pediatricnews.com article, about five percent of the cases 
were considered serious, 38 cases occurred on the vaccination 
day, and 37 cases required hospitalization. As of May 2009, out 
of 24 million vaccinations, 13,758 VAERS reports were filed. 93 
percent of those reports were considered not serious, including 
symptoms such as fainting, swelling, fever, headaches, and nausea. 
However, seven percent of those events were considered serious 
(Sullivan, 2009).
Immune response difference
Throughout studies, it has become evident that Cervarix produces 
a larger antibody response than Gardasil. In one study performed 
by GSK testing the two vaccines, “geometric mean titers of serum 
neutralizing antibodies ranged from 2.3- to 4.8-fold higher for 
HPV-16 and 6.8- to 9.1-fold higher for HPV-18 after vaccination 
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with Cervarix, compared with Gardasil, across all ages” (Einstein 
et al., 2009). One major possibility which researchers focus on 
is the ASO4 adjuvant, as both vaccines use VLPs. Although it is 
unknown for how long each vaccine is viable, one study claims 
Cervarix lasts up to 6.4 years. However, both manufacturers be-
lieve that they will know when the vaccine becomes irrelevant 
before the people who were already vaccinated will lose their 
protection.
How do most healthcare professionals decide which of the two to 
give? It will usually depend on the cost. However, patients should 
be notified of the benefits and differences of the two vaccines be-
cause they are not interchangeable in their protection (Pichichero, 
2009).
HPV infections cannot be treated; only their lesions may undergo 
treatment. Treatment options for the precursors of genital wart, 
vaginal and vulvar lesions have different options of removing the 
lesion and therapy. 
Methods
The information in this research paper was obtained from many 
journals, studies and research papers from the national website 
of Pubmed and Touro College’s Online Library and Database. This 
paper’s purpose is to educate the reader about what HPV is, how 
it develops into a cancer, why a vaccine is necessary, and how 
the vaccine is assembled. In addition, this paper will point out the 
different treatments for HPV, cancer, and genital warts and how a 
vaccine will make an imprint on the world. Using the manufactur-
ers’ (Merck’s and GSK’s) websites the reader will develop a vast 
knowledge of every aspect of the vaccines, ranging from what they 
cover to who should be vaccinated. Also, studies conducted on 
the vaccines will be examined to find any inaccuracy that exists 
which might lead those who are not knowledgeable in this area 
to be misinformed, and to help the reader develop his/her own 
opinion on the matter. Lastly, the effects of the vaccine on the 
world will be analyzed to see what the future has in store for its 
future of HPV and all that it may cause. 
Discussion
A study was done in 2003 by the Future II study group of the New 
England Journal of Medicine on a newly developed quadrivalent 
vaccine, which eventually became Gardasil, on the recommenda-
tions of the World Health Organization (WHO) and the FDA. The 
goal of the study was to determine the efficiency of the vaccine 
against HPV 6, 11, 16, and 18 and lesions. The study consisted of 
12,167 non-pregnant women from 131 different countries who 
had normal Papanicolaou smear results and had not had more 
than four partners in their lifetimes. After the subjects were vac-
cinated, they were evaluated by gynecologists for the average of 
the three years for which they were observed. At the conclusion 
of the study, it appeared that the vaccine is 98% effective in the 
population that was never exposed to HPV 16 and 18. However, 
the vaccine was only 44% effective in the pre-exposed popula-
tion to HPV and cervical lesions. In other words, 42 subjects of 
this study were infected within the first three years. Once again, 
the idea that researchers do not know what to expect past the 
years of research is alarming. Also, the pharmaceutical company 
Merck, which is currently the supplier of Gardasil, sponsored this 
study. There might be a risk of bias because of the financial backer 
(Future II Study Group, 2007).
Prophylactic vaccines that fight against HPV 16 and 18 have a 
high success rate against CIN 2 and 3 and some external genital 
lesions. However, because much is needed to persuade the pop-
ulation of the success of the vaccine to prevent CIN, a study was 
done to create a baseline before the creation and availability of 
HPV vaccines to the world. 
The subjects of this study were from population-based reg-
istries from Denmark, Iceland, Norway and Sweden who were 
“diagnosed with incident cervical vulvar and vaginal cancer and 
pre-invasive neoplasia  from January 1, 2004 until December 31, 
2006, with only the primary tumors allowed to be included yield-
ing to over 100,000 subjects in the number.” According to the 
data collected in all countries, the age range of 20 through 29 
years old experienced an immense increase of cases and a peak 
in the thirties age range for cervical cancer, yielding about 10 per-
cent of the cases. However, cervical pre-invasive neoplasia was 
most commonly found in people in their twenties in all four coun-
tries. Nevertheless, vulvar and vaginal cancer peak past the age 
of 40 and peak in women over 70. These researchers were able 
to mathematically predict the impact of vaccination by including 
the fact that only 30% of CIN3 would develop into cancer if not 
treated. Besides the fact that overtreatment of CIN3 is costly, it 
is dangerous for those in their reproductive years, as it increases 
the risk of preterm births. Therefore, it is in the best interests of 
all involved to prevent neoplasia in women. The researchers state 
that if the vaccine is really close to 100% efficacy, based on liter-
ature review, the cases of pre-invasive neoplasia should decrease 
by 52 to 67 percent, totaling about 2,471 to 2,911 fewer cases 
of diagnosed and treated cervical cancer in these four countries 
(Nygard et al., 2014).
Another study was done in England on the effects of Cervarix 
and its ASO4 adjuvant. The study was a PATRICIA (Papilloma 
Trial against Cancer in Young Adults) trial which was “phase III, 
double-blind, randomized and using the Hepatitis A vaccine as a 
control.” The study did not exclude anyone based on previous 
or current history of genital warts.  The subjects had a cervical 
sampling done every six months for HPV DNA typing and tested 
for 14 cancerous HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, and 68) and another 11 non-cancerous HPV 
genotypes.  In addition, all women were examined every twelve 
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months and had a colposcopy if necessary. In total, 18,644 women 
received at least one dose and were included in this study from 
May 2004 until November 2009. The average monitoring time was 
43.7-47.4 months. The results of this study are quite interesting: 
although the bivalent vaccine only officially covers HPV 16 and 
18, a cross-protection was found that prevents HPV 6, 11, 31 and 
45. The reason for cross-protection may be from the similarities 
in structure and homology within the L1 VLP. However, when 
comparing the response from the L1-specific T helper cell that 
are caused by HPV 6 and 11 in the bivalent and the quadrivalent 
vaccines, the numbers of cells were analogous to each other.  The 
study also proves that there was a greater helper T cells response 
for HPV 31 and 45 in the bivalent vaccine.  The reason for cross 
protection may be from the similarities in structure and homology 
within the L1 VLP. The study concluded that the risks of persistent 
effects decreased with the use of vaccines (Szarewski et al., 2013).
England was the first country to try a national immunization pro-
gram involving Cervarix.  As a result, researchers were able to 
study the records from the general practices and the genitouri-
nary medicine clinics of the general public to observe the trends 
of genital warts. Although it has been proven that Gardasil pre-
vents HPV 6 and 11, the main causes for genital warts, Cervarix 
seems to cross-protect them, which also results in a prevention 
of genital warts. This was proven when the study conducted in 
England noticed the large decrease in genital warts in the immu-
nized female teenage population. The teenage male population 
also had a decreasing rate in reports of genital warts, but it was 
not as significant as the female’s population.  However, there are 
many reasons that may have contributed to the decline; one big 
factor is that the population became more aware of the dangers of 
HPV and genital warts and therefore realized the need to protect 
themselves by abstaining from unsafe intercourse.  More studies 
like this one are needed in order to conclusively state 
that it is the vaccine lowering the cases of genital 
warts in England (Howell-Jones et al., 2013).
Beginning in 2006, the National Immunization Survey-
Teen in the United States conducted a study by calling 
random landlines and cellular phones for its sample. In 
total, 14,133 adolescents (with their guardians’ consent) 
submitted their vaccination history. The results showed 
that the number of adolescents receiving the vaccine for 
each dosage increased each year until the number stag-
nated in 2012. However, in 2012, questionnaires began 
to ask why people opted not to vaccinate their daugh-
ters. The most common answers were that the vaccine 
is not needed, the vaccine is not recommended, there 
are questions about the safety of the vaccine, there is 
a lack of knowledge about the vaccine or disease, and 
that their daughter is not sexually active (Centers for 
Disease Control and Prevention [CDC], 2013).
According to the CDC, about 56 million dosages of Gardasil 
were administered from June 2006 through March 2013, and 
from October 2009 through May 2013, about 611,000 dosages 
of Cervarix were administered in the United States. Analysis of 
vaccine safety by the CDC is limited to Gardasil because it cov-
ers 99% of the vaccinated population. Of the 54 million vaccines 
administered, 21,194 unusual cases were reported in females, and 
92.1% of those cases were considered non-serious. The main bulk 
of these reports were from 2008. Yet, the remaining 7.9% of those 
cases were considered serious, with the highest total from 2009. 
However, these symptoms that occurred after patients received 
the dose are usual symptoms that may occur for most vaccines 
(CDC, 2013).
The ACIP conducted its own trials and safety studies on Cervarix. 
Each Cervarix vaccine administration was observed for any symp-
toms upon injection, like development of a new autoimmune dis-
ease or chronic diseases, injection-site reaction, systemic symp-
toms, and death. Of the 23,713 females studied in the study, 92% 
complained of injection-site swelling, 48% had redness, and 44% 
had swelling. Other common side-effects were myalgia, fatigue and 
headaches.  Only about 5.3% complained of serious results; how-
ever, 5.9% in the control group also complained of serious results 
(CDC, 2010).
Gardasil also performed its own studies on a variable population 
with all different types of ethnicities, ages, gender, and previous his-
tory.  In total, 28,413 people participated in this study, the majority 
of whom were women. In the 16-26 age range for females, the 
efficacy, which was marked by almost one hundred development 
of CIN, VAIN, AIS, VIN, and genital warts, was close to 100 percent 
in all categories, with the lowest rate at 96.9%. The rate in older 
women was not as high as the younger population, where the 
Figure 2: 
The number of serious and non-serious reports of side effects of Gardasil by year from June 
2006-March 2013 (CDC, 2013).
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efficacy rate was approximately 85%.  Men ranging from 16-26 had 
about a 90% efficacy rate. However, the numbers dipped, even at 
some points close to 60% efficacy, in the prior or currently HPV-
infected population. The immunological tests showed good results 
for geometric mean titers and a high percentage of antibodies that 
are anti-HPV 6, 11, 16 and 18 in all subjects. During clinical trials, 
safety was a major area of observation; very few abnormal cases 
and mainly all typical vaccines reactions, like headache, pyrexia, 
diarrhea, nausea, and vomiting were noted. In addition, 258 out of 
29,323 subjects complained of serious reactions like headache, ap-
pendicitis, gastroenteritis, urinary tract infection, and pneumonia. 
Forty people were healthy and died from motor vehicle accidents, 
overdose, cancer, gunshot wounds and pulmonary embolus. Those 
people reflect the all deaths notified in their report so no person 
actually died from the vaccine directly.   
Many more studies like the ones mentioned above have been con-
ducted and analyzed. The common thread among all of them is 
that the vaccine causes an increase titer of antibodies in close to 
100% of the subjects, subjects’ side effects include the regular side 
effects common to all vaccines with the additional of chance of 
syncope, and only less than 10 percent may have had serious impli-
cations afterwards, but nobody ever came close to death because 
of vaccination (Gardasil.com, 2013).
Based on all of these studies, the vaccine seems to enable the 
production of antibodies against HPV in all those vaccinated to 
prevent future cancer. The side effects seem reasonable in com-
parison to all other vaccines. No serious ailments are connected 
to the vaccine directly and the vaccine is deemed to be safe. The 
biggest concern that still remains is how long the vaccine’s im-
munity will last. Since Gardasil has only been distributed to the 
population for eight years and has been studied for a bit over a de-
cade, not much is known as to the long-term effects, both positive 
and negative. Cervarix is even less studied because its worldwide 
distribution began only five years ago. Questions do remain on 
the preference of the two vaccines: Cervarix leads to more than 
double the number of antibodies, whereas Gardasil prevents more 
genotypes and genital warts. As mentioned before, it should be 
the patient’s choice as to which vaccine should be administered to 
him/her. Realistically, the fact that 54 million people had received 
Gardasil while only 600,000 had received Cervarix through 2013 
sheds light on the fact that doctors only have one vaccine in the 
office. This might be because of costs or health insurance cover-
age. Nevertheless, patients should be advised about both vaccines 
and should have the right to ask for whichever one they think is 
properly suited for them. 
Conclusion
In 2006, a new era of science began with the development of a 
cancer vaccine – the HPV vaccine. If an individual has persistent 
HPV infections, he/she has a chance of that HPV virus growing 
into an abnormal growing stage which will eventually become 
cancerous. The newly discovered vaccine has been proven to pre-
vent any further growth of lesions from the HPV virus and to 
prevent these lesions from becoming cancerous. The vaccine also 
gives the vaccinated community anti-HPV antibodies. Gardasil is 
a quadrivalent vaccine and protects against HPV 6,11,16,18 and 
genital warts. Cervarix is a bivalent vaccine that only protects 
against HPV 16 and 18. HPV 16 and 18 are the most significant 
strains as it causes about 70% of all HPV cases. Furthermore, each 
vaccine also cross-protects against other HPV genotypes. Both 
vaccines have an unusual and yet close to 100% efficacy rate and 
the sides-effect for each vaccine are minimal. Very few cases of 
serious side-effects have been reported, which none of them led 
near death or death situation. The vaccine is catered for the 10- 
to 25-year-old age range and best results occur when given to 
individuals who are not yet active or pre-exposed, because the 
vaccine does not cure HPV infections whatsoever.. Although most 
people think HPV is not “catchy,” it is in fact highly contagious and 
is similar to influenza and chicken pox in that it spreads through 
direct contact. HPV can spread from person to person in people 
ten years and older, with the help of the fact not everybody knows 
they have it. Therefore, HPV is a serious matter and the number 
of cases must lessen. If fewer individuals are infected, there will 
be fewer cancers in the world. Similarly, just like the polio vaccine 
fewer to less outbreaks of polio, hopefully one day fewer people 
will contract anal, vaginal, penile and cervical cancer because of 
the influence of the HPV vaccine.  It is important for the public to 
be educated about the harms of HPV, the cancers HPV cause, and 
the benefits and risks of preventive HPV vaccines, Gardasil and 
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Introduction
“Chicken pox is most commonly an annoying illness lasting three 
to seven days, and happily never seen again” (qtd. in Link 2005). 
This statement is by and large true about the actual chickenpox 
illness; in response to a chickenpox disease, the body builds immu-
nity against future occurrences, and rarely does a second case of 
chickenpox occur. However, the virus which caused the chicken-
pox may be seen again; it may resurface as a disease called shingles 
after years of lying dormant.
Chickenpox, the popular name for varicella, was a common child-
hood rash until the varicella vaccine was licensed for use in the 
United States in 1995. Prior to the introduction of the varicella 
vaccine, over 90% of Americans contracted chickenpox by age 
15 (Chickenpox 2013). Chickenpox symptoms typically last up 
to seven days (Simon 2012). However, even after recovery from 
chickenpox, the causative agent—varicella-zoster virus (VZV)—
remains dormant inside the body in sensory nerves. Reactivation 
of the virus later in life results in shingles, or herpes zoster, and 
presents differently than its predecessor. Chickenpox appears as 
an itchy rash and blisters all over the body, and shingles appears as 
a blistery rash restricted to one side of the body (Figures 1 and 
2). While chickenpox is generally considered a mild, unpleasant 
disease and is short lived, shingles is a more severe, painful disease 
which can have lasting effects. Generally, shingles symptoms clear 
in seven to ten days; however, it is not uncommon for it to take as 
long as a month to clear. The most common debilitating complica-
tion related to shingles is postherpetic neuralgia (PHN), defined as 
pain that persists longer than a month after the onset of shingles 
and lasts at least 90 days (Sampathkumar et al. 2009). The risk for 
PHN can reach 25-50% for shingles patients over the age of 50 
and up 75% for patients over the age of 70 (Giménez-Milà et al. 
2014). Other complications that may arise due to shingles include 
zoster ophthalmicus (reactivation of VZV in the trigeminal ganglia 
involving the ophthalmic division of the nerve, potentially damag-
ing the eye and surrounding structures), bacterial superinfections, 
and neurological  manifestations such as meningitis, encephalitis, 
myelitis, and complex regional pain syndromes I and II (Studahl et 
al. 2013 and Giménez-Milà et al. 2014).
Methods
In researching the background of varicella and herpes zoster, par-
ticularly theories regarding the reactivation of varicella-zoster 
virus, articles were gathered using various databases of scientific 
literature. These include PubMed,a service of the United States 
government, and various databases of health science journals 
made available through access to the Touro College and Ursuline 
College libraries.
Pathogenesis
Varicella zoster virus, the causative agent of varicella (or chicken-
pox), is a member of the herpesvirus family and alphaherpesvirus 
subclass. After the primary varicella infection, VZV withdraws to 
the dorsal root ganglia and trigeminal ganglia where it remains la-
tent. In fact, VZV in its latent stage can be found in multiple ganglia 
along the entire neuraxis (Liesegang 1999). It may remain dormant 
for the remainder of the life of its host, never causing any viral 
symptoms, or it may reactivate at any time as herpes zoster (HZ), 
more commonly known as shingles (Figure 3). However, according 
to Greg Bennett (qtd. in Polansky 2013), even during the latency 
period, which may last the entire lifetime of its host, VZV does not 
Abstract
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remain inactive; transcription of the VZV has been 
detected even during this period. Reverse tran-
scription polymerase chain reaction has identi-
fied multiple VZV transcripts in latently infected 
human ganglia (Baird et al. 2013). “Thus,” claims 
Bennet, “the idea that the virus is inactive and 
presents no risk during the so-called inactive pe-
riod is a misconception. Rather, the latent viruses 
are active and can be dangerous.” 
The dermatological signs (i.e. rash and blisters) of 
herpes zoster are similar in their centripetal distri-
bution to dermatological signs of varicella (Figure 
4). This is suggestive that during primary varicella 
infection, the virus (VZV) spreads from infected 
skin cells to sensory nerve endings and then to the 
ganglia where it remains dormant. Subsequently, 
when VZV reactivates, it appears with the same 
centripetal distribution (Liesegang 1999). However, 
writes Liesegang, despite the similar dermatological 
distribution, it does not necessarily have to be so. It 
may be that the ganglia are directly infected hema-
togenously during the viremic phase of the initial 
varicella infection, and the path VZV takes when it 
reactivates as herpes zoster is simply indicative of 
the ganglia most exposed to reactivation stimuli. 
Figure 2: 
Shingles appears as a blistery rash restricted to one side of the body. Source: Shingles Pictures 2014
Figure 1: 
Chickenpox appears as an itchy rash and blisters 
all over the body. Source: Chickenpox Photos 
2013
Figure 3: 
The varicella zoster virus is the causative agent for chickenpox and shingles. After chickenpox, the virus 
never goes away. Instead, it settles in nerve cells and may reactivate years later, causing shingles, also 
called herpes zoster. Source: Smith 2014
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Regardless of the path taken by VZV from initial varicella infection 
through latency and finally reactivation as herpes zoster, the cause 
of VZV reactivation remains unknown. There are numerous hy-
potheses as to what causes reactivation of VZV, although there is 
no concrete evidence supporting any one hypothesis and certainly 
no consensus among researchers. It is quite clear, however, that 
risk of herpes zoster increases with age. This is widely attributed 
to the decline of cell-mediated immunity (CMI) that progresses 
with aging. It is assumed that the dormant VZV is held in check 
by the cell-mediated immunity, not humoral immunity, so when 
CMI declines, the virus can flare up. Humoral immunity is assumed 
not to play a role in suppressing VZV, for herpes zoster has been 
shown to occur even in the presence of high levels of antibody 
titer, and antibody titer is a measure of humoral activity (Liesegang 
1999).
Genetic Correlation
Philip S. Rice (2011) suggests a genetic correlation as governing 
the latency and reactivation of herpes zoster virus. He hypothe-
sizes that exposure to the sun, or more particularly to ultra-violet 
radiation (UVR), plays a significant role in determining the gen-
otype of the VZV, and, thus, the virus has evolved into different 
genotypes based on climate. He builds his hypothesis on the fact 
that incidence of varicella is significantly lower in tropical regions 
than in temperate regions and that, even in temperate regions, 
varicella incidence is at its lowest in the summer. (In regions near 
the equator, i.e. tropical regions, the sun’s rays arrive almost per-
pendicular to them, thus higher levels of radiation. Near the poles, 
i.e. temperate regions, the angle of the sun’s rays spreads them out 
over a much greater area, providing less energy per unit of area 
(Raven et al. 2005).) He posits that in the tropics, the high levels of 
ultra-violet radiation may inactivate varicella virus in the vesicular 
fluid either before or after rupture of the vesicles. According to 
Asano et al. (1999), vesicular virus contributes more to the spread 
of the virus than the shedding of the virus from the respiratory 
tract. Consequently, in the tropics, transmission of varicella virus 
is significantly diminished due to ultra-violet radiation. As early 
humans lived in Africa—a tropical region— the virus evolved into 
a genotype resistant to ultra-violet radiation as a survival strate-
gy. When humankind spread to temperate regions, however, the 
virus shed its selective advantage of UVR resistance. However, as 
an evolutionary tradeoff for its lost advantage and, thus, reduced 
transmissibility (during the summer months when UVR is stron-
gest), the virus increased its propensity to reactivate as herpes 
zoster in order to ensure its continued survival in temperate re-
gions. Accordingly, the temperate genotype of VZV is prone to 
reactivation while the tropical genotype is not (except in severely 
immunosuppressed individuals). This explains why data of herpes 
zoster incidence in tropical countries is virtually absent. Rice, thus, 
suggests that the same mechanism responsible for UVR resistance 
in tropical VZV genotypes may also play a role in the latency and 
reactivation of temperate genotypes.
Quinlivan et al. (2013) also mention findings of various genotypes 
of VZV according to country. They write that VZV genotyping has 
identified five clades (a clade is a group consisting of an ancestor 
and all its descendants) of which clades 1 and 3 predominate in 
Europe, clade 2 in Japan, and clades 4 and 5 in Asia and Africa. 
Liesegang (1999) also notes the significant variation of VZV be-
tween tropical and temperate regions and insists that it must be 
due to agent specificity. 
A point one can take issue with and not addressed by Rice is that 
if the tropical genotype has acquired UVR resistance in order to 
avoid inactivation by ultra-violet radiation, then why is incidence 
of varicella lower in tropical regions than in temperate regions; 
shouldn’t the tropical genotype be able to thrive in constant sun-
light just as well as the temperate genotype does in decreased 
sunlight? The answer to this question may lie in that varicella is 
easily spread by respiratory route via airborne transmission, and 
this form of transmission is aided by winter weather. In addition 
to increased coughing during the winter months and the tenden-
cy to remain indoors due to the cold temperatures outside, the 
cold, wet weather may aid the survival of the virus outside a host 
(Zak-Prelich et al. 2002). In the tropics, despite the advantage of 
UVR resistance, the virus lacks the advantage of winter weather 
aiding in spreading it, and this may explain the lower incidence of 
Figure 4: 
The chickenpox rash exhibits centripetal distribution, meaning that the 
greatest concentration of lesions is on the trunk with fewer on distal 
extremities. This is in contrast to the smallpox rash which exhibits centrifugal 
distribution, meaning that the greatest concentration of lesions is on the face 
and extremities with fewer on the trunk. Source: Antipuesto 2008
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varicella there. Although, as Rice quoted from Asano et al. (1999), 
vesicular virus contributes more to spreading of the virus than 
does airborne transmission from the respiratory tract, and the 
tropics have the advantage of vesicular transmission even in pres-
ence of ultra-violet radiation, the lack of increased airborne trans-
mission may still be a viable explanation for the significantly lower 
incidence rate in the tropics.
Another setback to Rice’s hypothesis is a suggestion from 
Gallerani and Manfredini (2000) that ultra-violet radiation might 
be responsible for increased incidence of herpes zoster in the 
summer months (in temperate regions) due to its ability to sup-
press cellular immune response (Figure 5). When immunity to 
VZV is reduced, the latent virus is then able to reactivate as her-
pes zoster. This would suggest that ultra-violet radiation aids in 
virus activation, while Rice suggests that ultra-violet radiation is an 
inactivator of VZV. However, this is easily answered by the differ-
ent methods of activation in both diseases. Varicella is transmitted 
from person to person by vesicular route or respiratory route. 
Thus, because the virus in the vesicles (in the temperate geno-
type) is inactivated by ultra-violet radiation, spread of the virus 
is decreased. Herpes zoster, on the other hand, can only develop 
from reactivation of a latent VZV; it is never transmitted from one 
person to another (Simon 2012). Reactivation of the latent VZV 
is largely due to immunosuppression. Thus, ultra-violet radiation 
does not actually reactivate the virus, it merely suppresses the 
immunity that is keeping VZV dormant, and this allows VZV to 
reactivate. In other words, ultra-violet radiation may, in fact, inac-
tivate vesicular varicella virus as Rice posits, and the fact that ul-
tra-violet radiation is also responsible for increased herpes zoster 
incidence is not contradictory, because ultra-violet radiation does 
not actually activate herpes zoster.
While Rice suggests that genetic variations in the VZV itself result 
in prevalence or scarcity of VZV reactivation, others suggest that 
genetic variations in human subjects may be responsible. Schmader 
et al. (1998), in a study of communities in North Carolina over 
a six-year period, found significantly fewer herpes zoster cases 
among black subjects than among white subjects. To explain this 
phenomenon, they suggest that decline in cellular immunity due to 
aging may be less in black people than in white people, although 
they offer no explanation as to why. However Thomas and Hall 
(2004) take a novel approach in explaining why this may be so. 
They suggest that a less significant decline in cellular immunity 
among aging black subjects may be due to differential survival, 
or natural selection. “In populations with higher mortality rates, 
those who survive to old age may have robust immune systems 
(and therefore lower susceptibility to zoster),” they write. (They 
may be referring to the high mortality rate of even young children 
in Africa. They may also be referring to the increased mortality 
rate, even in the US, among African American children [Infant 
Mortality and African Americans 2013] Another approach Thomas 
and Hall take is that it may be caused by genetics; genetic differ-
ences between black subjects and white subjects may result in 
decreased or increased incidence of VZV reactivation, respectively. 
This approach suggests that genetic variations among the human 
race may be behind the propensity toward VZV reactivation. 
One can also argue that the difference in herpes zoster incidence 
between black subjects and white subjects is due to variations of 
the VZV genotypes rather than genetic variations among humans, 
based on the findings of five different clades of VZV, with clade 5 
predominant in Africa and Asia (Quinlivan et al. 2013). This argu-
ment adds credence to Rice’s position that tropical VZV genotypes 
are less prone to reactivation than temperate genotypes. Although 
Figure 5: 
Annual trend of monthly incident cases of herpes zoster and varicella in 2000–2009. Notice that herpes zoster spikes during the warmer months. Source: Wu et 
al. 2013
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Rice writes that immigration from Africa to temperate regions 
gave way to the temperate VZV genotype, such a transition might 
take some time, and recent immigrants and their offspring may 
still harbor the tropical genotype. This is especially plausible when 
taking into account that the reactivating strain of VZV is identi-
cal to the strain that had caused the primary varicella infection 
(Sengupta et al. 2007). Thus, the tropical VZV genotype can persist 
and still be widespread in aging African American populations long 
after immigration from Africa.
Another genetic correlation is suggested Haanpää et al. (2002). 
They suggest that susceptibility to herpes zoster may be geneti-
cally predetermined. Interleukin-10 (IL-10) is an anti-inflammatory 
cytokine; it downregulates the production of the proinflammatory 
cytokines, thus decreasing cell-mediated immunity. The promoter 
region of the gene for IL-10 is polymorphic, producing three dif-
ferent haplotypes (combinations of DNA sequences on one chro-
mosome that are inherited together): GCC, ACC and ATA. Blood 
samples taken from herpes zoster patients and from controls not 
infected with herpes zoster showed a significantly higher pres-
ence of the ATA haplotype in the blood of herpes zoster patients. 
This suggests that IL-10, its presence detected by detection of the 
ATA haplotype, may play a role in VZV reactivation. The explana-
tion of this is that VZV reactivation is largely due to decreased 
cell-mediated immunity, and this immunity is decreased by IL-10. 
Consequently, inheritance of the ATA haplotype may predispose 
one to herpes zoster. This idea is echoed by Cho (2007) who 
writes that in Korea, the GCC haplotype is significantly higher in 
herpes zoster patients than in controls not infected with herpes 
zoster, and this may point to the role of IL-10 in reactivation of 
VZV and a possible genetic predisposition to herpes zoster. Cho 
attributes the differences in increased haplotype findings between 
the previous study conducted in Finland and his own study con-
ducted in Korea simply to ethnic differences between European 
and Asian populations. Their differences notwithstanding, the ideas 
of both studies are the same—that IL-10 may be a factor in VZV 
reactivation leading to herpes zoster, and genetic inheritance of 
a specific haplotype of the IL-10 promoter gene may predispose 
carriers to herpes zoster. This suggestion, too, assumes genetic 
variations in human hosts, rather than genetic variations in the 
VZV itself, to be behind increased or decreased incidence of her-
pes zoster.
Gender Correlation
Numerous studies and trials report a higher incidence of herpes 
zoster in females than in males (Figure 6). In one such report, 
Fleming et al. (2004) investigate the gender differences in inci-
dence of herpes zoster by dividing patients into age groups: 0-14, 
15-24, 25-44, 45-64, 65-74, and 75 and older. Over the eight-year 
study, there were 14,532 cases of herpes zoster, of which 59.3% 
were female patients and 40.7% male patients. Female herpes zos-
ter incidence exceeded males in all age groups except for the 
15-24 age group in which the rates were almost equal for both 
genders. The greatest female risk appeared in the 45-64 age group 
followed by the 0-14 age group.
There are numerous attempts to determine what is behind the fe-
male predisposition to herpes zoster incidence. Possibly, resolving 
what is behind increased female incidence can shed some light on 
the mechanism of VZV reactivation in general.
Various reasons for the female excess are given. One suggestion 
is that there are more herpes zoster cases among females due to 
their longevity; because women live longer than men, there are 
more occasions for them to contract herpes zoster. Fleming et al. 
(2004) write, however, that their analysis disproves the theory, for 
it indicates female excess in nearly all age groups. If increased fe-
male incidence were due to female longevity alone, an increase in 
female incidence would only be evident in older age groups—age 
groups in which females generally outlive males. Another sugges-
tion given is that women tend to seek medical advice more readily 
than men, and, thus, there are more reported cases of females 
with herpes zoster than of males (Thomas and Hall 2004). This 
Figure 6: 
Annual incidence per 100,000 of shingles by age group and gender in years 
1994–2001 with superimposed regression line. Source: Chapman et al. 2003
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would suggest that, in truth, females are not more susceptible to 
herpes zoster than males; it only appears that there is higher her-
pes zoster incidence in females, because they are quicker to see 
a doctor for symptoms, and, thus there are more female herpes 
zoster patients recorded in the system. (In one case, a 60 year 
old man waited ten days before making an appointment to see a 
doctor despite pain rated 6 out of 10 on the pain scale and a rash 
which appeared within a week of the onset of the pain! (Martić 
2014)) This theory, however, would seem to be disproved by the 
data provided by Fleming et al. (2004) which finds that in the age 
group of 15-24, female rates of herpes zoster did not exceed male 
rates and by data provided by Ragozzino et al. (1982) which actu-
ally finds lower incidence of herpes zoster in females aged 35-44 
than in males of the same age group.
A more sophisticated approach to explain the increased herpes 
zoster incidence in females is taken by Fleming et al. (2004). They 
suggest that there may be a true gender difference in the way 
the body responds to reactivation of a latent virus. They base this 
theory on the fact that there is also a significant female excess in 
incidence of herpes simplex virus, another member of the her-
pesvirus family and alphaherpesvirus subclass, which is also a virus 
that reactivates after a long latency period in ganglionic tissue. 
Although they do not specify what might be behind the difference 
in reactivation response based on gender, the suggestion of Studahl 
et al. (2013) may shed some light on it. Studahl et al. suggest that 
the difference in herpes zoster incidence between genders may be 
due to hormonal differences between men and women. It may be 
the hormonal differences between the genders that affect the way 
the body responds to virus reactivation. 
In a similar vein, the menopause transition period females go 
through is also suspected to be responsible for increased female 
herpes zoster incidence due to hormonal changes to their im-
mune response (Saunders 2014). This theory is supported by the 
aforementioned findings of Fleming at al. that females aged 15-24 
did not exceed males in herpes zoster incidence and the findings 
of Ragozzino et al. that females aged 35-44 actually have lower 
herpes zoster incidence than males, for they have not yet reached 
the menopausal stage. This theory, however, fails to address in-
creased herpes zoster incidence in females past the menopausal 
stage, when hormone levels are static.
It should be pointed out that, even according to hypotheses cor-
relating increased herpes zoster incidence in females with their 
hormones or menopausal shifts, they do not claim these to be the 
sole causes of VZV reactivation, for herpes zoster occurs in males 
too, albeit not as prevalent as in females. They simply suggest that 
among other factors influencing VZV activity, these contribute on 
greater levels to its reactivation. Thus, while even those lacking 
these factors may get herpes zoster, those that have these factors 
are at a greater risk of getting herpes zoster.
Still, there does not seem to be a clear understanding as to the 
exact role hormones play in increasing herpes zoster incidence, 
and no explanation has been offered as to which hormones might 
be involved. Are female hormones responsible for the increased 
herpes zoster risk in females, or are male hormones responsible 
for decreased herpes zoster risk in males? After all, males have a 
higher risk for a severe case of chickenpox than females (Simon 
2013). Maybe this points to some type of male hormone influ-
ence on VZV. On the other hand, there is more fluctuation in fe-
male herpes zoster incidence between the different age groups, 
suggesting that female hormones more likely play a role in VZV 
reactivation and that fluctuation in their levels contributes to an 
increase or decrease in herpes zoster incidence. In addition, as 
previously mentioned, the latent VZV is held dormant by cell-me-
diated immunity, not humoral immunity. In pregnant women, “the 
fetoplacental unit redirects maternal immunity away from cell-me-
diated immunity towards enhanced humoral responsiveness” 
(Wegmann et al. 1993). This would lead to the assumption that 
women are at a high risk for VZV reactivation during pregnancy. 
This, however, is not the case. According to Simon (2012), herpes 
zoster is extremely rare in pregnant women. While this phenome-
non is not well understood, it does strengthen the case for female 
hormone involvement in increased female incidence as opposed 
to male hormone involvement in decreased male incidence.
Conclusion
While the particular method of VZV reactivation remains unclear, 
numerous hypotheses are offered based on various presentation 
patterns of herpes zoster. Some suggest that genetics plays a role. 
One such study focuses on regions where herpes zoster is or is 
not prevalent and suggests that VZV genotypes differ according to 
region with temperate genotypes prone to VZV reactivation while 
tropical genotypes are not. Another study focuses on the decreased 
herpes zoster incidence among African Americans and suggests that 
genetic differences between white subjects and subjects of color 
may increase or decrease susceptibility to VZV reactivation. Yet an-
other study suggests that inheritance of certain genetic haplotypes 
may predispose one to herpes zoster. Others focus on the differ-
ence in herpes zoster incidence by gender. Instead of citing genetics 
as possibly influencing increased female incidence, some suggest 
that female hormones may be largely responsible. Similarly, others 
suggest that menopausal instability may prompt VZV reactivation. 
“The peculiar pathogenetic mechanism of herpes zoster infection, 
its capacity to migrate after the primary infection (varicella) to 
the dorsal root ganglia and remain silent throughout life, makes 
it somewhat difficult to put forward convincing hypothetical ex-
planations” (Gallerani and Manfredini 2000). Nonetheless, each of 
these observations of herpes zoster patterns and diverse sugges-
tions as to what is behind the patterns and what they mean sheds 
some light on the mechanism or mechanisms of VZV reactivation. 
Each insight offers a unique angle at which the phenomenon of 
VZV reactivation can be further studied.
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Drug resistance in Mycobacterium tuberculosis (TB) has become 
a severe global health threat. The fight against TB faces major chal-
lenges due to the appearance of Multi-Drug Resistant Tuberculosis 
(MDR-TB) and more recently, the virtually untreatable Extensively 
Drug Resistant Tuberculosis (XDR-TB). MDR-TB are strains that 
are resistant to both top first-line drugs, Isoniazid and Rifampin, 
while XDR-TB are MDR-TB strains that are also resistant to any 
fluoroquinolone and one or more of 3 injectable drugs. With this 
new resistance there emerges a need to find new drugs that are 
as effective yet bypass the problem of resistance. One method 
of research is to find new vulnerabilities of M. tuberculosis to 
use as new target sites of drugs. This method is highly expensive 
and requires intense and lengthy research just to implicate a new 
target site (Scheffler et al., 2013). An alternative is to develop new 
drugs that work on the same known targets as the first-line drugs 
but by different mechanisms thereby bypassing the resistance of 
TB to the drug.
Isoniazid (INH) is a powerful anti-TB drug that works by inhibiting 
the action of InhA, a crucial enzyme in the process of manufactur-
ing the cell wall. Instead of searching for new targets on TB, there 
is a goal to expand on this target and develop drugs that inhibit 
InhA by different mechanisms and thus show anti-tubercular activ-
ity against MDR-TB strains. 
The virulence of tuberculosis is due to its greatly complex cell 
envelope. Mycobacteria contain cell walls with unusually high lipid 
content due mainly to the presence of mycolic acids which are 
alpha-alkyl, beta-hydroxy fatty acids with atypically long alpha alkyl 
chains (up to C ). The existence of mycolic acids in the cell wall 
makes the cell impervious to common antibiotics (Niederweis et 
al., 2010). Mycolic acids were shown to be essential for the sur-
vival of tuberculosis thereby making them a great target for drug 
therapy. InhA (NADH-dependent-2-trans-enoyl-ACP-reductase)’s 
role in mycolic acid biosynthesis is catalyzing the final step in a 
cycle of elongation by reducing 2-trans-enoyl chains to their satu-
rated forms (Takayama et al., 2005).
Isoniazid (INH) has been used to treat tuberculosis since 1952. It 
is a prodrug that enters cells via passive diffusion where is it then 
converted from an inactive nontoxic form to its active toxic form. 
This conversion is mediated by KatG, a mycobacterial multi-func-
tional catalase-peroxidase that activates INH by peroxidation to 
form a variety of intracellular INH-derived radical species. The key 
intermediate in this reaction is the isonicotinoyl radical (Figure 1, 
compound 3) which then covalently binds to coenzyme NAD+ 
to generate an isonicotinoyl-NAD adduct (INH-NAD) (Timmins, 
Deretic, 2006). The addition of the isonicotinoyl radical to NAD+ 
creates a stereocenter in the INH-NAD adduct, and it is the acy-
clic 4S isomer that selectively binds to InhA as a slow tight-binding 
competitive inhibitor (K = 0.75 nM) (Rozwarski et al., 1998; Rawat 
et al., 2003). The binding of the INH-NAD adduct inhibits InhA 
from taking part in mycolic acid biosynthesis leading to impaired 
cell wall integrity and eventual cell death. 
Abstract 
Isoniazid (INH), one of two first-line drugs used to treat tuberculosis (TB), has been shown to be a potent inhibi-
tor of InhA, the mycobacterial enoyl reductase. However, the increasing resistance to INH makes it imperative to 
find alternative drugs that are as effective as the first-line drugs, yet active against INH-resistant strains. Since InhA 
has been validated as an excellent target of TB, there have been attempts to find novel inhibitors of InhA. Through 
rational drug design, a variety of high affinity InhA inhibitors were synthesized. Triclosan itself was observed to be a 
suboptimal inhibitor of InhA with a K  of .22 µM, but with modifications to the 5-position of the A ring, the new di-
phenyl ether compounds demonstrated higher affinities with nanomolar constants. A particularly potent triclosan 
derivative, compound PT70, showed slow, tight-binding inhibition with a K value of 22 pM. In addition, arylamides 
showed moderate to high inhibition of InhA. They did not show sufficient anti-tubercular activity, and therefore 
future modifications are needed before they can be considered seriously for use against TB. Lastly, pyridomycin, 
a natural anti-tubercular drug was rediscovered and confirmed to have high activity against TB. It was found to 
be the first compound ever published to bind to both binding sites of InhA simultaneously. Current research is 
ongoing in the synthesis and testing of pyridomycin analogs to further increase their anti-tubercular properties.
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Despite its powerful anti-TB potential, the foremost problem with 
INH is the increasing resistance to the drug. In fact, INH resistance 
is the most common type of drug-resistant TB. The predominant 
mechanism of such resistance involves a single point mutation in 
the gene that codes for the KatG enzyme which results in an 
amino acid change from serine to asparagine at position 315 in the 
heme binding catalytic domain of KatG (Zhang, Yew, 2009). This 
S315T mutant is observed to contain a narrower heme access 
channel on KatG (4.7 Å compared to the wild type 6 Å) suggest-
ing that the loss of INH access to the oxidizing site of KatG might 
be the key to INH-resistance (Timmins, Deretic, 2006). While 
isolates with this mutation completely lose the ability to form 
the INH-NAD adducts, most retain good catalase activity and are 
therefore able to survive despite the mutation (Gumbo, 2011). 
Less commonly, resistance is also seen to occur by mutations in 
the promoter region of the InhA gene, leading to overexpression 
of InhA; or by mutations at the active site of InhA, resulting in 
lower InhA affinity to the INH-NAD adduct (Zhang, Yew, 2009). 
There are many methods of drug development. Older methods 
rely on trial and error testing of chemical substances on cells or 
whole organisms. This method is extremely lengthy and expensive 
as it requires the screening of hundreds of thousands of com-
pounds for activity. A newer method called rational drug design 
employs prior detailed knowledge of a vulnerable target and its 
three-dimensional structure to synthesize biologically active com-
pounds that specifically interact with the target. One manner of 
rational drug design is structure-based drug design, which employs 
the principle of SAR (Structure-Activity Relationship) that the-
orizes that similarly structured molecules have similar activities. 
Thus, if a compound is known to possess a desired activity, the 
essential functional groups and moieties responsible for this activ-
ity can be identified and a variety of new compounds containing 
those groups can be synthesized. The new compounds will then 
be tested for efficacy and functional similarity to the parent com-
pound. SAR commonly employs the use of molecular mechanics/
dynamics software to analyze and predict the conformations of 
known molecules and to subsequently model the conformational 
changes that occur in a bound target molecule. This information 
is then used to predict how similar synthesized compounds may 
interact with the target. Additionally, the 3D structure of a target 
molecule both alone and in complex with the synthesized com-
pounds is frequently obtained through X-ray crystallography and 
NMR spectroscopy to determine the underlying basis for the effi-
cacy (or lack thereof) of the newly synthesized compounds.
In the following literature review, a variety of SAR studies that 
attempted to find novel InhA inhibitors are summarized. The ma-
jority of the compounds discussed used a backbone of the biocide 
triclosan to create triclosan derivatives and substituted diphenyl 
ethers that exhibit InhA inhibition as well as efficacy against a 
variety of tuberculosis strains. Additionally, arylamide moieties 
have been confirmed as good InhA inhibitors although additional 
research is still needed to improve their anti-tubercular activity. 
Lastly, pyridomycin, a natural anti-Mycobacterial drug was recently 
rediscovered and shown to be effective against multiple strains of 
TB, as well as showing inhibition of InhA in a unique manner.
Methods
Literature searches were performed using the Touro College 
Online Library. In particular, the Health Sciences related databases 
(Medline, PubMed, Proquest Medical Library (Health and Medical 
Complete), and EBSCO Multisearch were employed. Additionally, 
Google Scholar and the Touro Quicksearch option proved to be 
very helpful in finding the necessary relevant articles. The follow-
ing keywords were searched: Mycobacteria, tuberculosis, InhA 
inhibitors, triclosan, triclosan derivatives, high affinity InhA inhibi-
tors, SAR, rational drug design, arylamides, pyridomycin. As a final 
point, only articles published in scholarly peer-reviewed journals 
after the year 2005 were included in the search. 
Results and Discussion
Triclosan derivatives and diphenyl ethers
The biocide triclosan (Figure 2), originally thought to have non-
specific antimicrobial activity, has been shown to target and un-
competitively inhibit enoyl reductases, the family of enzymes that 
includes InhA (Heath et al., 2001). Consistent with uncompetitive 
inhibition, triclosan binds to the enoyl reductases in the presence 
of NAD+. Triclosan is an excellent inhibitor of the E. coli enoyl 
reductase FabI with a picomolar inhibition constant (K = 7 pM) 
but is shown to be only a submicromolar inhibitor (K = 0.2 µM) 
of InhA (Ward et al., 1999). To understand the 30,000 fold differ-
ence in triclosan’s affinity for FabI versus InhA, crystal structures 
of FabI in complex with NAD+ and triclosan were compared to 
structures of InhA in complex with NAD+ and triclosan, so as to 
compare the ligand bindings and use the information to develop 
new inhibitors with high affinity for InhA (Sullivan et al., 2006).
The structures of triclosan bound to FabI and to InhA were gener-
ally very similar yet an important difference was seen with respect 
to the ordering of the amino acid loop that covers the substrate 
Figure 1
Structures of isoniazid (1), the isonicotinic hydrazyl radical (2) and the 
isonicotinoyl radical (3) Timmins, Deretic, 2006
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binding site of each enzyme. In the FabI:NAD:triclosan molecule, 
the substrate binding loop (residues 195-200) is ordered when 
triclosan is bound to it. In contrast, the substrate binding loop of 
InhA (residues 197-210) is disordered when triclosan binds to it. It 
has been suggested that ordering of the loop is indicative of slow, 
tight binding inhibition (Heath et al., 2001). When the substrate 
binding loop becomes structured, additional Van der Waals inter-
actions strengthen the binding. A key feature of slow-binding inhib-
itors is a conformational change in the enzyme upon drug binding. 
This is likely the slow step in the reaction, a hypothesis that is sup-
ported by the fact that triclosan has been identified as a slow, tight 
binding inhibitor of FabI but not InhA. Since slow-order kinetics 
has not been determined in the inhibition of InhA by triclosan, the 
loop is disordered in InhA (Sullivan et al., 2006). Ordering of the 
loop has been observed in the inhibition of InhA by the INH-NAD 
adduct, which has also been identified as a tight-binding inhibitor 
of InhA (Rawat et al., 2003), further supporting the hypothesis that 
connects slow, tight-binding inhibition to ordering of the active 
site loop.
Comparison of FabI and InhA crystal structures showed that InhA 
contains a larger substrate binding loop than FabI (14 residues vs. 
6 residues), making it harder to order the loop in InhA. Sullivan et 
al. hypothesized that longer substituents on the diphenyl ether A 
ring of triclosan might result in additional hydrophobic contacts 
between triclosan and the substrate binding pocket residues, and 
thereby increase the affinity for InhA. They removed the chlorine 
atoms from the B ring and substituted the chlorine atom on the A 
ring with alkyl groups of varying length (Figure 3).
As the length of the alkyl substituents increased from 2 carbons to 
8 carbons, the IC value (the concentration of inhibitor needed to 
inhibit 50% of the enzymes) decreased significantly from 2 µM to 
5 nM, indicating considerably higher affinity for InhA. In each case, 
the compounds were rapid, reversible uncompetitive inhibitors 
like the parent molecule triclosan. The most potent diphenyl ether, 
which was identified as 5-octyl-2-phenoxyphenol (8PP), displayed 
an IC of 5 nM (K =1.1 nM). The octyl chain in this molecule adopt-
ed a linear confirmation and burrowed into the pocket, forming 
numerous hydrophobic interactions with residues in the substrate 
binding loop which led to the observed significant increase in in-
hibitory activity. In addition to lower IC  values, the alkyl diphenyl 
ethers showed significantly lower MIC (minimum inhibitory con-
centration) values than triclosan (MIC 6.5µM vs. 43.1µM) against 
drug sensitive TB (H37Rv strain) as well as 5 INH resistant strains, 
thus demonstrating their potential for use against MDR-TB and 
validating the hypothesis that compounds that do not require ac-
tivation by KatG will be active against most INH resistant strains 
of TB. The results of this study revealed that the reason for the dif-
ferences in triclosan’s inhibition of FabI and InhA is that InhA has 
a large substrate binding loop that triclosan cannot fill as entirely 
as it can the smaller active site of FabI. Substituting alkyl chains 
on the triclosan molecule thus allowed for more hydrophobic in-
teractions deeper into the binding site and consequently higher 
affinity was demonstrated for InhA. Testing of the alkyl diphenyl 
ethers on H37Rv and 5 INH resistant strains confirmed that this 
higher affinity also led to greater anti-tubercular activity (Sullivan 
et al., 2006).
Treatment of TB is lengthy (6-24 months), so toxicity is a signif-
icant concern in the development of potential anti-tubercular 
drugs. The two most potent inhibitors identified by Sullivan et al., 
6PP and 8PP, were tested using a Vero cell line and shown to be 
five times less toxic than triclosan with a therapeutic index of 5-6 
compared to <1 for triclosan. Treatment with triclosan at 1xMIC 
for one day proved lethal to the cells. Furthermore, TB-infected 
macrophages treated with 2xMIC of 6PP and 8PP demonstrated 
high level growth inhibition, indicating an ability of these drugs 
to enter macrophages and remain effective against intracellular 
tuberculosis growth. Oral administration of 6PP and 8PP in mice 
also showed no adverse effects, substantiating a lower toxicity 
for these molecules. These studies demonstrated that alkyl substi-
tuted diphenyl ethers exhibited lower toxicity towards cells and 
TB-infected macrophages than did triclosan (Boyne et al., 2007).
While 6PP and 8PP showed high potency against InhA (nM inhibi-
tion constants) and improved efficacy against both drug-sensitive 
and drug-resistant strains, they were observed to have low bio-
availability with significantly high cLogP (partition coefficient) val-
ues (6PP= 6.47). The clogP value is important for predicting oral 
Figure 2:   
Molecular structure of triclosan Sullivan et al., 2006
Figure 3
Modified diphenyl ether inhibitors Sullivan et al., 2006
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absorption as it relates to a compound’s solubility and ability to 
permeate through cell membranes. Compounds that are too hy-
drophilic (low cLogP) are not able to pass through the hydropho-
bic membranes, while compounds that are too hydrophobic (high 
cLogP) tend to be insoluble and have trouble permeating through 
membranes because they can get stuck in the hydrophobic bilayer. 
In general, a cLogP greater than 5 predicts poor absorption or 
permeation (Lipinski et al., 2001).  
To lower the cLogP values, modifications were made to the B 
ring of the diphenyl ether backbone of 6PP. A series of analogs 
that incorporated different functional groups on the ring, designed 
to increase the polarity of the alkyl diphenyl ethers, were syn-
thesized. Two series were made: one series replaced the B ring 
with isosteric heterocycles that incorporated nitrogen atoms into 
the ring to increase polarity without added steric strain while the 
other series incorporated polar bulky substituents at different po-
sitions on the B ring. The results were primarily stereoselective. 
Overall, the addition of bulky substituents at either ortho, meta, 
or para positions of the B ring and the incorporation of most ni-
trogen heterocycles caused significantly higher MIC values and re-
duced inhibitory activity. However, the addition of nitro or amino 
substituents at ortho/para positions only slightly reduced inhib-
itory activity. While none of the newly synthesized compounds 
showed IC or MIC values lower than the parent compound 6PP, 
compounds 3c and 14a (Table 1) had inhibitory values similar to 
6PP but also had lower cLogP values (4.97 and 5.24 respectively). 
The results demonstrate that the addition of nitrogen containing 
compounds at certain positions on the B ring can lower the hy-
drophobicity of the compounds. Additional studies are needed to 
test whether the modifications result in increased bioavailability 
and improved in vivo antibacterial activity (amEnde et al., 2008). 
InhA has two hydrophobic cavities that are capable of being filled: 
the hydrophobic substrate binding pocket in which the substrate 
of InhA (2-trans-dodecenoyl-CoA) binds, and the NADH binding 
Table 1
Inhibition and solubility data for modified B ring heterocycles
Compound Structure IC5((nM) MIC (µg/ml) ClogP LogP
19 (6PP) 11± 1 2.1± 0.9 6.47 5.76
3c 160± 16 3.13 4.97 4.93
14a 62± 5 3.13 5.24
14b 1090± 90 100± 0
5.24
5.27
14c 55± 6 12.50 5.24 4.93
amEnde et al., 2008
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active site. The NADH active site sits underneath the substrate 
binding pocket and is lined primarily with hydrophobic residues. 
Most InhA inhibitors, including triclosan and its derivatives, inhibit 
InhA through binding to the substrate binding pocket. The compet-
itive inhibitor INH-NAD adduct, is one of the few inhibitors that 
binds directly to the NADH active site. Freundlich et al., (2009) 
observed the structure of InhA:NAD+:triclosan superimposed on 
InhA:INH:NAD and saw that the chlorine atom at position 5 of 
the triclosan A ring was only 2 Å from the binding pocket of the 
isonicotinoyl moiety of the INH-NAD adduct (Figure 4). They hy-
pothesized that triclosan derivatives can be synthesized that can 
extend into the hydrophobic isonicotinoyl binding pocket and in-
crease inhibition of InhA by occupying both the substrate binding 
pocket and the NADH binding site. This hypothesis was different 
than Sullivan et al. (2006) who created analogs to increase inter-
actions with the substrate binding loop, mimicking the structure 
of the substrate.
The analogs of Freundlich et al., were similar to those of Sullivan 
et al., but differed in that a variety of both hydrophobic and hy-
drophilic substituents were added to position 5 on the A ring. 
Additionally, contrary to the previous studies of Sullivan et al., it 
was suggested that the two chlorine atoms on the B ring do in fact 
participate in hydrophobic interactions with Phe97 and Met103 
residues and so they remained in the compounds. The results 
showed that the compounds with alkyl (hydrophobic) substitu-
ents were the more potent inhibitors. As seen with Sullivan et 
al., inhibition of InhA increased with increasing alkyl chain length. 
The highest inhibitory potencies for the alkyl chain additions were 
observed in the 4 carbon chain compounds (Table 2), namely 
compound 10 (Freundlich et al., 2009). 
Surprisingly, while most hydrophobic substituents were observed 
to show lower IC values, the addition of a phenyl group at the 5 
position (Compound 6) showed a much greater IC  (IC >10,000 
nM) than even triclosan (IC =1,100 nM). The same values were 
obtained for a pyridyl group at the 5 position. Modeling the inhibi-
tors in the active site showed that the aryl group was too far from 
the isonicotinoyl binding pocket by 2.5 Å and was also positioned 
too close to Phe149 which led to steric clashes. Therefore, to 
better fit the phenyl group into the hydrophobic pocket, a carbon 
linker chain consisting of 1-3 carbons was added to the 5 position 
(Compounds 24-26) between the phenyl group and the A ring. 
This resulted in significantly increased inhibitory potency of the 
phenyl substituted compounds (IC of 21-51 nM). Compound 25, 
with a 2 carbon linker chain showed the lowest IC of all the com-
pounds tested with a measured potency 50 times that of triclosan. 
Adding linkers to the pyridyl substituents (Compunds 17-19) also 
proved effective in producing powerful inhibitors (IC  of 29-75 
nM).
Through analysis of crystal structures, it became apparent that the 
goal of mimicking the isonicotinoyl moiety and reaching the ison-
icotinoyl binding site was not possible. The triclosan derivatives 
did reach the isonicotinoyl binding site but they did not occupy 
the same volume as the INH-NAD adduct. Instead, their actions 
mimicked the substrate analogs like Sullivan et al.’s compounds 
did. Attempts to increase the volume of the triclosan analogs in 
order to mimic the isonicotinoyl moiety would cause a rotation 
of Phe149, which in turn would displace Tyr158 and result in the 
loss of a crucial hydrogen bond, leading to the complete loss of 
inhibitor binding. Therefore, it was concluded that triclosan deriv-
atives can only attempt to place their substituents near the bind-
ing pocket and increase hydrophobic interactions in a way that 
mimics the substrate rather than the isonicotinoyl-NAD adduct 
(Freundlich et al., 2009).
Six of Freundlich et al.’s compounds (three alkyl and three aryl 
with IC < 110 nM) were tested for anti-tubercular activity. All of 
the compounds were more active than triclosan against H37Rv 
strain (wild type). Additionally, all showed high inhibition against 
five INH resistant strains demonstrating their potential for use in 
treatment against MDR-TB. These results revealed that while tri-
closan analogs cannot be used to mimic the INH-NAD adduct in 
the isonicotinoyl binding pocket they can act as substrate analogs. 
The aryl and pyridyl substituents with carbon chain linkers as well 
as many straight chain substituents showed considerably lower 
IC  values than triclosan, displaying higher affinity for InhA. They 
also showed greater anti-tubercular activity than triclosan when 
tested against both drug-sensitive and drug-resistant tuberculosis 
(Freundlich et al., 2009).
Figure 4: 
Cross-section of the InhA active site with superimposed structures of InhA in 
complex with the INH-NAD adduct (colored in gold) and triclosan (white). 
The A ring chlorine of triclosan (cyan) is observed to be very close to the 




Feundlich et al., 2009
In vitro activities of select triclosan derivatives against InhA
Compound R1 R2 InhA IC5(nM)
Triclosan Cl Cl
1100± 180
6 Ph Cl >10000
10 (CH2)3 CH3 Cl 55± 20
14 2-pyridyl CN >10000
15 3-pyridyl Cl >10000
16 4-pyridyl CN >10000
17 CH2 (2-pyridyl) Cl 29± 11
18 CH2 (3-pyridyl) Cl 42± 10
19 CH2 (4-pyridyl) CN 75± 16
24 CH2 Ph Cl 51± 6
25 (CH2)2 Ph Cl 21± 8
26 (CH2)3 Ph Cl 50± 14
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One problem with the triclosan derivatives and diphenyl ethers 
thus far is that they are shown to be rapid reversible inhibitors of 
InhA. An important and vital factor of in vivo drug activity is long 
residence times on the targets. Furthermore, structures of the 
previous compounds had indicated a disordered substrate binding 
loop. It had earlier been theorized that slow onset inhibition is 
coupled with ordering of an active site loop, which leads to the 
closure of the substrate binding pocket. Luckner et al., (2010) at-
tempted to create a slow onset triclosan-derived inhibitor of InhA 
using the hypothesis that compounds with the ability to order 
the loop will be slow tight-binding inhibitors of InhA. They used 
Sullivan et al.’s 6PP analog as a backbone and introduced a variety 
of groups onto the B ring in the hopes of promoting increased 
hydrophobic interactions between the inhibitor and the loop 
residues. 
One resulting compound, PT70 (Figure 5), contained a methyl 
group ortho to the diphenyl ether linkage and showed a substan-
tially higher affinity for InhA, with a K  of 22 pM, a value 430-fold 
lower than that of 6PP (K =9.4 nM). Additionally, PT70 displayed 
slow-onset inhibition which is essential for in vivo antibacterial 
activity. Crystal structures of InhA:NAD+:PT70 showed that PT70 
binds to InhA in almost the same way that triclosan and its de-
rivatives do. The main difference in the binding is that the methyl 
group on PT70 generates additional hydrophobic interactions 
with Ala198, Met199, Ile202 and Val203 residues on the substrate 
binding loop, leading to a defined loop structure (Figure 6). The 
Figure 6
Loop ordering is observed upon slow binding inhibition. A) InhA•NAD+•8PP complex in the binding of 8PP (Sullivan et al.’s most potent inhibitor) to InhA. NAD+ 
is displayed in cyan and the 8PP molecule is in black. The substrate-binding loop is disordered in the 8PP structure, and the loop ends are depicted in red. B) 
InhA•NAD+•PT70 complex. The PT70 compound is depicted in black. The substrate-binding loop (shown in red) is ordered in this structure and covers the binding 
pocket. Luckner et al., 2010
Figure 7
Scaffold of He et al.’s arylamides He et al., 2007
Figure 5
Addition of a methyl group on the ortho position of the B ring of 6PP led to 
PT70, a slow onset, tight binding diphenyl ether inhibitor. Luckner et al., 2010
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ordered binding loop covers the entrance to the binding pocket 
locking PT70 inside and increases the residence time on the tar-
get. Kinetic data show that PT70 has a residence time of 24 min-
utes on the target, a 14,000 fold increase over the residence time 
of its parent compound 6PP (0.1 sec). This study also confirmed 
the hypothesis that ordering of the active site loop is coupled to 
slow-onset inhibition. Further research is needed to test PT70 
on tuberculosis strains to confirm that the increase in affinity of 
PT70 for InhA does indeed correlate with enhanced anti-bacterial 
activity (Luckner et al., 2010). 
Triclosan has been recognized as a great molecular scaffold for 
InhA inhibition. The previous studies all employed the diphenyl 
ether backbone of triclosan. Modifications to both the A and B 
ring demonstrated increased affinity for InhA which was also 
coupled to greater anti-tubercular activity. The compounds show 
tremendous promise for rational drug design and SAR use in the 
treatment of TB. Significantly, it was confirmed that these com-
pounds do not require KatG activation affording them great 
potential against the most common strains of drug-resistant TB. 
Further research is still needed to test the compounds in vivo to 
confirm their anti-tubercular capacity.
Arylamides
Arylamides (Figure 7) have also been identified as a potential scaf-
fold of InhA inhibitors. Using High Throughput Screening (HTS), 
He et al., (2007) identified a variety of arylamides all of which 
contained either a piperazine or piperidine compound as the core 
structure. Compounds with the piperazine scaffold exhibited the 
best inhibitory activity among the initial compounds tested, with 
compound a4 being the most potent inhibitor (IC =3.07 µM) 
(Table 3). In order to enhance inhibition, He et al. crystallized 
Compound b3 (IC  = 5.16 µM), containing a piperidine with InhA 
and NADH and that structure was used as a reference for future 
compounds. The key hydrogen bond seen in all enoyl reductase 
inhibition reactions, involving the catalytic residue Tyr158 was ob-
served in the structure. The carbonyl oxygen of the arylamide was 
hydrogen bonded to both the 2’-hydroxyl moiety of the nicotin-
amide ribose and to the hydroxyl group of Tyr158. The unsubsti-
tuted B ring fit into the substrate binding pocket and interacted 
with many hydrophobic residues there. However, underneath the 
B ring, extra space was observed (Figure 8). He et al. hypothesized 
that addition of hydrophobic substituents to the B ring could form 
more interactions and lead to higher affinity (He et al., 2007).
The most potent inhibitors found by He et al. using High Throughput Screening
Compound X N R1 R2 IC 5((µM)
a4 N 0 4-CH3 3-Cl 3.07± 0.48
b3 C 1 4-CH3 H 5.16± 0.45
He et al., 2007
Table 3
Figure 8
a) Inhibitor b3 bound to the active site of InhA. As illustrated, extra space 
is observed in the area below the B ring of the inhibitor b) Details of the 
InhA-b3 interactions. Relevant residues of the binding pocket are shown. The 
amide oxygen hydrogen-bonds with the 2`-hydroxyl moiety of the nicotinamide 
ribose and the hydroxyl group of Tyr158 (blue arrows). He et al., 2007
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A variety of arylamides containing the piperazine scaffold were 
synthesized. 12 of the 60 compounds synthesized showed high 
InhA inhibitory activity. All 12 contained large polyaromatic moi-
eties on the B ring, substantiating the hypothesis that larger sub-
stituents on the B ring form more interactions and lead to higher 
affinity. Compound p2 (Table 4) of the newly synthesized mole-
cules showed the highest inhibitory activity (IC = 90 nM), a 34 fold 
decrease in IC  when compared to compound a4, the most potent 
of the HTS compounds (He et al., 2007).
Unfortunately, when the new compounds were tested against the 
H37Rv strain for anti-tubercular activity, most had MIC values 
>125 µM (He et al., 2007). This data suggests that the inhibitors 
do not possess optimal membrane permeability, likely due to their 
amphiphilicity, caused by the hydrophobicity of the B ring substitu-
ents and simultaneous hydrophilicity of the potentially protonated 
C ring piperazine. 
Figure 9
Compound p2, the most potent arylamide inhibitor synthesized by He et 
al. (yellow) with NADH (purple) in the InhA substrate binding site. The rigid 
residues around the binding site are displayed in green, while the flexible 
residues are displayed in orange. As discussed, the A ring of the arylamide is 
situated near the rigid residues, while the B ring is near the flexible residues. 
Punkvang et al., 2010
Table 4
He et al., 2007







Punkvang et al. (2010) attempted to identify the reasons behind 
the suboptimal anti-tubercular activity of the arylamides and to 
propose modifications to the compounds to increase both their 
affinity for InhA and anti-tubercular activity. Using molecular dy-
namics, a computer simulation that mathematically predicts the 
physical movements of atoms and molecules, they investigated the 
structural features and dynamic behavior of the InhA-inhibitor 
interactions providing detailed information about the molecule’s 
flexibility and conformation. RMSF (root mean square fluctuation) 
of residues around the substrate binding site of InhA was cal-
culated to reveal the mobile flexibility of the residues. Residues 
96-99, 155-165, and 192-200 (located around the binding pocket 
of the aryl A ring of the arylamide) were shown to be too rigid 
to bind the arylamide inhibitors (Figure 9). In contrast, most of 
the residues around the aryl B ring binding pocket (100-104, 149-
154, 201-223) indicated greater flexibility consistent with He et 
al.’s proposal that additional large substituents can be added to 
the B ring to increase the number of hydrophobic interactions 
(Punkvang et al., 2010).
Crystal structures and subsequent kinetic studies identify aryl-
amides as competitive inhibitors of the substrate binding site 
of InhA. Consequently, arylamides should mimic the binding of 
the substrate. Superimposition of arylamide inhibitors bound to 
InhA and a substrate analog (trans-2-hexadecenoyl-(N-acetyl-
cysteamine)-thioester) (Figure 10a) bound to InhA shows the 
conformational change that occurs in the enzyme when the aryl-
amide or the substrate bind. It was observed that the A ring of 
the arylamide binds to the hydrophilic part of the pocket where 
the hydrophilic acetylcysteamine moiety of the substrate binds. In 
contrast, the B ring lies in the same site as the fatty acyl chain of 
the substrate surrounded by flexible hydrophobic residues (Figure 
10b). The hydrophilic A ring is favored in the hydrophilic site and 
the hydrophobic B ring substituent is favored in the area with the 
hydrophobic residues (Punkvang et al., 2010).
Based on this data, Punkvang et al. proposed a series of modifica-
tions to the arylamides to mimic substrate binding and increase 
inhibitory activity. Introduction of small hydrophilic substituents 
such as an NH moiety or an acetyl oxygen on the A ring can be 
used to mimic the analogous part of the substrate and increase 
the hydrophilicity of the ring. Care must be taken, however, to 
ensure that the substituents are not too large and do not lead to 
steric interactions with the inflexible A ring residues and preclude 
proper binding as discussed. Additionally, binding affinity of aryl-
amides can be increased with the addition of bulky hydrophobic 
substituents to the B ring (Punkvang et al., 2010). 
These results explained the findings of He et al. and led to sug-
gested future modifications of arylamides that may increase their 
inhibitory potency. Molecular dynamic simulations showed that 
only the hydrophobic part of the substrate binding pocket is flex-
ible enough to bind arylamide inhibitors. Therefore, the addition 
Figure 10a
Structure of the substrate analog, trans-2-hexadecenoyl-(N-acetylcysteamine)-
thioester Punkvang et al., 2010
Figure 10b
Superimposition of x-ray structures of compound p3, an arylamide inhibitor 
synthesized by He et al. (pink) and fatty acid substrate (purple) in the InhA 
substrate binding site. As discussed, the A ring binds to the hydrophilic part of 
the binding site where the acetylcysteamine moiety of the substrate binds. The 
B ring is shown to bind to the hydrophobic part of the binding site where the 
fatty acid chain of the substrate binds. Punkvang et al., 2010
Figure 11 
Pyridomycin structure Hartkoorn et al., 2012
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of bulky hydrophobic substituents on the B ring can increase the 
binding affinity for the arylamides and also potentially increase 
membrane permeability. More research is needed to synthesize 
these proposed compounds and to measure their InhA inhibitory 
properties as well as their anti-tubercular properties and to see if 
membrane permeability indeed increased.  
Pyridomycin
Discovered in 1953, pyridomycin (Figure 11) is a natural antibiot-
ic produced by the bacteria Streptomyces pyridomyceticus and 
Dactylosporangium fulvum that exhibits specific activity against 
Mycobacteria (Maeda et al., 1953). Nevertheless, since it was only 
discovered a short time after the introduction of isoniazid as an 
exceedingly effective treatment for tuberculosis, pyridomycin was 
neglected and research into the drug ceased. Presently, with the 
rise of INH-resistant strains of TB, it is imperative to reexamine 
effective alternatives to INH. Despite earlier reports of pyrido-
mycin’s effectiveness against Mycobacteria as a genus, its efficacy 
against M. tuberculosis specifically had not yet been completely 
demonstrated. Additionally, pyridomycin’s target and mechanism 
of action had also not yet been elucidated. Hartkoorn et al. (2012) 
ascertained the drug’s target and specificity, and assessed its effi-
cacy against TB.
Pyridomycin was tested to confirm earlier reports about its spec-
ificity, efficacy, and low toxicity. The new research showed pyrido-
mycin to be a competent inhibitor of all species of Mycobacteria 
including tuberculosis (MIC= 0.62-1.25 µg/ml). It remained inef-
fective against other genera of both gram positive and gram neg-
ative classification (MIC > 100 µg/ml), confirming its specificity 
to a feature unique to Mycobacteria. It effectiveness against TB-
infected THP-1 derived macrophages was verified which indicat-
ed its ability to physically enter macrophages and inhibit growth. 
Toxicity testing demonstrated pyridomycin’s higher selectivity for 
tuberculosis than for human cells with a selectivity index of >100-
fold. (Hartkoorn et al., 2012) 
The identity of the target of pyridomycin was obtained by select-
ing for mutant pyridomycin-resistant strains (PYR7) on solid me-
dium containing pyridomycin at 10xMIC (3µg/ml). The genome of 
mutant PYR7 was referenced to H37Rv (wild type strain) and an 
a443g point mutation in InhA was isolated in PYR7 which resulted 
in replacement of the aspartic acid at position 148 by a glycine 
(D148G). Asp148 was previously identified in the binding pocket 
of InhA thus validating this as pyridomycins’s target. Subsequent 
experiments involving overexpression of InhA and the resulting 
increase in pyridomycin resistance further confirmed these find-
ings (Hartkoorn et al., 2012).
Since the primary goal of research into pyridomycin was to de-
termine its potential as an alternative to isoniazid, pyridomycin 
was tested against INH-resistant strains of TB. KatG mutants 
(the majority of the resistant strains), despite being highly resis-
tant to INH (MIC >10 µg/ml), showed no resistance to pyrido-
mycin. This demonstrated that pyridomycin does not depend on 
catalase-peroxidase bioactivation and therefore holds increased 
potential for use against the more common KatG INH-resistant 
strain (Hartkoorn et al., 2012). The results of this research con-
firmed previous reports of pyridomycin’s selectivity for and effica-
cy against tuberculosis including H37Rv and INH-resistant strains.
As discussed earlier, InhA contains two essential sites: the NADH 
binding site and the lipid substrate binding pocket. Crystal 
structures and kinetic experimentation show that pyridomycin 
is a direct competitive inhibitor of NADH binding in InhA and 
occupies the NADH binding site. Pyridomycin forms several in-
teractions with residues in the NADH binding site including the 
crucial hydrogen bond between the side chain of Tyr158 and the 
C7 carbonyl oxygen of pyridomycin. Loss of this hydrogen bond 
and consequent lack of the crucial enoyl reductase-inhibitor inter-
action in D148G mutants (pyridomycin-resistant InhA) resulted 
in markedly decreased affinity for pyridomycin. Crystal structures 
show that, as a result of its unusually large size, pyridomycin not 
only occupies the NADH binding site, but its upper hemisphere 
also extends into the substrate binding pocket forming a hydro-
phobic interaction with Phe149. While previously identified InhA 
inhibitors exclusively inhibited only one of the sites, pyridomycin 
is the first published compound to bridge the gap between both 
sites and simultaneously inhibit the lipid substrate binding pocket 
as well as the NADH binding site (Figure 12) (Hartkoorn et al., 
2014).
Figure 12
Binding comparison of various InhA inhibitors. The blue area represents the lipid 
substrate binding pocket, while the red area represents the NADH binding site. 
a) The lipid substrate is bound to the substrate binding site. b) Triclosan 
derivatives have all been shown to bind solely to the substrate binding site. c) 
The INH-NAD adduct binds solely to the NADH binding site. d) Pyridomycin 
binds to the NADH binding site and, because of its large size, extends into the 
lipid substrate binding site as well. Hartkoorn et al., 2014
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Pyridomycin is a naturally produced antibiotic and efforts to syn-
thesize it have been hampered by the inability to form the double 
bond of the enol ester moiety between C1 and C2. The com-
pound was instead synthesized with a saturation in that position 
(and a replacement of the sec-butyl group with a symmetrical iso-
propyl group) to identify if the double bond was indeed necessary 
for anti-tubercular activity. Saturation generated a new stereo-
center, producing two stereoisomers: the R isomer (OH141) and 
the S isomer (OH139) (Figure 13). Both compounds, as well as 
natural pyridomycin were then tested for anti-tubercular activity. 
Pyridomycin was the most effective against TB (MIC = 0.39 µg/ml). 
OH139 had a MIC value 32-fold higher than pyridomycin while 
OH141 measured only 4-fold higher, indicating that the enol ester 
moiety is not actually a critical requirement for anti-TB activity 
(Horlacher et al., 2013).
X-ray crystallography and in silico modeling highlight the reasoning 
behind the difference in efficacy between the two stereoisomers. 
Superposition of InhA:pyr on InhA:OH141 show pyridomycin and 
OH141 occupying the same position in the active site. The isopropyl 
group of OH141 was found in the equatorial position avoiding any 
steric clashes with residues in the active site. OH139 however, was 
shown with its isopropyl group in a steric interaction with the side 
chain of Met199 in the substrate binding loop, indicating why OH139 
has a lower affinity for InhA than does OH141 (Horlacher et al., 
2013). The slight decrease in the activity of OH141 compared to pyr-
idomycin could be due to the lower hydrophobicity of the isopropyl 
group compared to the 2-butan-2-ylidene substituent. The results of 
this research demonstrate that pyridomycin can be synthesized with 
a saturation in the C1-C2 bond without significantly impacting its 
anti-tubercular activity. This establishes the potential for future SAR 
work in the development of pyridomycin-derived drug candidates 
for TB treatment. Current research is now focused on using OH141 
as a scaffold for synthesis of new pyridomycin variants.
Conclusion
In this review, SAR has been shown to be an effective means to 
structurally design and modify drugs to increase their InhA in-
hibition abilities. The underlying assumption of the research was 
that compounds that do not require KatG activation would be ef-
fective against most INH-resistant strains. This hypothesis proved 
correct in the case of triclosan and pyridomycin derivatives. 
Additional modifications to arylamides are needed to optimize 
their activity. Through analysis of crystal structures, along with 
computer-assisted molecular dynamics and modeling, a variety 
of high affinity compounds were synthesized. Current efforts are 




MDR-TB Multi Drug Resistant Tuberculosis
XDR-TB Extensively Drug Resistant Tuberculosis
INH  Isoniazid 
SAR  Structure Activity Relationship
IC50  Half maximal inhibitory concentration (the con-
centration of inhibitor at which half of the enzymes are inhibited)
K i    Inhibitory constant
MIC  Minimum Inhibitory Concentration
H37Rv  Wild type strain of TB 
cLogP  Calculated partition coefficient
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Introduction
Does Pediatric Gastroesophageal Reflux Disease (GERD), also 
known as acid reflux, exist? GERD is a condition in which over 
60 million Americans suffer from at least once a month (Maddox 
2012); this condition is commonly called heartburn. Acid reflux 
is not the typical pain felt after eating a heavy meal or the wrong 
kinds of foods. It is a much stronger and severe condition. Reflux 
is defined as the passage of gastric contents into the esophagus 
and is a physiologic process. (Vandenplas, et al. 2009)  Doctors 
have questioned whether it is a possibility for infants and children 
to suffer from such a condition, which is often believed to come 
with age or bad eating habits. The NIH and many other prestigious 
organizations and hospitals in the United States and around the 
world are doing extensive research on this condition (Nelson, et 
al. 1997). This review will attempt to present the known research 
on the acid reflux-like symptoms in infants and children and what 
evidence there is to prove if it is indeed pediatric GERD, as well 
as present the possible medical ways of alleviating their suffering.
Methods
General websites like NIH.gov, and Webmd.com, with defini-
tions of what GERD is were accessed first and reviewed to gain 
a general knowledge about GERD. The NIH’s scholarly website, 
Pubmed, with original research and review articles from all types 
of medical and research journals was accessed. Information about 
GERD in infants was evaluated. General data regarding GERD, 
GERD in infants and any diagnostic testing and treatment of the 
disease were researched and evaluated for relevant information. 
In Touro College’s library, the Touro Ebsco search engine was ac-
cessed and utilized to locate useful articles and original research 
papers as well.
Discussion
Many people feel the sensation of food “coming up” on them after 
eating heavy foods. This sensation may indeed be food escaping the 
lower esophageal sphincter and rising upward into the esophagus 
(fig.1). There is no cause for alarm when the person does not feel 
any troubling symptoms as a result of this; at this stage the condi-
tion is not called GERD and is not labeled a disease (Rudolph, et 
al., 2001). It is simply called GER, Gastroesophageal Reflux. Once 
the condition crosses over to the point of symptoms with major 
side effects, it is called GERD, Gastroesophageal Reflux Disease. 
The same parameters of diagnosis are applied for infants. When a 
child is thriving and growing healthily, despite showing symptoms 
for GERD, it is not regarded as a disease (Vandenplas, et al. 2009). 
The symptoms for this condition in infants include spitting up, 
vomiting, refusal to eat, feeding difficulties, colic, incessant crying, 
arching the back and neck, hoarseness and cough (Brodsky, et al. 
2000). Some say that there are even a wide range of respirato-
ry problems as a result of acid reflux as well. The problem with 
Abstract
This objective of this review is to present the known data in regards to Gastroesophageal Reflux Disease (GERD) 
in infants. Articles with relevant definitions, diagnosis and treatment options were evaluated. It is evident that 
much controversy exists in the diagnosis and treatment of this disease, and there is the question as whether 
this disease can be called GERD. Current ability to attribute the symptoms infants present with the disease is 
still difficult to clarify, despite the fact that as many as 60% of infants show symptoms of this disease. The current 
testing options have proven to be insufficient in concretely diagnosing infants. Treatment for GERD has proven to 
be controversial as well. The medications for acid suppression are not a guaranteed cure and are being proven to 
have a lack of efficacy, show adverse effects and other negative aspects. The invasive options are not always ideal 
either. Altering changes in lifestyle helps, but is usually not the cause or cure when it comes to infants. Research 
is being done to come up with a test that is a definitive diagnosis, as well as a treatment option that is completely 
effective. Research has shown that despite the fact that acid suppression therapy is the most common answer by 
physicians today, it does not effectively work to eliminate all the symptoms. This does suggest that either GERD 
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needed on the subject.
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diagnosing GERD  based solely on an infant’s symptoms is that 
these are symptoms for many other conditions as well (Ghezzi, 
et al.  2010). Guaranteeing that they are a result of reflux is very 
hard to prove. 
Many infants may show signs for some or all of these symptoms. When 
it comes to diagnosing adults, doctors can rely on asking the patient 
about the symptoms they feel. The patient would be able to describe 
when, how, what time of day, before or after or even during meals, 
what specifically they feel regarding their symptoms. However, it is 
very different with an infant. They do not have the ability to specifically 
communicate what they are feeling. Infants have one means of commu-
nication for all of their necessities and issues, good or bad. Infants cry 
as their means of indicating something is not right with them. Parents 
are asked many questions to help doctors understand what exactly 
their child may be feeling and what symptoms they may have (Deal, 
et al. 2005). Figures 2 and Table 1 have a list of some of the questions 
a doctor might ask the parents. Doctors have to rely on the parents 
of the infants to relate what they presume is going on with their child. 
This hinders the ability to properly diagnose the disease tremendously.
Figure 2
Cohn, et al. 1996
82
Adina Mezrahi
GERD is considered a very complicated disease to diagnose. As of 
now there is no one test that has received the “gold star” as the 
perfect test to diagnose the disease. (Arko, et al.  2009) When it 
comes to children, the process of diagnosing is even harder. Much 
of the research on the subject begun because of parents coming 
forward with their infants because they did not understand what 
is wrong with their children. Parents have come forward when a 
child refuses to eat as an infant (from as early as four weeks old.) 
Other parents came forward because of incessant vomiting;the in-
fant would not stop vomiting and presented no signs of  infection 
or virus (Omari, et al. 2002). These are just two of the more com-
mon symptoms that cause parents to approach a doctor about 
their child’s issue. Without parents taking the initiative to ask the 
doctor what issue their child has, research may not exist.
One wonders if the parents themselves are a blind spot in the di-
agnosis. If the parents have GERD themselves, it may hinder their 
ability to objectively see what is going on  with their child and 
relay all pertinent information to the doctor. Another aspect that 
may need to be brought for further research is whether there is a 
genetic component to GERD. If the parents have it as adults, could 
their children have it as infants? Do doctors and researchers need 
to take this into account when setting up parameters for diagnosis 
and treatment? 
There exists a few means of testing patients for GERD. The prob-
lem with many of them is that they are not perfect and by no 
means perfect for infants. Another issue that arises is that many 
doctors suspect that reflux is just a cover for a real condition 
that is going on in the body, like anatomical abnormalities or her-
nias,  for example (Rudolph, et al., 2001). The doctors questioned 
whether they should begin invasive testing for severe conditions 
and possible surgeries, or to first try out the known protocols for 
testing for reflux and the treatments done on adults . As many of 
these doctors do not believe reflux exists in infants, they begin 
intense procedures to discover what is really wrong with the 
child. One theory was that the H. Pylori bacteria was causing over 
production of acid in infants. This theory was soon dismissed as 
eradicating the bacteria made no change in the patients’ condition 
(Maris, et al. 2013). Other doctors who do not believe it exists 
either,take the approach of ignoring the matter and waiting until 
the child outgrows the condition, which is often the case with 
infants (Carroll, et al. 2002). Most research indicates that infants 
do outgrow this condition by 24 months of age. A third approach 
is to follow the protocol done on an adult, with the future risks to 
the infant still unknown. 
Testing
The first test commonly done when reflux is suspected is called 
the Barium Study Swallow Test. (Arko, et al. 2009). This test is con-
sidered to be the least invasive test of all the reflux diagnostic 
tests. This test is done to determine if there are any blockages in 
the anatomy of the patient or anomalies or conditions that do not 
belong there. The infant is given Barium Sulfate, a white substance, 
to drink; Barium Sulfate  is opaque to x-rays causing a contrast in 
the body. X-rays are taken immediately and during swallowing of 
the liquid to highlight the upper gastrointestinal tract and show 
if anything is out of the ordinary. This test does not indicate any 
form of acid levels in the body or if reflux is the diagnosis. It sim-
ply rules out other issues like pyloric stenosis, tracheoesophageal 
fistulae as well as other abnormalities associated with the upper 
gastrointestinal tract.
Endoscopy with pH probe testing is another means of testing for 
GERD. This method was the focus of testing for many years. This 
method looks to see what the acid levels within the infant are and 
shows any signs of damage to the esophagus (Hauser, Novario, 
Salvatore, Vandemaele, & Vandenplas, 2005). Research indicates 
Figure 3
Hauser, et al. 2005
Figure 3: Questionairre
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that when the pH testing showed the child having an esophageal 
pH of less than 4, reflux was the main cause. This test uses an 
endoscope probe that has a camera attached at the end, as well as 
an LED light to aid in visualization. It is inserted down the patient’s 
throat (some up the nose and down the throat) and lowered 
down the esophagus. (Ferreira, et al. 2012) This test is considered 
invasive for infants and children and does require general anes-
thesia. The pH probe is attached to the endoscope, so both are 
lowered down the esophagus together. 
If the readings of the pH levels indicate lower than 4, acid is pres-
ent and reflux is suspected. The endoscope will indicate how much 
damage has been done to the esophagus, if any. Most children did 
have less damage to the esophagus when the symptoms they ex-
perienced did start to get alleviated. This test is not considered 
perfect because many times the lower esophageal sphincter may 
have just opened and released a little acid into the esophagus, 
altering the validity of the pH probe’s results (Ferreira, et al. 2012). 
Another issue is that the pH probe missed acid levels in some 
childrenwho showed signs of severe esophageal damage, which 
clearly indicated that acid was present. The endoscopy test also 
is not a clear indicator for acid reflux. Infants/Children may have 
damage to their esophagus for other reasons, and not everyone 
with GERD has damage to their esophagus.  Both of these indi-
cated that the means of diagnosing at that time was terribly insuf-
ficient. The logical conclusion is that further research was needed 
to come up with a new, more accurate test. (Badriul, et al.  2004)
Another option for diagnosis is to do pH-probe tests over an 
extended 24-hour period. This tested for pH dropping to levels 
below 4 and infants having the symptoms during or after the drop. 
This test data did show that some patients have a correlation 
between reflux like symptoms and the test scores. However, the 
research tests do not don’t show a big difference in acid reflux 
levels between those undergoing the 24-hour test and those being 
evaluated for reflux-like symptoms. (Badriul, et al. 2004). This has 
to mean that the test is not perfect as well.
 The next test available is called the pH-MII test, Multichannel 
Intraluminal Impedance Test. It is similar to the pH probe. It also 
goes through the nose and down the throat to the esophagus 
where it stays for 24 hours. This test measures acid levels, esoph-
ageal flow and bolus presence. It has small detection devices at 6 
levels along the catheter within the esophagus. It can test for acid 
or non-acid reflux and whether it is liquid or gas. When research-
ers define non-acid reflux, as having a pH of greater than 4, this 
test was able to detect reflux in infants, that the standard pH test 
missed 89% of the time. (Omari, et al. 2002) 
This test helps infants that were being diagnosed simply by eval-
uation of symptoms. If the patient was treated solely based on 
symptoms, they might have been misdiagnosed. This test shows 
that the regurgitation may have nothing to do with pH levels.  It 
greatly proved that the old pH test was not enough. The need to 
come up with a better means of diagnosis was clearly evident. The 
pH-MII test does provide more accuracy. However, it also causes 
more questions. Even if the pH is less than 4, and is recorded 
by the probe, how close in time does the reflux event need to 
happen next to the appearance of a symptom to be considered 
associated? And how many events and symptoms need to occur 
together in a day, for example, for it to be considered problematic 
and relevant for diagnostic purposes?  Another question is why is 
there a correlation between the non-acid reflux and symptoms? If 
it is all an indication of the presence of acid in the infant’s esoph-
agus, how could the test show that acid levels were above pH 
of 4, and yet there was a bolus present at the same time as the 
symptoms? One has to wonder if there is a third entirely different 
option going on that just has not been recognized yet. 
The pH-MII test was good for eliminating GERD as a diagnosis in 
some patients, however, for those that didn’t fit into the category, 
all it did was raise more questions.Another study questioned if 
raising the pH level to between 4.5-5.5 in different positions was 
the answer. (Chiou, et al. 2011) Many more infants were diagnosed 
with GERD when this was the new parameter for acid reflux. 
Parents that need some reprieve were provided with an answer 
and some form of treatment. Indeed, many did respond to treat-
ment. As of yet this is the best test there is. It is not perfect but it 
does provide some answers.
Treatment
An interesting factor in treatment for GERD is that it can also be 
diagnostic. If the patient gets better with the treatment, doctors 
presume they had the disease. When it comes to infants, the first 
treatment tried is called nonpharmacological therapies (Carroll, et 
al. 2002). This includes positioning the infant differently, thickening 
the child’s formula, changing the formula and modifying how many 
times a day the infant has a meal.  The positioning changes only 
worked on some patients and only in some positions. Thickening 
the formula helped with caloric intake, but it did not reduce the 
symptoms or reflux episodes in infants. (Khoshoo, et al.  2000) 
Changing the formula from a milk protein to a different amino acid 
basis did help some of the symptoms. Symptoms of milk allergy or 
intolerance are very similar to reflux  (for example: regurgitation, 
fussiness, colic, etc.); however the research doesn’t show that it 
limited reflux episodes (Nielsen, et al.  2004). Infants that did show 
improvement with the switched formula usually did so as a result 
of not having reflux to begin with. Their symptoms  were mistaken 
for reflux because the symptoms of a milk allergy or intolerance 
do overlap with reflux in many areas. Research indicates that 
these therapies of altered lifestyle tend to help a little, but most 
do not last very long. 
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The most common treatment done for infants with reflux is acid 
suppression.  This is done through medications. They are divided 
into histamine 2 (H2) antagonists and proton pump inhibitors. 
(Bachmaier, et al. 2014) Both of these reduce gastric acidity and 
help heal damage to the esophagus. Very often the medication is 
prescribed without doing a test like an endoscopy or pH probe. 
So there is no way of knowing what caused the symptoms to be 
alleviated or if the acid content and production in the stomach 
was ever there. (Comer, et al. 2010)
H2 blockers work by decreasing the amount of acid produced 
by the stomach. Brand name examples of these medications are 
Pepcid AC, Tagament and Zantac. The symptoms in infants did tend 
to improve. However, a double blind research study indicated that 
infants with the medication did not show improvement in symp-
toms greater than those with the placebo (Comer, et al., 2010). So 
the question remains, what made the child get better and why isn’t 
another child getting better? Figure 4 shows a list of common H2 
receptor drugs as well as proton pump inhibitor drugs. 
Proton Pump Inhibitors work by suppressing acid production as 
well. However, the mechanism is different and they target different 
types of acid and different means of acid production. They seemed 
to work a little better than H2 antagonists for those with more 
severe GERD symptoms. The issue arises though, that with both 
types of medication acid is being minimized in the gastric area. The 
infants do become more prone to GI tract and pulmonary infec-
tions. The question remains, what is worse- reflux or infection? 
Many doctors will not give medication for those infants who seem 
to be growing well, despite the other symptoms.  There have been 
some adverse effects by some of these medications too. One has 
been removed from the market because of the possible neuro-
logical damage as a side effect (Chen, et al. 2012). Despite all this, 
medication does seem to be the most common form of treatment 
for infants with GERD.
One other means of treatment is surgical; the most common being 
inserting a feeding tube. (Kuwata, et al. 2013) This did alleviate the 
symptoms to a great extent, however at a great price. These chil-
dren did tend to develop issues with eating orally later on; they had 
trouble with chewing, swallowing and sensory issues, to name a few. 
The children needed physical and occupational therapy to help them 
learn how to properly eat, chew and not have an aversion to the dif-
ferent textures of their food. Most physicians deem this option to be 
a last resort because of the developmental issues that can arise later 
on, as well as the invasiveness of the procedure. Doctors generally 
have seen that infants do outgrow the condition with age. When 
evaluating treatment options, this fact has to be taken into account.
Figure 4: 
Drugs demonstrated to be effective in gastroesophageal reflux disease (Rudolph, et al. 2001)
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Conclusion
As of yet there is no way to conclude with absolute certainty 
that GERD exists in infants. All the evidence linking the two is not 
definite. Most infants did tend to get better over time as they aged, 
or with symptom alleviation due to one form of treatment or 
another. (Or unfortunately death caused the subject to no longer 
be in the research data.) None of these indicate with absolute 
certainty that the GERD was ever there to begin with.  Thorough 
evaluations are needed to properly diagnose GERD in infants. 
Further research is needed in order to come up with a diagnos-
tic test that clearly identifies GERD as the condition. Physicians 
should take a conservative approach in treating patients whom 
they suspect have this condition, because more damage than good 
can be done to these infants in the process of trying to alleviate 
their symptoms.  
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Heart failure is one of the most prevalent causes of death in the 
world. There are many different diseases affecting the heart. For 
many of them, the only answer is a heart transplant. Although this 
has saved countless lives, transplants remain an imperfect solution. 
Firstly, the list of people requiring new hearts is a long one, but the 
amount of donor hearts available is few. Once a patient is approved 
for a heart transplant, s/he is added to a waiting list, which is part 
of a national allocation system run by the Organ Procurement 
and Transplantation Network (OPTN). There are approximately 
3,500 people on the list, and waiting times can range from about 
six months to more than a year. 
Even once a heart is found for the patient, and the transplant is 
successful, the patient is still not out of danger. Although the heart 
itself is healthy, it may not function properly in the recipient, caus-
ing a number of complications. One such concern is Primary Graft 
Dysfunction, which is the most frequent cause of death in the first 
30 days after a transplant (National Institutes of Health, 2012). 
According to the OPTN, the one year survival rate for patients 
in the U.S. aged 18-34 is almost 85%, with 75% 3 year survival 
rate, and 66% five year. The 1, 3 and 5 year survival rate for recipi-
ents age 35-50 is slightly higher, at 88%, 81% and 74% respectively 
(OPTN). Although these numbers are relatively high, one of the 
main causes for heart transplant failure in the first year after the 
transplant is due to the patient’s immune system rejecting the 
foreign organ. To prevent this, immunosuppressant drugs are ad-
ministered; however, this can cause damage to other organs such 
as the kidneys and liver. High cholesterol, diabetes and cancer are 
also some risks of the anti-rejection drugs (Bhimji, 2011). The gap 
between the supply and demand for donor organs, as well as the 
lifelong consequences for the patient, make the creation and im-
plantation of a bioartificial heart a desirable alternative. While the 
construction of a functional whole organ has not yet been accom-
plished, tissue engineering and regenerative medicine research 
have obtained promising results for heart regeneration.
Bioengineers have been working on creating fully functioning or-
gans that would eliminate the need for donors. This would solve 
the issue of patients not receiving a heart in time, in addition to 
getting rid of any concerns of rejection. There have been many 
studies done all in the hope of answering the question, is growing 
a new heart for a patient a foreseeable goal of the near future?
When trying to solve such a complicated issue there are numer-
ous factors that must be taken into account, and many different 
angles that the problem can be studied through. With the case 
of the engineered heart, some of those factors include finding a 
suitable base, or scaffold for the organ, deciding what kind of cells 
would be appropriate for actually building the organ, and matur-
ing the construct to develop some form of contractile and pump 
function. 
Methods
The information in this paper was obtained by analysis of scien-
tific articles and research papers. Various online databases and 
medical journals were used, accessed mostly via PubMed or the 
Touro College database. Most of the information is based on ex-
periments done using rat cells since this is the most practical way 
of obtaining the large quantity of cells needed. Although the data 
is not completely applicable to human cardiac cells, researchers 
hope that these studies will provide insight into bioengineering of 
human hearts. 
Discussion 
The first major issue in organ engineering is creating a scaffold 
with enough elasticity, porosity, and strength to enable the cells 
to grow correctly, thus resulting in a functioning organ or tissue. 
The makeup of the scaffold is vital to the process because native 
tissues contain different cell types, with each cell type having its 
own unique three-dimensional (3-D) extracellular matrix environ-
ment, and mechanical properties. In addition, there are many other 
structures that must be taken into account, such as blood vessels. 
An ideal construct should display the functional and structural 
properties of natural heart muscle, and therefore should be con-
tractile, vascularized, and electrophysiologically stable. To recreate 
such complexity in engineered tissues various approaches have 
been used. 
Abstract
Heart disease is one of the highest causes for fatality in the world. Although many such diseases can be treated by 
a heart transplant, this in itself can cause countless problems. Aside from the high demand for donor hearts, there 
is the risk of the patient’s immune system rejecting the transplanted heart. A bioengineered heart would reduce 
the need for donor hearts, and thus save countless lives. Finding a suitable scaffold, obtaining appropriate cells, and 
ensuring that the tissue will function properly are the main focuses in creating an artificial heart. While most of the 
studies done have been concentrated on creating cardiac tissue rather than the full organ, with the integration of 
these aspects scientists are getting closer to the goal of engineering a fully functioning artificial heart.
Bioengineered Hearts
By: Rivky Loeb
Rivky graduated in June 2014 with a B.S. in biology.
88
Rivky Loeb
Much of the research on cardiac tissue engineering that has been 
done was focused more on small sections of tissue than on the 
whole heart. However, this can be an important start to full organ 
engineering, as the results of such studies can be incorporated 
into studies dedicated to heart engineering. 
Scientists have approached the issue of scaffolds from many differ-
ent angles. In one such approach, cells are seeded on a degradable 
scaffold on which they reorganize into engineered tissues. 
A group of bioengineers set out to research different designs for 
scaffolds to determine which would be most conducive to cardiac 
tissue growth. They were able to create two layer scaffolds, with 
fully interconnected pore networks, which aided in guiding the 
pattern of cell growth. The material used was a synthetic elas-
tomer poly(glycerol sebacate), known as PGS. This polymer was 
chosen because of its ability to reproduce the mechanical stiff-
ness and elasticity of the extracellular matrix. Additionally, PGS is 
supportive of blood vessel formation, and cardiogenesis. Different 
scaffolds were created with different properties, such as pore size, 
and thickness. Two layer scaffolds 200μm in total thickness, with 
interconnected pores were found to be the most effective for al-
lowing heart cells to survive and form functional connections. PGS 
scaffolds provided a platform for patterned cell distribution while 
maintaining the geometric and mechanical properties of normal 
heart muscle (Neal, et al., 2013). A similar study done at Duke 
University used the flexible material PDMS (polyDimethylsilox-
ane) to create molds with elliptical pores. Such pores enabled the 
enhanced diffusion of oxygen and nutrients to the cells (Liau, et 
al., 2011).
In addition to the design for the scaffold, researchers must deter-
mine what kind of material should be used. One material, called 
Poly(N-isopropylacrylamide) or PNIPAAm, is a polymer recently 
emerging as a possibility due to its favorable properties. PNIPAAm 
has controllable features and switchable surface properties, making 
it an ideal option for scaffold formation. For example, PNIPAAm 
has a lower critical solution temperature (LCST) of 32oC. This is 
important because it will shrink and become hydrophobic at tem-
peratures above the LCST, and hydrophilic at temperatures below. 
Whereas hydrophobic surfaces are attractive for cell attachment, 
detachment of cells and tissues from these templates requires 
either an enzymatic reaction or physical scraping, both of which 
can damage the cells. The use of PNIPAAm enabled controlled cell 
detachment by adjusting the temperature (Tekin, et al., 2011).
Another advantage to using PNIPAAm is its dynamic properties. 
Previously, micromolds were used to create microgels. However, 
these scaffolds had static structures, meaning the surface proper-
ties and patterns could not be changed after fabrication. PNIPAAm 
gel molds were able to be engineered to control 3-D organization 
of the cells by mimicking the complex native tissue architecture. 
Additionally, the polymer is a hydrogel, which would enable blood 
vessels to form in the organ. Coating surfaces in PNIPAAm served 
to induce capillary network formation. This is especially important 
for tissues to function properly (Tekin, et al., 2011).
Recently, a group of scientists experimented with adding sin-
gle-wall carbon nanotubes (SWCNTs) to PNIPAAm to improve 
the function of the base gel for use in myocardial repair. SWCNTs 
are sheets of graphene rolled into a seamless cylinder. They have 
remarkable electrical properties, which may even exceed the best 
metals or semiconductors known, as experiments have shown 
(McEuen, et al., 2002). They theorized that the SWCNTs would 
improve the bioactivites and adhesion of the hydrogel to the cells. 
After the cells were applied to the gel, it was observed that as 
expected, cell adhesion and proliferation was about 1.71 times 
greater in the PNIPAAm/SWCNT hydrogel than in the PNIPAAm. 
The results indicated that the incorporation of SWCNTs greatly 
enhanced the bioactivity of the PNIPAAm and aided in its func-
tioning as a scaffold (Li, et al., 2014). Finding a suitable material for 
the scaffold is one main step in the process of tissue engineering. 
Another option recently being explored for use as scaffolds, are 
decellularized organs. As mentioned previously, even if donor or-
gans were not in short supply, the transplant recipient would still 
be at risk of immune rejections and lifelong immunosuppression 
treatment. To date, although numerous modern technologies have 
been employed to fabricate new tissues, the creation of a func-
tioning whole organ is still in progress. The use of decellularized 
matrices would be a step in the right direction, as it would over-
come the need for the bioengineer to artificially recreate the con-
ditions for cell deposition. It would offer a microenvironment with 
preserved natural geometry and vascular networks, which would 
enable cells to grow in the correct patterns (Moroni , Mirabella, 
2014). 
In one such study, hearts were decellularized with detergents, 
which preserved the underlying ECM, providing acellular, per-
fusable vascular architecture, and intact chamber geometry. All 
cellular material which would induce an immune response, such 
as cardiac and smooth muscle cells, DNA, RNA and soluble pro-
teins, were removed. This left behind only the collagen, laminins 
and other structural proteins as a scaffold. Fiber orientation and 
composition remained intact, as did the arterial and venous base-
ment membranes. As shown in figure 1, the detergent SDS was 
successful in removing all cells, while the Triton detergent left cells 
behind (Ott, et al., 2008).
The scaffold or decellularized organ now must be seeded with 
cells. This leads to the next issue regarding tissue engineering: what 
kind of cells should be used. Many researchers in the field use a 
mixture of two or more cell types, such as endothelial precur-
sor cells to line blood vessels, and muscle progenitors, which are 
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similar to stem cells, to seed the walls of the chambers. These can 
be derived from induced pluripotent stem (iPS) cells- adult cells 
genetically reprogrammed to an embryonic stem cell-like state, 
which can be coaxed by scientists to become any kind of cell. This 
is useful because these can be taken from the patient, and used 
to make immunologically matched tissues (Maher, 2013). A team 
from the University of Pittsburgh recently used iPS cells generated 
from human skin cells to create precursor heart cells called MCPs. 
The cells were placed on a decellularized scaffold, and grew and 
developed into heart muscle. After 20 days, the tissue began show-
ing cardiac muscle function (Discovery News, 2013). 
 Alternatively, as in a different study, heart cells were isolated from 
neonatal rats and digested in a trypsin solution until dissociated 
into a single cell suspension. Other steps were done to isolate the 
cells, and at the end of this method 63% cardiomyocytes, 33% car-
diac fibroblasts, 3-4% smooth muscle cells and 2-3% endothelial 
cells were collected to be used to seed the scaffold (Neal, et at., 
2013). Tissues constructed from these heart cell mixtures showed 
advanced structure, determining that creation of optimal cardiac 
tissue constructs depends on a mix of non-monocytes and cardiac 
monocytes (Zimmermann, et al., 2004).
A group of scientists using similar neonatal cells performed ex-
periments to determine the effect of different factors on the 
growth of the cells in cultures and on the scaffold. For example, 
by analyzing the gas and CO2 levels in different vessels, they were 
able to determine what environment would be best for the cell 
growth. Additionally, by analyzing the density of the seeded cells, 
they determined that the minimal cell seeding density necessary 
to maintain construct structural integrity was achieved by using 
1.4x106 cells per scaffold. For interconnected tissue structure, 
8x106 cells per scaffold were required. From all the collected data, 
the researchers concluded that structural and functional proper-
ties of constructs were improved by seeding polymer scaffolds 
at high densities using rotating vessels. This study demonstrated 
that dissociated cells cultured on 3D scaffolds under favorable 
conditions were capable of forming engineered constructs with 
features resembling those of native tissues (Carrier, et al., 1998). 
Other favorable properties for cell growth were determined in 
another study. Various factors were tested for their role in engi-
neered heart tissue. High collagen content in the mixture yielded 
tissue with higher stiffness, but less contractile force development. 
Decreasing the collagen content yielded tissue with soft matrix 
structure, but improved contractile properties. Additionally, the in-
clusion of horse serum was found to be beneficial for engineered 
heart tissue development (Zimmermann, et al., 2004). 
Once the scaffold is prepared and the cells cultured and seeded, 
the next step is to observe and determine whether the cells will 
behave as cardiac muscle cells. This includes being able to contract, 
and electrically conduct signals. While full engineered heart trans-
plants have not been perfected, scientists have been successful on 
smaller scales. Biomedical engineers at Duke University were able 
to grow a three dimensional human heart muscle that acted like 
Figure 1: 
Hearts decellularized using different detergents. Asterisks indicate intact vascular network. 
Source: Ott HC, et al. 2008
90
Rivky Loeb
natural tissue, in that it conducted electricity at about the same 
speed as natural heart cells, and contracted appropriately (Duke 
University, 2013). Using pluripotent embryonic stem cells perme-
ated with fibroblasts, cardiac tissue was created with the capabil-
ities of generating fast, uniform action potential propagation with 
velocities ranging from 17.8cm/s to 24.1 cm/s, and contractile 
force of 2mN (Liau, et al., 2011).
With the decellularization method, the recellularized hearts were 
placed in bioreactors that mimicked the sensation of beating. A 
combination of electrical signals was used to help synchronize the 
cardiocytes seeded on the scaffold, along with physical beating 
motions induced by a pump. After eight to ten days in the biore-
actor the hearts were able to beat by themselves. However, when 
the team implanted the engineered hearts into rats, none of the 
hearts were able to perform the blood-pumping function at the 
degree that is required of the heart (Maher, 2013).
In a study done in Tokyo, layered cell sheets coated with PNIPAAm 
were created and implanted into the hearts of rats. At first the 
beating of engineered tissue, at 96bpm, was relatively slow in com-
parison to host hearts, 332bpm; after four weeks it had gotten 
stronger, though not as fast as the host tissue. A positive factor 
was that neovascularization occurred in the tissue, which aided it 
in functioning properly (Shimizu, et al., 2002).
In a different experiment, engineered heart tissue was created and 
implanted onto an infarcted area in rat hearts. When evaluated 
later, the engineered tissue showed electrical impulses in synch 
with the native tissue. It was also evident that the implanted tis-
sue had prevented further dilation and induced wall thickening of 
infarcted myocardial segments. The epicardial activation of hearts 
with the tissue graft was normal, indicating undelayed coupling of 
the grafted tissue to the host tissue. The tissue was also able to 
propagate electrical potentials (Zimmermann, et al., 2006). This 
shows that tissue created in vitro can possibly function as natural 
cardiac tissue in vivo.
Conclusion
Although a completely functioning heart has not yet been engi-
neered, scientists are headed in the right direction. Using scaffolds 
made of different materials and with different designs, they have 
been able to stimulate cell growth in the right patterns for tissue 
construction. Under the right conditions, the constructs behaved 
in a manner similar to native cardiac tissue. Such engineered tis-
sues have even been shown to function almost as well as natural 
tissue in vivo. With the integration of these different aspects, and 
advances in bioengineering, scientists are getting closer to the goal 
of creating a fully functioning artificial heart. 
References
Bhimji S. Heart transplant. Medline Plus. http://www.nlm.nih.gov/
medlineplus/ency/article/003003.htm. Updated May 4, 2011. 
Carrier RL, Papadaki M, Rupnick M, Schoen FJ, Bursac N, Langer 
R, Freed LE, Vunjak-Novakovic G. Cardiac Tissue Engineering: 
Cell Seeding, Cultivation Parameters, and Tissue Construct 
Characterization. Biotechnology and Bioengineering. Nov 1998; 
64(5): 580-589.
Discovery News. Stem Cells Grow Beating Heart. Aug 2013. 
http://news.discovery.com/tech/biotechnology/stem-cells-grow-
beating-heart-130814.htm
Duke University. Biomedical engineers grow 3D human heart 
muscle that acts just like natural tissue. News Medical. http://
www.news-medical.net/news/20130507/Biomedical-engineers-
grow-3D-human-heart-muscle-that-acts-just-like-natural-tissue.
aspx. May 7, 2013.
Health Resources and Services Administration. Organ 
Procurement and Transplantation Network. http://optn.trans-
plant.hrsa.gov/latestData/viewDataReports.asp.
Li X, Zhou J, Liu Z, Chen J, Lu S, Sun H, Li J, Lin Q, Yang B, Duan 
C, Xing M, Wang C. A PNIPAAm-based thermosensitive hydrogel 
containing SWCNTs for stem cell transplantation in myocardial 
repair. Bio Materials. July 2014; 35(22): 5679-5688.
Liau B, Christoforou N, Leong KW, Bursac N. Pluripotent stem 
cell-derived cardiac tissue patch with advanced structure and 
function. Biomaterials. Dec 2011; 32(35): 9180-9187.
Maher B. Tissue engineering: How to build a heart. Nature 
International Journal of Science. July 2013; 499(7456): 20-22. 
McEuen PL, Fuhrer M, Park H. Single-Walled Carbon Nanotube 
Electronics. IEEE Transactions on Nanotechnology; 2002 
Moroni F, Mirabella T. Decellularized matrices for cardiovascular 
tissue engineering. Am J Stem Cells. Mar 2014; 3(1): 1-20
National Institutes of Health. What are the risks of a Heart 
Transplant. National Heart Lung and Blood Institute. http://www.
nhlbi.nih.gov/health/health-topics/topics/ht/risks.html. January 3, 
2012.
Neal RA, Jean A, Park H, Wu PB, Hsiao J, Engelmayr GC Jr, Langer 
R, Freed LE. Three-dimensional elastomeric scaffolds designed 
with cardiac-mimetic structural and mechanical features. Tissue 
Eng Part A. Mar 2013; 19(5-6): 793-807.
91
Bioengineered Hearts
Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, Netoff TI, 
Taylor DA. Perfusion-decellularized matrix: using nature’s plat-
form to engineer a bioartificial heart. Nature Medicine. Jan 2008; 
14: (213-221).
Shimizu T, Yamato M, Isoi Y, Akutsu T, Setomaru T, Abe K, Kikuchi 
A, Umezu M, Okano T. Fabrication of Pulsatile Cardiac Tissue 
Grafts Using a Novel 3-Dimensional Cell Sheet Manipulation 
Technique and Temperature-Responsive Cell Culture Surfaces. 
Circulation Research. Jan 2002; 90:e40-e48
Tekin H, Sanchez JG, Tsinman T, Langer R, Khademhosseini 
A. Thermoresponsive Platforms for Tissue Engineering and 
Regenerative Medicine. AIChE J. Dec 2011; 57(12): 3249-3258.
Zimmermann WH, MeInychenko I, Eschenhagen T. Engineered 
heart tissue for regeneration of diseased hearts. Biomaterials. 
April 2004; 25(9): 1639-1647. 
Zimmermann WH, Melnychenko I, Wasmeier G, Didie M, Naito 
H, Nixdorff U, Hess A, Budinsky L, Brune K, Michaelis B, Dhein S, 
Schwoerer A, Ehmke H, Eschenhagen T. Engineered heart tissue 
grafts improve systolic and diastolic function in infarcted rat 
hearts. Nature Medicine. April 2006; 12(4): 452-458.
 Notes
 Notes
 Notes
 Notes
 Notes

